2018 Annual Report 2018 Our year of big thinking, collaboration and discovery.
Our vision Our values
We see a future where everyone lives a longer, Excellence healthier life. Innovation
Our mission Collaboration We will harness all the information encoded in Community the genome to make pioneering discoveries that Integrity predict, treat and prevent diseases that have the deepest impact on society. Respect
2018 Garvan Annual Report Our values Who we are, what we do Aspirations
Excellence Garvan is leading the nation in using genomic analysis • To become the most advanced institute in the to accelerate discovery and enable personalised, region in the adoption, application and integration Innovation precision medicine. of next‑generation genomic and computational approaches and technologies in investigative and Collaboration Our researchers pioneer studies into some of the most translational research. difficult to solve and widespread diseases affecting the Community community today. Garvan is focused on understanding • To advance knowledge in our key areas of critical the molecular and cellular processes in health and mass that will lead to better understanding, reduced Integrity disease, putting people and patients at the centre of incidence and improved treatments for cancer, leading-edge local and global research expertise and immune deficiency, inflammatory and autoimmune Respect networks as the basis for developing future preventions diseases including diabetes, osteoporosis, and and treatments. diseases of ageing affecting the brain and other organs. For 56 years, Garvan scientists have been achieving significant breakthroughs in the understanding and • To attract, develop and support exceptionally talented treatment of diseases. researchers with leading‑edge programs addressing key conceptual and practical questions in human biology, and the translation of new knowledge and technologies into clinical applications.
• To embrace and uphold a culture of collegiality, collaboration, inclusivity, consideration, safety, transparency, and the highest ethical standards.
• To engage stakeholders and the community through our achievements and research vision so that we attract the significant government and donor support needed to empower our transformative agenda.
garvan.org.au 11 The organisation As at 31 December 2018
Garvan Institute of Medical Research
Board of Directors Executive
Chair Dr John Schubert AO Executive Director Prof Chris Goodnow FAA FRS Chief Operating Officer Kate Gunn Chief Scientific Officer Prof Marie Dziadek
Garvan Research Foundation
Board of Directors Executive
Chair Russell Scrimshaw Director Mara-Jean Tilley Deputy Director Brad Timms
Research Divisions
Bone Biology Cancer Diabetes and Metabolism Genomics and Epigenetics
Head Head Head Head Prof Peter Croucher Prof David Thomas Prof Mark Febbraio Prof Susan Clark FAA Faculty Faculty Faculty Faculty A/Prof Paul Baldock Dr Christine Chaffer Prof Trevor Biden Dr Ozren Bogdanovic Prof Jacqueline Center A/Prof Elgene Lim Prof Lesley Campbell AM A/Prof Marcel Dinger Prof John Eisman AO Prof Chris Ormandy Prof Don Chisholm AO Prof Vanessa Hayes Prof Tuan Nguyen Dr Marina Pajic Prof Jerry Greenfield A/Prof Tim Mercer Prof Mike Rogers A/Prof Joseph Powell Prof Ted Kraegen Prof Seán O’Donoghue A/Prof Alex Swarbrick A/Prof Ross Laybutt Prof John Shine AO FAA A/Prof Paul Timpson Prof Katherine Samaras Prof Neil Watkins A/Prof Carsten Schmitz- Peiffer The Kinghorn Cancer Centre Director Prof David Thomas
Immunology Neuroscience Kinghorn Centre for Garvan-Weizmann Centre Clinical Genomics for Cellular Genomics
Head Prof Stuart Tangye Head A/Prof Antony Cooper Clinical Head Head A/Prof Joseph Powell Faculty Faculty Mary-Anne Young Prof Antony Basten AO FAA FTSE Prof Herbert Herzog Prof Robert Brink Prof John Mattick AO FAA FTSE Scientific Head Prof Daniel Christ Prof David Ryugo A/Prof Sarah Kummerfeld Dr Tatyana Chtanova Dr Robert Weatheritt Dr Elissa Deenick Prof Chris Goodnow FAA FRS A/Prof Shane Grey A/Prof Cecile King A/Prof Tri Phan Prof Jonathan Sprent FAA FRS
Genome.One Chief Executive Officer A/Prof Marcel Dinger
Development and Support
Chief Operating Officer Kate Gunn Chief Scientific Officer Prof Marie Dziadek Australian BioResources: Dr Jenny Kingham Grants Administration: Sonja Bates & Grainne Mullen Business Development & Innovation: David Barda Human Research Governance: Therese Yim Finance & Accounting: Samantha Malone Animal Ethics: Dr Rayson Tan Human Resources: Simon Hamilton Animal Welfare Officer: Dr Vivian Song Internal Audit & Business Improvement: Carolyn Loughnan Student Programs: Dr Tracy Anderson Information Technology: Esteve Mayolas, Jackson Chan Legal Counsel: Christina Hardy Building Services: Lynn Croft Engineering Services: Ryan Kolster Facilities: Julie Miller Scientific Support Services: Rebecca Brown WHS and Compliance: Lisa Moncur
2 2018 Garvan Annual Report Contents
4 Garvan Institute Chairman 33 Division Report: and Executive Director’s Neuroscience Report 35 Microsoft cloud computing 5 Garvan Research grant to support Garvan’s Foundation Chairman and genomic research Director’s Report 36 Centre Report: 6 The year at a glance Kinghorn Centre for Clinical Genomics 7 Garvan at a glance 38 Centre Report: 8 Collaborations Garvan-Weizmann Centre 9 Publications for Cellular Genomics
10 Awards and achievements 40 Ga rvan Institute of Medical Research Board of Directors 13 Division Report: Bone Biology 43 G arvan Research Foundation Board of 15 El lie’s story: from intensive Directors care to the playground 46 PhD completions 16 Division Report: Cancer 47 P ost-Doctoral 19 Ta king genomic cancer Development Committee medicine national 48 F ranklin Women’s 21 Division Report: Academic Partners Diabetes and Metabolism 49 In Memoriam 23 A pioneering partnership 50 Leaders in Science and 25 Division Report: Society seminars Genomics and Epigenetics 51 A shared vision for a 27 A national genomics healthier future mission for Australia 52 Partners for the Future 28 Division Report: Immunology 54 Garvan community
31 UNSW Cellular Genomics 60 Scientific publications Futures Institute launches 78 Peer reviewed funding
84 Financial highlights
We would like to acknowledge the Gadigal people of the Eora Nation, the traditional owners and custodians of the land on which the Garvan Institute of Medical Research is located. We pay respects to the Elders, past, present and future, and recognise the continuing connection and contribution to this land.
A digital version of this report is available at garvan.org.au/2018‑annualreport.
garvan.org.au 3 Garvan Institute of Medical Research Report
In 2018 the Garvan Institute of Medical the application of single-cell genomics and Research embraced change under new bioinformatics in a broader genomics and leadership, and celebrated numerous precision medicine framework. scientific achievements. Our talented researchers continued their pursuit of With thanks to your ongoing support, the discoveries to better predict, prevent Institute is in great shape. Our Garvan family and treat a wide range of diseases with raised more than $41 million in philanthropic the aim of giving everyone a shot at funding to catalyse and accelerate research a longer, healthier life. discoveries, and our scientists attracted $24 million in critical competitive peer- Garvan continues to be a world leader in reviewed funding. Our research discoveries genomics-led research and translation. were published in prestigious scientific Genomics – the study of all the information in journals – an important measurement of our DNA – is and will continue to revolutionise Garvan’s success and crucial to ensuring Dr John Schubert AO health care. Our strategic research centres our findings are disseminated globally Chairman – The Kinghorn Cancer Centre, the Kinghorn within the medical community. Centre for Clinical Genomics and the Garvan- Weizmann Centre for Cellular Genomics – Throughout 2018, Garvan’s work, at the ensure Garvan scientists, and the research intersection between research and clinical community, are able to pioneer human- care has resulted in life-changing treatments centred research which will be translated for people, such as Ellie (page 15) through the into clinical practice for the benefit of all. Zero Childhood Cancer Program.
2018 also saw us formalise a partnership The executive leadership of the Institute between Genome.One, our wholly owned continues to excel; we are appreciative of subsidiary providing clinically accredited the passion and skill of Professor Marie whole genome sequencing, and pathology Dziadek as Chief Scientific Officer, Kate Gunn company Australian Clinical Labs. This new (following Philip Knox) as Chief Operating partnership is translating Garvan’s genome Officer, Mara-Jean Tilley (following Andrew sequencing and analysis capabilities into a Giles) as Director of the Garvan Research critical diagnostic service, serving families Foundation, and our research leaders: and doctors across Australia. Drawing upon Professor Susan Clark, Associate Professor Professor Chris Goodnow FAA FRS the very best of Garvan’s cutting-edge Antony Cooper, Professor Peter Croucher, Executive Director research, this service has already changed Professor Mark Febbraio, Professor Stuart young lives and transformed the care of many Tangye and Professor David Thomas. Australians. It is now set to do even more. Of course Garvan is nothing without its people, and we warmly acknowledge the Following the launch of the Australian Federal dedication of our 47 faculty scientists, Government’s $500 million genomics mission 700+ researchers and support staff. in May, Garvan’s Genomic Cancer Medicine Program (page 19) was awarded a $50 We are immensely grateful to our Board million grant from the Federal Government of Directors, who offer their extensive and a $12.4 million grant from the NSW expertise and valuable time to Garvan Government to nationalise the program, on a voluntary basis. the Australian Genomic Cancer Medicine Centre, for individuals with rare and advanced Finally, we acknowledge the generosity of cancers. The closer affiliation with UNSW, the individuals, groups and organisations including the establishment of the Garvan-led that form the Garvan family. At Garvan, UNSW Cellular Genomics Futures Institute we see a future where we can stop disease (page 31), will foster even closer collaboration before it starts. between Garvan and UNSW scientists in
4 2018 Garvan Annual Report Garvan Research Foundation Report
In 2018 the Garvan Research • We moved closer to a potential blood Foundation, the marketing and test for the efficacy of chemotherapy for fundraising arm of the Institute, men with advanced prostate cancer; was proud to continue its purpose of supporting Garvan scientists to • We launched an e-learning module to make discoveries that will enhance help physicians integrate genomics into human health now and for the benefit clinical care; of future generations. • We uncovered the first-ever evidence Over the course of 2018, the Garvan of advanced DNA regulation in Research Foundation was the beneficiary invertebrates; and of more than $41 million dollars in donations to directly support Garvan’s • We used cellular genomic technology talented scientists, strategic programs to reveal how to turn human stem cells Russell Scrimshaw and most innovative projects. We into heart cells. Chairman cannot underestimate the impact of this investment, and we thank you, our Garvan The continued philanthropic investment family, for your generous foresight. of individuals and organisations – in particular long-term members of the The Foundation team is small yet mighty; Garvan family, including The Kinghorn our team is passionate, dedicated Foundation, Mrs Janice Gibson and the and driven. We raise the profile of our Ernest Heine Family Foundation, Mr Len scientists, promote their work and join Ainsworth AM, Mrs Jane Hemstritch, with other like-minded organisations The Bill and Patricia Ritchie Foundation, to create a stronger voice for medical Mr & Mrs Alan and Lynne Rydge, Mr John research. Most importantly, we are Roth and Ms Jillian Segal AO, Mr and Mrs privileged to work with you – our Garvan Bob and Ruth Magid, The Paramor Family, family of supporters – to enable Garvan’s Mr & Mrs John and Megan Wade, Ms vital research. Thank you! Lysia O’Keefe and Nelune Rajapakse AM and Anna Guillan AM from The NELUNE We would like to especially acknowledge Foundation – has been absolutely crucial Garvan’s Partners for the Future, to Garvan’s continued success. Mara-Jean Tilley visionary individuals who have left a Director gift to Garvan in their Will to provide We sincerely thank our Board of Directors incredibly generous and critical support for their generous commitment, passion for Garvan’s medical research. and extensive contributions.
Just some examples of our research We see a future where an individual’s achievements in 2018: DNA is used to prevent, diagnose and treat disease. Thanks to your support • We discovered an entirely new form and the dedication of our researchers, of DNA called the ‘i-motif’; it’s within reach.
• We revealed the molecule that could be the key to better tuberculosis prevention;
garvan.org.au 5 The year at a glance
The Garvan Research Foundation continued to receive generous support from a wide cross section of the community during 2018 and philanthropic investment increased by $14 million compared to 2017. The Institute continued to make significant investments in direct research support and underwriting of Garvan’s scientists. In mid-2018, a restructure of Genome.One was undertaken and, as a result, the clinical diagnostics division of the business was sold to Australian Clinical Laboratories, with other divisions either wound down or their operations transferred to Garvan. During 2018, an affiliation agreement with the University of New South Wales was signed with the intention of driving closer strategic collaboration between the entities.
As at 31 December 2018 Total income Total expenditure All figures are A$’000
Total income Total expenditure $107,265 $107,597
NHMRC Grants $16,480 Employment costs $57,386
Other Peer Reviewed Grants $18,438 Sequencing consumable expense $5,466
NHMRC and UNSW Infrastructure $7,023 Research expense $10,278
NSW Government Support $7,169 Depreciation and amortisation expense $11,302
Donations and Bequests $41,148 Administration expense $10,344
Sequencing and facility charges $15,878 Fundraising and marketing investment $3,244
Other Income $1,129 Building and scientific expenses $8,862
Finance costs $715
Philanthropic income
$50,000 $49,359
$41,148 $40,000 $33,985 Philanthropic income with bequests $30,000 $27,197 $21,622 $29,869 Philanthropic income without bequests $20,000 $24,245 $25,434 $21,136 $18,067 $10,000 2014 2015 2016 2017 2018
6 2018 Garvan Annual Report Garvan at a glance
Research staff by Division As at 31 December 2018 Total staff
Bone Biology 52 813
Cancer 182 Research staff Diabetes and Metabolism 73 473 516 Genomics and Epigenetics 54 Kinghorn Centre for Clinical Genomics 22 339 Immunology 87 Neuroscience 46 1
Average age in Honours and Undergraduate students 6 years 38 Masters students 1 PhD students 81 Scientific support 84 Visiting scientists 133 Visiting students 38 Research staff 299 Foundation staff 35 Development and Support Group 136
Public and community engagement and education 1,097 550 832 58 Attended Attended Attended Small group tours 4 public seminars 12 external presentations 50 public tours were attended 60 120 177 Attended Teachers attended Attended 1 careers day career development KCCG showcases
garvan.org.au 7 Collaborations
Collaborating around the world
Ambitious and collaborative endeavours of many kinds – both on a national and an international scale – are essential to modern medical research. Here are the many locations that Garvan connects with to allow us to advance our ground-breaking discoveries. The numbers refer to joint publications with other institutions.
UK 71 Europe 104 North America 106 Israel 7 Middle East 12 Asia 47
Africa 12
South America 10
NZ 6
8 2018 Garvan Annual Report Publications
Top ten publications by impact factor 384 The impact of an academic journal is a measure reflecting the yearly average number of citations to recent articles. total publications in 2018, including journal articles, Nature Science Cell Annual Review reports, reviews, letters Amphioxus Germinal center A mild PUM1 of Immunology and book chapters functional antibody mutation mutation is Self-reactive genomics and trajectories are associated with B cells in the the origins of determined by adult-onset germinal center vertebrate gene rapid self/foreign ataxia, whereas reaction 309 regulation discrimination haploinsufficiency causes original research papers developmental delay and seizures 87 publications in journals with an impact factor Nature Genetics greater than 8 Plain-language Nature Reviews Nature Reviews medical Genetics Molecular Cell vocabulary Autism spectrum Biology for precision disorder: insights Functions and Nature Medicine diagnosis into convergent mechanisms Microenvironmental mechanisms from of epigenetic control of breast transcriptomics inheritance in cancer subtype animals elicited through paracrine platelet-derived growth factor-CC signaling
For a full list of Garvan’s 2018 publications, Nature please see page 60 Meta-analysis and Cell the science of Recovering gene research synthesis interactions from single-cell data using data diffusion
garvan.org.au 9 Awards and achievements
Dr Dunia Alarkawi
Australia Day Award for Garvan’s The 2018 Champ Young Pioneer Award Estée Lauder Breast Cancer Awards Dunia Alarkawi This annual award from Champ Private Estée Lauder Companies presented Garvan researcher Dr Dunia Alarkawi’s Equity was awarded to Dr Michelle two awards to talented young breast (Bone Biology Division) outstanding McDonald (Bone Biology Division). cancer researchers at Garvan, accomplishments have been The award is granted to a young Dr Simon Junankar and Dr Neil Portman, acknowledged with an Australia Day researcher to test an early stage idea to support them in investigating a Award from the National Council in an innovative research project. novel breast cancer research concept. of Women of NSW. Dr Alarkawi’s Dr McDonald will use the award in award recognises her exceptional her work understanding how to stop The two awards mark the 25th achievements so far in her medical the growth of cancers that spread anniversary of The Estée Lauder research career, in particular the amount (or metastasise) to bone. She will use Companies’ Breast Cancer Campaign she has accomplished in less than two a specific imaging technique to study and were presented at Garvan’s years of PhD research. how tumour cells interact with bone annual breast cancer community cells, and the effects on this interaction forum, From The Breast Cancer Lab of drugs that prevent bone resorption. To You. Each award will support the Ridley Ken Davies Award researchers to progress their projects The 2018 Ridley Ken Davies Award to a stage where they have sufficient was presented to Dr Liz Caldon The Heliflite Award data to ensure they are competitive for (Cancer Division). The annual grant, This award supports two of Garvan’s peer reviewed funding. Dr Junankar, which honours Mr Ken Davies, a Ridley most outstanding early career Senior Research Officer in the Tumour employee who sadly passed away from researchers, to facilitate international Progression Laboratory will use his cancer in 2015, supports an early to travel to conferences and laboratories award to investigate how breast cancer mid-career Garvan researcher to test to foster their career development. evades a patient’s immune response. an innovative research idea. Dr Caldon The 2018 winners are Dr Maria Findeisen Dr Portman, Senior Research Officer will use the award to analyse which (Diabetes and Metabolism Division) in the Connie Johnson Breast Cancer proteins in breast cancer change as and Dr Nathan Zammit (Immunology Research Laboratory will use his award a tumour is developing resistance to Division). Dr Findeisen is interested to investigate how some breast cancers a promising new class of drugs called in the development of drugs to treat develop a resistance to a class of drugs ‘CDK4/6 inhibitors’. The outcome of obesity-induced metabolic disease. called hormone or endocrine therapies. this project will be the identification In December she traveled to the 18th It is hoped this will help inform strategies of potential diagnostic markers of International Congress of Endocrinology to prevent endocrine therapy resistance resistance and drug targets, with the in Cape Town, South Africa to present and to improve patient outcomes. aim of developing new clinical tools her work. Dr Zammit will spend 8-9 for advanced breast cancer. weeks at the University of Alberta in Edmonton, Canada in the lab of a William E Paul Memorial Award collaborator to learn techniques using Professor Chris Goodnow was pig pancreatic islet cells in his work on awarded the William E Paul Memorial islet transplantation for type 1 diabetes. Award by the Foundation for Primary Immunodeficiency Diseases, in Newport Beach, California.
The prestigious award recognises excellence in immunology and cell biology, and cites Chris’ seminal contributions to understanding how the body functions in autoimmune diseases.
10 2018 Garvan Annual Report Dr Liz Caldon Dr Michelle McDonald Dr Simon Junankar and Dr Neil Portman
Pancreatic cancer leader honoured The 2018 Pathfinders Award Millennium Award from in Queen’s Birthday list Dr Venessa Chin will be exploring Diabetes Australia Professor Anthony Gill FRCPA, was new ways to match therapies to lung Professor Jerry Greenfield from Garvan’s named a Member of the Order of cancer patients, thanks to support from Diabetes and Metabolism Division and Australia in the 2018 Queen’s Birthday Pathfinders – a Sydney-based collective St Vincent’s Hospital Department of Honours list. Professor Gill was group with a mission to support cancer Diabetes and Endocrinology received awarded an AM ‘for significant service research at Garvan. The Pathfinders one of two Diabetes Australia Millennium to medical research in the field of Award 2018 will enable her to kickstart Research Awards of $150,000. The surgical pathology as an academic, an innovative new project to ‘fingerprint’ award will support Professor Greenfield’s author, adviser and mentor’. A leading lung cancer – which could one day help novel study of insulin resistance in pathologist and pancreatic cancer clinicians decide on the most effective people with type 1 diabetes – a group researcher, Professor Gill holds a treatment for each patient. who have previously been thought only research position at Garvan, where he to have a defect in insulin production. chairs the Australian Pancreatic Cancer Genome Initiative, and at University Al & Val Rosenstrauss Fellowship of Sydney, where he is Professor Dr Andy Philp was awarded the Al & Val The Palmer Innovation Prize of Surgical Pathology. In addition, Rosenstrauss Fellowship, generously Provided by Joseph Palmer & Sons, he is a Senior Staff Specialist at provided by The Rebecca L. Cooper this annual prize encourages research Royal North Shore Hospital. Medical Research Foundation. Dr Philp, innovation at Garvan and recognises group leader of Garvan’s Mitochondrial the development of a product, process Metabolism and Ageing Laboratory, or technology. It was presented to Dr Eight new NHMRC fellowships aims to harness the effects of exercise Nenad Bartonicek and his team: Dr The eight Research Fellowships from into therapies for diseases of ageing. Martin Smith, Mr James Ferguson the National Health and Medical and Dr Kirston Barton. The team has Research Council to Garvan researchers The Fellowship will provide funds for formed a small company, Cerebro were in recognition of their outstanding four years. With this support, Dr Philp Biosystems, to develop a diagnostic test research into cancer and cancer will study the relationship between for microbial infections using real-time epigenetics, antibody therapies, reduced mitochondrial function and the DNA sequencing. immunology, and neurodegenerative onset of sarcopenia, and test whether disease. increasing mitochondrial function with BGP-15, a small pharmaceutical Garvan makes a splash at Professor Susan Clark FAA received a compound, can prevent the onset of Lorne Genome Conference Senior Principal Research Fellowship. sarcopenia, with the goal of finding a The Lorne Genome annual meetings Senior Research Fellowships went viable treatment strategy to combat are a highlight in the research calendar to Associate Professor Daniel Christ, sarcopenia and promote healthy ageing. for many at Garvan, and 2018 was Associate Professor Tri Phan and no exception. Scientists from across Associate Professor Alex Swarbrick. Garvan travelled to Lorne, Victoria in Career Development Fellowships were February to present their work at the awarded to: Dr Thomas Cox, Dr Marina 39th Lorne Genome Conference, and Pajic and Dr Ozren Bogdanovic. four researchers – Dr Marina Pajic from Simon Hardwick received a CJ Martin the Cancer Division, and PhD students Biomedical Early Career Fellowship. Qian Du, Ira Deveson and Katherine Giles from the Genomics and Epigenetics Division – received awards at the event.
garvan.org.au 11 12 Garvan Annual Report 2018 We see a future where we’re able to stop disease before it starts. It’s within reach.
12 2018 Garvan Annual Report garvan.org.au/bone-biology
Division Report Bone Biology
From the Head Research highlight Professor Peter Croucher Broken bones and the risk of death In the Bone Biology Division, we examine skeletal diseases, A broken bone in an older person increases their risk of death – focusing particularly on and the risk stays high for up to 10 years, according to a study osteoporosis, on rare diseases published in the Journal of Clinical Endocrinology & Metabolism. of bone, and on cancers that Hip fractures are known to increase the mortality risk, but this grow in bone. All these diseases study confirms that breaking a different bone (which accounts share profound clinical consequences, particularly fractures, for more than two-thirds of all fragility fractures) also increases which have a stark impact on quality of life and dramatically the risk. It is also the first study to report how long the worsen prognosis. I’m often struck by how our work on one heightened mortality risk lasts for different fractures. disease informs our understanding of another, and I’m proud that we communicate these insights with one another, and with Importantly, the risk of dying is highest in the year immediately researchers around the world, to accelerate progress towards after the fracture. improved outcomes for skeletal disease. “The heightened risk can last for over a decade after a hip The skeleton is anything but inert. Bone cells are constantly fracture, and for most other fractures (apart from distal or building and breaking down bone, immune cells are ‘growing minor fractures), the increased risk is for about five years,” up’ inside the bone marrow, the bone is acting on signals from said Professor Jacqueline Center, who led the study. elsewhere in the body and sending information back, and sometimes, cancer cells are taking up residence. “A fracture is the starting point for much wider health issues that persist long after the bone has healed and can ultimately For the first time, we’re in a position to explore this activity result in earlier death. Our findings emphasise just how in extraordinary detail, at the level of individual cells and crucial early intervention is. We need to understand the risk genes. We are examining the entire transcriptome (all the of breaking a bone before the fracture happens and treat genes ‘switched on’ in a cell) of cells in bone, and we are using that individual accordingly.” cutting‑edge imaging technology to watch how individual cells in bone behave, in real time and in living animals. Tran et al., J Clin Endocrinol Metab 2018;103:3205-14. doi: 10.1210/jc.2017-02656 We’re also exploring the genome of people, in combination with rich information about their bone health, to help understand which genes are most important in controlling our skeleton. Research highlight All this information will help us better predict, prevent and treat diseases of bone. The atlas of ‘osteoporosis genes’
The Bone Biology Division has a strong clinical team who A study by an international research team has compiled an focus on osteoporosis and on fracture prevention. Our dual ‘atlas’ of genetic factors associated with bone mineral density, research and clinical focus is a particular strength of our a key risk factor for fragility fractures. Published in Nature Division, and helps ensure that our research is always squarely Genetics, the study identifies over 500 sites across the human aimed at improving outcomes for individuals. genome that determine bone mineral density.
Much of our work is being made possible through the outstanding support of Mrs Janice Gibson and the Ernest Heine Family Foundation. garvan.org.au 13 Division Report Bone Biology
Professor Peter Croucher, who led Garvan’s contribution News highlight to the study, says, “This is the largest ever study of its kind – and it defines the landscape of genes that are believed to A decade of the fracture risk calculator control the amount of bone in our skeleton.” The study looked at genetic markers and bone mineral density in almost half a March 2018 marked the 10th anniversary of the Garvan million individuals from the UK Biobank. Fracture Risk Calculator. Distilled from decades of research from Garvan’s Dubbo Osteoporosis Epidemiology Study, the The findings in humans were also tested in mice and calculator is a deceptively simple tool that can uncover a showed similar changes, illustrating that these genes person’s risk of fracture due to osteoporosis. The calculator have a functional role. gets tens of thousands of visits every year and has helped transform the clinical management of osteoporosis worldwide. The study identifies many potential targets for future osteoporosis drug development. The search for new drugs In the 10 years since it was launched, the calculator has been is crucial because existing treatments cannot rebuild bone, further streamlined and refined. In particular, new findings make but only slow the rate of bone loss. it clear that when genetic information is added, the calculator can predict individual fracture risk with even greater accuracy. Morris et al., Nat Genet 2019;51:258-66; published online And in 2016, a version of the calculator was integrated into 31 Dec 2018. doi: 10.1038/s41588-018-0302-x Know Your Bones– an app that helps people to assess their own risk of fracture, and supports them to make wise health choices in discussion with their GP. Know Your Bones was Research highlight developed by Osteoporosis Australia and Garvan.
A missing link between brain, blood sugar and bone mass Bone Biology Research Laboratories and Groups
When we gain or lose weight, our skeleton has to adjust Bone Biology Lab accordingly: the heavier we are, the stronger our bones need Head: Prof Peter Croucher to be. A study by Garvan’s Bone Biology and Neuroscience Divisions has uncovered how the brain, bone and the Bone Microenvironment Group bloodstream communicate with one another to coordinate Leader: Dr Michelle McDonald weight changes and bone mass. Bone Therapeutics Lab The researchers, led by A/Prof Paul Baldock (Bone Biology) and Head: Prof Mike Rogers Prof Herbert Herzog (Neuroscience), zeroed in on a molecule called osteoglycin. Working with mice, the researchers found Imaging and Inflammation Group that osteoglycin is important in situations of changing energy Leader: Dr Marcia Munoz balance (when weight is being gained or lost). In obesity, they found, osteoglycin is blocked. This has the effect of making Clinical Studies and Epidemiology Lab more glucose available to form bone, which strengthens the Head: Prof Jacqueline Center skeleton. Conversely, in weight loss situations, osteoglycin is activated – so that the buildup of bone is limited. Genetic Epidemiology of Osteoporosis Lab Head: Prof Tuan Nguyen Importantly, osteoglycin appears to act in a similar way in people who have undergone gastric band surgery, so it may be Osteoporosis and Translational Research Lab important for regulating energy and bone mass in humans too. Head: Prof John Eisman AO
The study advances our understanding of the body’s Skeletal Metabolism Lab remarkable ability to deal with changes in energy availability. Head: A/Prof Paul Baldock
Lee et al., Mol Metab 2018;13:30-44. doi: 10.1016/j. molmet.2018.05.004
14 2018 Garvan Annual Report 2018 Spotlight Ellie’s story: From intensive care to the playground
If Ellie had been diagnosed two years The Zero Childhood Cancer team were earlier, she would have died. But the Zero then able to identify a drug that targeted Childhood Cancer trial and generous the particular genetic change. The timing Lions support mean Ellie’s story has a was just right. The drug had very recently happy ending. been discovered, and the US company Loxo Oncology agreed to provide it on Two years ago, Mina and Rob gave compassionate grounds, so treatment birth to a beautiful baby girl — Ellie. All could begin. seemed well, yet only 11 months later, Ellie was admitted to the Sydney Children’s Within four weeks of beginning treatment, Hospital, Randwick. A scan revealed Ellie’s cancer had shrunk to a point a tumour in her chest so large it was where she could breathe on her own and pushing her tiny heart and lungs to one no longer needed life support. And six side. Within days, she was on life support, weeks later, she was home. This targeted Ellie, now two, with mum Mina and no longer able to breathe. The tumour therapy also appears to be both more dad Rob. Image courtesy of the was aggressive, rare and resistant to effective and less toxic than standard Zero Childhood Cancer personalised medicine program. chemotherapy. chemotherapy.
Ellie’s case was immediately referred Now, a clinical trial of larotrectinib, the to the Zero Childhood Cancer program, drug used to treat Ellie, is open in Australia “We were told to think Australia’s child cancer personalised for all children whose cancer is identified medicine program. The world-first clinical by the Zero Childhood Cancer program about saying goodbye, she trial, led by Children’s Cancer Institute as having the same genetic marker. This was so sick we didn’t even and the Kids Cancer Centre at Sydney means that the work done to save Ellie will Children’s Hospital, Randwick, uses help other children as well. know if she would reach complex genomic tests including whole her first birthday. Today genome sequencing and dedicated One year since its launch, Zero Childhood drug discovery research to identify Cancer has produced remarkable results she is such an active and personalised treatments for children with for children like Ellie. Almost 130 children serious and aggressive cancers. with serious and aggressive cancers energetic two-year-old... have been enrolled. This state‑of‑the‑art beyond our wildest dreams. The teams jumped to find out what personalised medicine clinical trial aims was pushing Ellie’s cancer to grow so to give them the best possible chance of We can’t thank the teams at large — and how it might be stopped. survival and quality of life. Sydney Children’s Hospital Through Genome Power (the Lions Kids Cancer Genome Project, funded by the As Ellie’s mum Mina explains, “We were and Children’s Cancer Lions Clubs International Foundation told to think about saying goodbye, she and the Australian Lions childhood was so sick we didn’t even know if she Institute enough.” Cancer Research Foundation), Garvan would reach her first birthday. Today – Mina, Ellie’s Mum scientists sequenced the whole genome she is such an active and energetic of Ellie’s tumour. Then, at speed, they two-year-old... beyond our wildest dreams. worked with the Zero Childhood Cancer We can’t thank the teams at Sydney team to zero in on the specific genetic Children’s Hospital and Children’s Cancer change that was driving the cancer. Institute enough.” Whole genome sequencing and other tests identified Ellie’s cancer as infantile fibrosarcoma with a rare ‘translocation’ – a reorganisation of DNA – that was likely to be driving her cancer’s growth.
garvan.org.au 15 garvan.org.au/cancer
Division Report Cancer
From the Head Research highlight Professor David Thomas Understanding pancreatic cancer’s moving targets Our cancer program is very broad and addresses almost every cancer In a pioneering study, Associate Professor Paul Timpson and type — from the most common his team have discovered a new approach to fight treatment- to the rarest types, from cancer in resistant regions within pancreatic cancer – one of the world’s children to breast and pancreatic deadliest cancers. For the first time, they have monitored these cancer, sarcomas and many more. drug‑resistant regions in pancreatic tumours as they travel, spread and grow in real time – and are finding new ways to Cancer is fundamentally a genetic disease — and occurs neutralise these moving targets. when cells lose control of their genome and begin to proliferate wildly. It’s a disease that shifts and changes as it develops — Regions of low oxygen, which move around within tumours, irrespective of where it’s located in the body. So we need to are a hallmark of pancreatic tumours. Importantly, these come at cancer from every angle. travelling pockets of low oxygen are resistant to treatment.
We use genomic technologies including cellular genomics, To tackle this problem, Associate Professor Timpson and his complex data modeling, and devise new detection methods to team developed an innovative live tracking approach, allowing treat and ultimately prevent cancer growth. And more commonly them to observe the drug response of these treatment-resistant this means using precision medicine to target treatment at the compartments in pancreatic tumours. particular cancer types, based on the tumour’s DNA. It can also mean repurposing existing drugs to find new therapeutic targets. Beyond pancreatic cancer, these results have the potential to change the wider landscape of cancer treatment. Treatment We are collaborative by nature, and The Kinghorn Cancer Centre, resistance as a result of low oxygen is a fundamental problem which houses many of our labs and groups, aligns our research across many cancers, and these findings are likely to have a broad with cancer services at St Vincent’s Hospital, to facilitate rapid impact in paving the way to more effective cancer therapies. translation to the clinic and develop innovative approaches in personalised medicine. Conway et al., Cell Rep. 2018 Jun 12;23(11):3312-3326. DOI: 10.1016/j. celrep.2018.05.038 The main goal of The Kinghorn Cancer Centre is to realise the promise of innovative personalised medicine for people affected by cancer, which simply would not be possible without the generosity and foresight of The Kinghorn Foundation and our Research highlight visionary donors. Turbo-charging chemotherapy for lung cancer A major achievement in 2018 was the establishment of the Australian Genomic Cancer Medicine Program; see our story A naturally occurring hormone could help make chemotherapy on page 19. This program, which enrolled its thousandth patient much more effective for many Australians with lung cancer. in December, established The Kinghorn Cancer Centre as the The hormone – follistatin – also appears to prevent kidney epicentre of Australian precision oncology. damage, a serious side effect of chemotherapy.
16 2018 Garvan Annual Report Despite advances in immunotherapy for lung cancer, most patients that were not previously possible. For example, the researchers are still treated with chemotherapy based on a drug called cisplatin. watched cancer cells migrating to the liver of a mouse from the However, less than a third of these patients will see benefits, and spleen over 24 hours. Using a fluorescent biosensor, they showed they often develop serious side effects including kidney damage. that a repurposed drug interferes with how well the cells can attach to the liver. In an effort to improve outcomes for lung cancer patients, Professor Neil Watkins, Petre Chair in Cancer Biology, and Galene could help researchers study a wide range of biological his team discovered that a protein called activin is a culprit in processes in living animals. The software can also be applied to both chemotherapy resistance and chemotherapy-induced existing data to clarify blurred images. kidney damage. Warren et al., eLife 2018;7:e35800. DOI: 10.7554/eLife.35800.001 Professor Watkins says the use of follistatin is likely to be a safe and effective approach to making chemotherapy more effective in lung cancer. “Because follistatin is a hormone already found in the human body, there is much less potential for toxicity than Research highlight with other drugs used to reduce chemoresistance.” Promising new breast cancer treatment Marini et al., Sci Transl Med. 2018 Jul 25;10(451). pii: eaat3504. DOI: 10.1126/scitranslmed.aat3504 Our researchers have found a molecule that reduces the spread of cancer, slows tumour growth, increases sensitivity to chemotherapy and improves survival in mouse models.
Research highlight Surprisingly, the potential treatment targets non-cancerous cells within breast tumours, instead of the cancer itself. The team We can see living cells clearly now found that triple negative breast tumours – which are the most aggressive and have the fewest treatment options – could be A new software created here at Garvan allows us to see, far more susceptible to an existing drug. It works by stopping tumour cells clearly than ever before, what is happening in the body. from ‘talking’ with nearby normal cells, which effectively stops tumour growth. Understanding how molecules and cells behave in living animals can give us key insights into what goes wrong in diseases such The collaboration between our researchers Dr Aurelie Cazet, as cancer, and how well potential treatments for these diseases Dr Mun Hui and Associate Professor Alex Swarbrick, the Centre work. High resolution microscopy makes it possible to image for Cancer Biology (Adelaide) and GEICAM (Spain’s leading breast events happening in single cells, or even specific parts of a cell. cancer research group) was supported by funding from Love Your However, small movements like those due to the heartbeat can Sister, John and Deborah McMurtrie, the National Breast Cancer blur the images, making it difficult to study living animals. Foundation, RT Hall Trust and Novartis. The researchers will next explore whether this has potential to work on other cancer types Dr Sean Warren and his team have developed a new software tool that behave in the same way. called Galene. The tool can correct for small movements in images collected by a technique called fluorescence lifetime imaging Cazet et al., Nat Commun. 2018 Jul 24;9(1):2897. microscopy. As a result, clear images can be captured in situations DOI: 10.1038/s41467-018-05220-6
garvan.org.au 17 Division Report Cancer
Research highlight Cancer Research Laboratories and Groups
Some tumours have a pause button Clinical Cancer Research Cancer Biology Research Coordinated by Prof David Coordinated by Prof Chris When cancer cells break away from the primary tumour, they Thomas and A/Prof Elgene Lim Ormandy travel elsewhere and can grow into secondary tumours. New research from Dr Christine Chaffer and her team has uncovered a Connie Johnson Breast Cancer Cancer Biology Lab natural process in breast cancer, in which some primary tumours Research Lab Lab Head: Prof Chris Ormandy can signal the immune system to follow the breakaway cells and Head: A/Prof Elgene Lim ‘freeze’ them. In this ‘frozen’ state, the cells can’t grow effectively Cell Survival Group — thereby stopping secondary tumour growth in its tracks. Genomic Cancer Medicine Lab Leader: Dr Samantha Oakes Head: Prof David Thomas “We know the response is a consequence of the tumour eliciting Replication and Genome an immune reaction. We want to understand exactly what the Immunobiology of Stability Group tumour is releasing to activate this response, and how immune Cancer Group Leader: Dr Liz Caldon cells are targeting the secondary sites,” explains Dr Chaffer. Leader: Dr Maya Kansara Tumour Development Group The hope is that if we can exploit this signaling process in breast Genetic Cancer Risk Group Leader: Dr David Gallego- cancer, we may find controls that pause other types of cancer as Leader: Dr Mandy Ballinger Ortega well. Dr Chaffer holds the Rebecca Wilson Fellowship in Cancer Research, funded by The NELUNE Foundation. Australian Pancreatic Genome Cancer Cell Plasticity Lab Initiative Head: Dr Christine Chaffer Castaño et al., Nat Cell Biol. 2018 Sep;20(9):1084-1097. Head: Prof Anthony Gill DOI: 10.1038/s41556-018-0173-5 Cancer Developmental Clinical Prostate Cancer Biology Lab Research Group Head: Prof Neil Watkins Celebrating giving Leader: Prof Lisa Horvath Network Biology Group Vanessa Juresic: changing the world for the better Hormones and Cancer Group Leader: Dr David Croucher Leader: Dr Ann McCormack Vanessa Juresic was 36 years old and dreamt of starting a Invasion and Metastasis Lab family with her partner — instead an insidious disease ripped Head: A/Prof Paul Timpson those dreams away. Translational Cancer Research Coordinated by Dr Alex Swarbrick Matrix and Metastasis She was diagnosed with stage four triple negative breast cancer, and Prof Sandra O’Toole Group which is particularly aggressive and difficult to treat — with survival Leader: Dr Thomas Cox rates of less than 12 months if chemotherapy doesn’t help. Tumour Progression Lab Head: Dr Alex Swarbrick Personalised Cancer Ms Juresic’s friends set up a GoFundMe page to help her go on Therapeutics Lab one last adventure, but she tragically passed away on May 11. Translational Breast Cancer Head: Dr Marina Pajic It was her generous and visionary wish that the money raised Research Group should instead support the research of her oncologist and breast Leader: Prof Sandra O’Toole Single Cell and Computational cancer researcher at Garvan, Associate Professor Elgene Lim. Genomics Lab A total of $34,000 has since been raised. Head: A/Prof Joseph Powell
Her final letter to friends and family, full of life lessons and courageous advice, was read at her funeral and later shared online.
“In a world where you can be anything ... be kind. And don’t let anyone make you cruel. No matter how badly you want to give the world a taste of its own bitter medicine, it is never worth losing yourself.” – Vanessa Juresic.
18 2018 Garvan Annual Report 2018 Spotlight Taking genomic cancer medicine national
The Australian Genomic Cancer Centred at the Garvan Institute, and Medicine Program launched in July, with with the support of the NHMRC-Clinical Federal Minister for Health, The Hon. Trial Centre, this partnership will Greg Hunt MP, announcing $50 million bring together clinicians, researchers, in funding over five years — the largest government, industry and patients. ever genomics grant in Australia. The program will be made available at: An innovative clinical trial program • St Vincent’s Hospital, NSW developed at the Garvan Institute, • Peter MacCallum Cancer Centre, VIC matches therapies to individuals with rare and uncommon cancers on the • Canberra Hospital, ACT basis of their unique genetic information. • Royal Adelaide Hospital, SA The funding will enable patients based outside of New South Wales to access • Princess Alexandra Hospital, QLD potentially lifesaving clinical trials in • Sir Charles Gairdner Hospital, WA The Hon. Greg Hunt, Minister for Health their home state. • Royal Hobart Hospital, TAS “This funding is a game changer for precision cancer medicine in Australia. • Royal Darwin Hospital, NT The expansion of the program enables The program is supported by Rare patients with rare cancers to access Cancers Australia, CanTeen, Cancer this critical trial closer to home, giving Voices, Brain Tumour Alliance Australia, hope to these individuals who have Pancare Foundation, #PurpleOurWorld, exhausted all other options. Further, Ovarian Cancer Australia, CanToo and their participation will see a radical the Unicorn Foundation. Philanthropic shift in our understanding of rare and partners include Paul and Wendy Jeans, uncommon cancers to help the patients The NELUNE Foundation, AccorHotels, of tomorrow,” said Professor David Paspaley and the Vodafone Foundation. Thomas, head of the Australian Genomic Cancer Medicine Program, Director of The program has built collaborations The Kinghorn Cancer Centre and Head, with the pharmaceutical, biotech and Cancer Division at the Garvan Institute. imaging industries, including Pfizer, AstraZeneca, Eisai, LOXO, Roche and The original Genomic Cancer Medicine Prof David Thomas, The Hon. Greg Hunt, Illumina, along with local business Program was made possible by an Kate Vines and Richard Vines Linear. The AGCMP collaborates with the investment of $7 million over four years Clinical Oncology Society of Australia, by the NSW Government. Since October Genomics England, the US National 2016, over 1000 Australians with early Institutes of Health and the International “This funding is a game onset, rare and less common cancers Rare Diseases Research Consortium. changer for precision cancer have travelled from all over Australia to The Kinghorn Cancer Centre to The ability to expand this program medicine in Australia. The participate in these Garvan-led research nationwide would not have been possible studies and clinical trials. without the vital contributions of the expansion of the program patients, whose participation has laid “Rare and uncommon cancers account the foundation for the expansion of this for over 50% of cancer deaths every enables patients with rare innovative clinical trial. year, and there is high demand for the cancers to access this critical Australian Genomic Cancer Medicine Program in the community. This funding trial closer to home, giving will enable us to provide better access hope to those who have to this transformative trial, not just in Sydney but across Australia.” exhausted all other options.” – Prof David Thomas
garvan.org.au 19 We see a future where an individual’s DNA is used to prevent, diagnose and treat disease. It’s within reach.
20 Garvan2018 Garvan Annual Annual Report Report 2018 garvan.org.au/diabetesmetabolism
Division Report Diabetes and Metabolism
From the Head The study helps to clarify some of the body-wide health effects Professor Mark Febbraio of working out and also underscores just how physiologically complex exercise is. Diabetes is now classed as a pandemic – and is fast becoming Vesicles are microscopic protein-filled packages within cells that one of the biggest challenges for contain tiny bits of biological material. Released into the blood, our health system. The incidence they once were thought to hold cellular garbage, as if the cells of type 2 diabetes is increasing were heaving out their trash. But we now know that vesicles can in tandem with the rapid rise of also contain useful matter, including tiny amounts of genetic obesity. Obesity is also associated with other debilitating chronic material and proteins that convey biological messages to conditions such as cardiovascular disease, cancer, Alzheimer’s other cells. disease and asthma. The scientists found that exercise prompts the creation of The Diabetes and Metabolism Division contributes to the vesicles that somehow know to go to the liver and tell it to worldwide effort to understand the relationships between ramp up energy production. genetics, the environment and the development of diabetes. With expertise in fundamental science and clinical research, The results also provide new insights into how exercise one of our aims is to build an accurate picture of how obesity pervasively affects our metabolism. It has not been altogether precipitates diabetes. We look at the molecular and genomic clear before, for instance, how the liver knows that exercise is level as well as the interplay of diet, appetite and exercise. underway and that cells far removed from that organ need energy.
Our teams are particularly interested in how fat and sugar Whitham et al., Cell Metab. 2018 Jan 9;27(1):237-251.e4. contributes to diabetes, and how insulin fails to work properly DOI: 10.1016/j.cmet.2017.12.001 in sufferers. This will all lead to better tools to predict, prevent and treat metabolic diseases in the near future. Research highlight It has been a privilege to work at Garvan for the last three and a half years – in early 2019 I’ll be returning to Melbourne to take Deciphering dangerous messages from fat up a position at Monash University. I would like to thank everyone at Garvan, the many fruitful collaborations and my inspiring We all carry a certain amount of fat – but did you know that fat colleagues in the Division. sends messages to the immune system that can affect our risk of diabetes and other diseases? Researchers from Garvan and the Baker Institute are making sense of how these messages are Research highlight sent, and how they might be intercepted to halt the development of disease. The mysterious interior world of exercise In obese individuals, fat pushes the immune system into When we exercise, far-flung parts of our bodies communicate with ‘inflammation mode’ – but crucially, fatty tissue in leaner one another. This is due to tiny, particle-filled balloons that move individuals doesn’t have the same effect. Researchers think purposefully through the bloodstream from one cell to another, this is why such a wide range of diseases are more common carrying biochemical messages, according to an important new in the obese. study undertaken by Professor Mark Febbraio and his team.
garvan.org.au 2121 Division Report Diabetes and Metabolism
Now, an Australian research team including Garvan researchers Diabetes and Metabolism Research Laboratories and Groups has published new findings that help uncover precisely how fatty tissue in obese individuals triggers inflammation. Their Beta Cell Regeneration Lab research up-ends our understanding of how ‘obese fat’ talks to Head: Dr Daniel Hesselson the immune system – and points to new possibilities for future therapies. Beta Cell Signalling Lab Head: Prof Trevor Biden The findings open up several new approaches to halting obesity‑induced inflammation. In particular, targeting Cellular and Molecular Metabolism Lab the changes to membranes is a promising approach for Head: Prof Mark Febbraio therapeutic discovery. “This will accelerate drug discovery for type 2 diabetes and a wide range of obesity-associated Myokine Biology Group diseases,” says Professor Mark Febbraio. Leader: Dr Martin Whitham
Lancaster et al., Cell Metab. 2018 May 1;27(5):1096-1110.e5. DOI: Mitochondrial Metabolism and Ageing Group 10.1016/j.cmet. 2018.03.014 Leader: Dr Andy Philp
Clinical Diabetes, Appetite and Metabolism Lab Research highlight Heads: Prof Lesley Campbell and Prof Jerry Greenfield
Does fat drive diabetes? Clinical Insulin Resistance Group Leader: Dr Dorit Samocha-Bonet Our researchers have discovered that, beyond the liver and the pancreas, one of the root causes of diabetes may lie in Prader-Willi Syndrome and Genetic Forms of fat tissue. This could have important implications for the Diabetes Group development of treatments. Leader: Dr Alexander Viardot
Associate Professor Carsten Schmitz-Peiffer and his team Clinical Obesity, Nutrition and Adipose Biology Lab have examined the protein PKCε, long known to be involved Head: Prof Katherine Samaras in the worsening of diabetes. In mice, removing PKCε from all tissue protects them from becoming diabetic. PKCε has always Insulin Signalling Lab been assumed to be working in the liver, but upon removal in Head: A/Prof Carsten Schmitz-Peiffer the liver alone, they found the mice were not protected. Islet Biology Lab Remarkably, they have now found that removing PKCε Head: A/Prof Ross Laybutt from fat tissue protects the mice from becoming diabetic – indicating that fat tissue may be playing a major role in the progression of disease.
Currently, the team is collaborating with the Monash Institute of Pharmaceutical Sciences to develop an orally available peptide that can disrupt PKCε activity. Therapeutically targeting PKCε, and fat tissue, would be a brand new approach to treating diabetes.
Brandon et al., Cell Metab. 2018 Oct 8. pii: S1550-4131(18)30578-3. DOI: 10.1016/j.cmet.2018.09.013
22 2018 Garvan Annual Report 2018 Spotlight A pioneering partnership
“My grandfather Nicholas Paspaley Two years ago, Garvan and Paspaley founded the company and I grew formed a partnership committed up hearing stories of his generosity to progressing Garvan’s cancer and focus on community. I believe research. Through donations from its as a company we share these same Kimberley Bracelets, Paspaley provides values today. As a family, we have considerable support to Garvan’s chosen to primarily focus on causes pioneering Molecular Screening and committed to supporting children and Therapeutics clinical trail. cancer,” says Chris Paspaley, Director of Merchandise, Retail.
Paspaley created the Kimberley Bracelet – featuring sandalwood, onyx and hand-selected Paspaley pearls, Chris Paspaley and Dr Mandy Ballinger and donates 25% of the sale to cancer research at Garvan.
Dr Holly Holliday
“I had always wanted these bracelets to give back to the community, so it was natural to partner the Kimberley Bracelet with the charity that had inspired me the most. We have received an overwhelming response from this design. Each client has not only supported the initiative, but shared their stories with us, which is amazing!” – Chris Paspaley
garvan.org.au 23 We see a future where prevention is the cure. It’s within reach.
Image by Dr Kate Patterson
24 2018 Garvan Annual Report garvan.org.au/genomicsepigenetics
Division Report Genomics and Epigenetics
From the Head Research highlight Professor Susan Clark FAA The ‘city’ of cells supporting prostate tumours Epigenetics is an exciting and relatively new field of DNA A study led by Dr Ruth Pidsley and Professor Susan Clark has research. The DNA structure shed light on the cells that surround and support prostate was discovered in the 1950s, tumours. The study investigated how cells that are adjacent and it was fully sequenced in to tumours differ from those that are more remote. The team the 2000s, but interestingly found key changes in the DNA, which may explain how adjacent we still don’t fully understand how it’s read and interpreted cells change their behaviour to help tumours grow. Dr Pidsley differently in each cell type. said, “The result of our work is a new molecular map of the cellular infrastructure that the cancer cells rely on.” At Garvan, we use sequencing every day to study diseases — but we need to know more than just the DNA sequence — The hope is to use that map to understand more clearly how it’s how the code is read differently in each cell that can reveal cancer cells grow and spread, and to improve identification the influence and impacts on disease. of prostate cancer in biopsies and improve patient care. The research was done in collaboration with St Vincent’s Hospital Epigenetics provides the grammar to our DNA in the form of and Monash University. chemical modifications that are different in each cell type and influence how genes are expressed, or read, as we develop and Pidsley et al., Genome Res. 2018 May;28(5):625-638. age. DNA methylation (which compacts the DNA) and histone DOI: 10.1101/gr.229070.117 modification (which can open and close DNA) are two of these modifications we study closely. Research highlight The new tools we’re developing to sequence and read methyl and histone tags bring us closer to deciphering the blueprint Early marine animal reveals the ancient history of life, which we call the epigenome. Our big data analysis and of DNA control 3D visualisation techniques help us interpret that blueprint and how it changes in space (that is, inside the cell) and time (during A ground-breaking new study has revealed that our genomes development and ageing). have much more in common with those of ancient organisms than we ever knew. The findings were published in the Our three pillars of research in the Division are understanding world‑renowned journal Nature. the mechanisms that create the epigenome and how this is altered in disease; finding new biomarkers and tests for disease In the study, Garvan’s Dr Ozren Bogdanovic and his detection; and identifying new therapies that treat disease by collaborators focused on a type of DNA regulation process targeting the genome and epigenome. called ‘DNA methylation’ – a chemical modification of the DNA that tells genes when to switch on or off. It’s an exciting new frontier — and also a major new puzzle — a 3 billion piece puzzle, if you count all the basepairs in the The team’s deep dive into the DNA of an ancient marine human genome. Our challenge now is to map the genome and organism has uncovered that the tricks DNA uses to control epigenome for each cell type and determine how this changes gene expression – which genes are turned on and off, in disease. and when – may have originated much earlier than was previously thought.
garvan.org.au 25 Division Report Genomics and Epigenetics
The ancient, translucent fish-like organism Amphioxus spends Celebrating giving the majority of its life buried in the sand, filter-feeding a variety of plankton. Although they have a similar body plan to fish, their Anonymous Garvan donor lack of paired fins or limbs makes them quite poor swimmers. “There are many good research institutions to support; but what In Amphioxus, the researchers found the first-ever evidence really struck us as being different about Garvan was the dedication of DNA methylation as a tool to regulate gene expression in of the younger students and staff. Garvan is full of passionate young an invertebrate. researchers who devote themselves to lifesaving research and their efforts to improve the world. Hearing these inspiring scientists talk Dr Bogdanovic plans to continue investigating the link between about their fields is awesome. We know our future is safe in their vertebrates and invertebrates. “This will allow us to deepen our hands.” understanding of how DNA regulation works, and especially how it goes wrong in disease.” “So we support Garvan not only for what it is and does, but also for its commitment to support the future: for the even more Marlétaz et al., Nature. 2018 Dec;564(7734):64-70. amazing things those younger scientists are yet to do, and will do, DOI: 10.1038/s41586-018-0734-6 but for which they need our support to get them on their way.”
Research highlight Genomics and Epigenetics Research Laboratories and Groups
DNA secrets of prostate cancer in African men BioVis Centre Head: Dr Seán O’Donoghue A study led by Garvan’s Professor Vanessa Hayes (who holds the Petre Foundation Chair of Prostate Cancer Research at Garvan Epigenetics Research Lab and The University of Sydney) is the first to sequence the entire Head: Prof Susan Clark tumour DNA of African men with prostate cancer. It revealed significant differences compared to non-Africans. Prostate Epigenetic Deregulation in Cancer Group tumours in African men have more DNA changes; with, on Leader: Dr Clare Stirzaker average, a doubling of mutational burden. Along with the higher mutational burden, there was also a higher level of ‘tumour driver Histone Variants Group mutations’, changes in the DNA that drive cancer and make it Leader: Dr Fatima Valdés Mora more aggressive, and a striking absence of commonly observed non‑African tumour mutational signatures. DNA Methylation Biomarkers Group Leader: Dr Ruth Pidsley “It’s crucial that we continue to explore how our genetic ancestry might affect our response to treatments, so that the full benefits Genome Informatics Lab of personalised medicine reach as many people as possible,” Head: A/Prof Marcel Dinger says Professor Hayes. Human Comparative and Prostate Cancer Genomics Lab Prostate cancer is particularly lethal in Africa: within five years Head: Prof Vanessa Hayes of diagnosis, five in 20 African men will lose their lives, compared to one in 20 Australian men. Transcriptomic Research Lab Head: Dr Timothy Mercer The research was done in collaboration with St Vincent’s Hospital, as well as the Universities of Limpopo and Pretoria Developmental Epigenomics Lab in South Africa. Head: Dr Ozren Bogdanovic
Jaratlerdsiri et al., Cancer Res. 2018 Dec 15;78(24):6736-6746. Molecular Genetics of Inherited Kidney Disorders Lab DOI: 10.1158/0008-5472.CAN-18-0254. Head: Prof John Shine
26 2018 Garvan Annual Report 2018 Spotlight A national genomics mission for Australia
The May Federal Budget announced • analytical power backed by national a $500 million genomics mission standards and protocols that ensure for Australia. The new mission secure data holdings, access, analysis seeks to save or transform the lives and sharing to benefit Australians. of more than 200,000 Australians through research into better testing, The mission’s first project will be diagnosis and treatment. the ‘Mackenzie’s Mission’ – a new $20 million trial in pre-conception The Australian Genomics Health Futures screening for rare and debilitating Mission was announced as part of genetic birth disorders. the 2018 Federal Budget. It forms the cornerstone of the $1.3 billion National Funding for the genomics mission will Health and Medical Industry Growth Plan. be sourced from the Medical Research Future Fund, and is the largest single The Department of Health says the disbursement to date from the fund. “This is a vital and timely $500 million mission will involve the following: Professor Chris Goodnow says that a national initiative, with national approach to genomic medicine • new and expanded clinical flagship is just what the doctor ordered for immense opportunity to studies to tackle rare diseases, rare Australia. improve Australians’ lives.” cancers and complex conditions; “This is a vital and timely national – Prof Chris Goodnow • new clinical trials and technology initiative, with immense opportunity applications allowing Australian to improve Australians’ lives. patients to benefit from the latest medical research; “Some things are best handled at scale. This new initiative gives us • increased academic and researcher all the opportunity to contribute to collaboration and new career pathways; something great, and take a truly strategic approach to the development • co-investment with philanthropy and of genomic medicine.” business to support new industries;
• community dialogue to better understand the value of genomics and gain appreciation of the privacy, legal, social and familial impact; and
garvan.org.au 27 garvan.org.au/immunology
Division Report Immunology
From the Head Research highlight Professor Stuart Tangye Your secret immunity weapon The immune system can hold the balance between health and For years, they’ve had a bad rap – a mysterious population of disease. An extremely complex cells in the immune system once thought to cause harm. But and sophisticated system, it plays Professor Chris Goodnow, Associate Professor Daniel Christ, a role in almost every disease – Dr Deborah Burnett and others from our Immunology Division from a common cold, to cancer have discovered that these antibody-producing cells (B cells) or a rare genetic disorder. could be a potent weapon against invading microbes. These ‘bad apples’ of the immune system are also its secret weapon, On the one hand, an overactive immune system results according to research published in the world-leading journal in immune dysregulation, manifesting as autoimmune Science. (rheumatoid arthritis, type 1 diabetes, lupus) or allergic diseases. On the other hand, an underactive immune system These B cells produce antibodies that bind to the body’s own can cause immunodeficiencies and recurrent infectious disease. tissues, meaning they could actually cause autoimmune disease. So why would the body keep them alive in the first In addition to studying autoimmune diseases, we’re also place? The new findings reveal these cells may be crucial to investigating the mechanics of donor organ rejection, fighting threats that trick our immune system by mimicking genetic defects and inflammatory diseases; and we’re the body’s own proteins. These immune cells can be activated committed to developing new drugs for immune-related to attack when required. Our researchers hope these cells will diseases. By leveraging the immune system’s natural one day be the basis of vaccines for viruses that hide from the signaling to eradicate cancer cells, we’re seeing great strides immune system, such as HIV. in immunotherapy as a cancer treatment. When combined with genomically targeted therapies, outcomes for patients Burnett et al., Science. 2018 Apr 13;360(6385):223-226. with cancer could still be further improved. DOI: 10.1126/science.aao3859
It is an incredibly exciting time to be an immunologist, because we’re at a point where immune research can rapidly Research highlight impact clinical medicine, diagnosis and disease management. This is why we’ve developed several large-scale, human-centred Found: a new form of DNA research programs that interface directly with clinicians and their patients. The Clinical Immunogenomics Research In a world first, our researchers Associate Professor Daniel Consortium Australia (CIRCA) for example is reaping significant Christ, Associate Professor Marcel Dinger and Dr Mahdi Zeraati rewards and having major impacts in the clinic. found a new DNA structure – a twisted ‘knot’ they call the i-motif – inside cells. We have a great breadth of knowledge within the Division and we’re uniquely placed to undertake basic, translational The iconic ‘double helix’ shape of DNA has captured the public and clinical research. CIRCA achieves this by collaborating imagination since 1953. We know that DNA can exist in a few with major hospitals, as well as prestigious international other shapes – in a test tube, at least. Until now, the i-motif research institutes, to understand the immune system in the had never before been directly seen inside living cells. In fact, setting of health and disease, and devise better treatments scientists had debated whether i-motif ‘knots’ would exist at all for immunological diseases. – a mystery that is now solved.
28 2018 Garvan Annual Report To detect the i-motifs, the researchers developed a precise Students engaged with a range of scientists at different stages new tool – a fragment of an antibody molecule – that could of their careers, each with a different story about how they got specifically recognise and attach to i-motifs with a very high to where they are now. affinity. Until now, the lack of an antibody that is specific for i-motifs has severely hampered our understanding of their role. Events like the Day of Immunology help support science education by providing a unique experience that places The researchers showed that i-motifs mostly form at a students at the heart of biomedical research. particular point in the cell’s life cycle – the late G1 phase, when DNA is being actively ‘read’. They also showed that i-motifs appear in some promoter regions (areas of DNA Research highlight that control whether genes are switched on or off) and in telomeres, the end sections of chromosomes that are New ‘micro-organ’ hiding in plain sight important in the ageing process. For the first time in decades, researchers have identified Zeraati et al., Nat Chem. 2018 Jun;10(6):631-637. a new anatomical structure within the immune system – DOI: 10.1038/s41557-018-0046-3 and an important step towards understanding how to make better vaccines.
News highlight Using sophisticated high-resolution 3D microscopy in living animals, Associate Professor Tri Phan and his team identified Engaging a new generation of researchers where immune cells gather to mount a rapid response against an infection in the body. These subcapsular proliferative foci Garvan’s researchers and Sydney high school students (or SPFs) were found inside sections of lymph nodes. This is came together to explore immunological research and to the first time these structures have ever been seen, and they discuss rapidly evolving careers in STEM research. The 60 were uncovered using technology developed at Garvan. high school science students came to participate in Garvan’s Day of Immunology event – a day of hands-on exposure to The researchers could see that several classes of immune cells research and research careers, with a focus on all things gather together in the new structure – including memory B cells, immune system-related. which carry information, or ‘memories’, about how best to attack an infection. They could also see that memory B cells were In each laboratory, students came to grips with cutting-edge changing into infection-fighting plasma cells. This is a key step biomedical research techniques that played out in real time in the fight against infection. – helping them understand how laboratory science can be translated into the treatment of real diseases. The discovery helps us understand the body’s response to an infection it’s been exposed to before. This could eventually help For event organisers Dr Joanne Reed (Group Leader us to make better vaccines. The study was made possible by in Rheumatology and Autoimmunity), Dr Angelica Lau generous support from Peter and Val Duncan. (B Cell Biology) and Julia Kiss (Public Engagement Officer), highlighting the possibility of a career in research was key Moran et al., Nat Commun. 2018 Aug 22;9(1):3372. to the day’s activities. DOI: 10.1038/s41467-018-05772-7
garvan.org.au 29 Division Report Immunology
Research highlight make a difference. Since meeting Professor Chris Goodnow and the leadership team, I have found them to be humble and Gene-hunters make sense of a new inspirational. We have absolute confidence that they will make immune disease a difference.
Researchers from Garvan collaborated with Rockefeller “Medical research is exploding as technology and data University (New York) and the Imagine Institute (Paris) to tackle analysis can now identify correlations previously unseen. an obscure disorder, first identified in eight individuals from Our expanding knowledge of the human genome for instance around the world suffering from the same unique symptoms. has confirmed that old age is a disease and not an outcome; and that age-related diseases are treatable. Suffering in others “These individuals had severe weaknesses in their body’s is very painful, and so medical research is the key to extended, defenses,” says Professor Stuart Tangye, who led the Garvan- healthier and more satisfying lives. based arm of the project. “They were incredibly susceptible to fungal and bacterial infections, they presented with severe “Garvan and other centres of research should be better understood allergies, and had a poor response to vaccination – it was clear by the broader public as their work can change everybody’s lives. their immune system was compromised.” Garvan also demonstrates the importance of globalised research — and Australia’s intellectual contribution to that is only constrained At Rockefeller University and Imagine Institute, Professor by support and not by talent.” Jean-Laurent Casanova and his team tracked down the faulty gene at the root of this disease – a brand new, previously Mr and Mrs Allen are generously supporting Hope Research: a unidentified gene, known asZNF341 . research program to find the underlying cause of autoimmune disease. Find out more: www.garvan.org.au/hope-research “To understand why this mutated ZNF341 gene was causing disease, we needed to figure out what this gene does normally, and how errors in ZNF341 were disrupting these patients’ ability Immunology Research Laboratories and Groups to fight off infections and build their immunity.” Antibody Therapeutics Lab Immunology and Through functional studies, Professor Tangye and his team Head: A/Prof Daniel Christ Immunodeficiency Lab discovered that a faulty ZNF341 gene leads to a ‘hole’ in Head: Prof Stuart Tangye immune defenses. Patients lack certain types of immune B Cell Biology Lab cells, which means they struggle to fight some infections Head: Prof Robert Brink Human Immune Disorders and acquire immunity. Also, they have an abundance of a Group different type of immune cell – which leads to severe allergy. Genomic Engineering Group Leader: A/Prof Cindy Ma Leader: Dr David Zahra “Successfully treating a disease requires more than just Innate and Tumour treating the symptoms,” adds Professor Tangye. “We can only Cellular Immunity Lab Immunology Lab begin to treat patients effectively when we understand the Head: Prof Jonathan Sprent Head: Dr Tatyana Chtanova cause. Finding the faulty gene raises the possibility of using tailored, gene-specific therapies to treat the disease at its core.” Immune Tolerance Group Intravital Microscopy Lab Leader: Dr Kylie Webster Head: A/Prof Tri Phan Béziat et al., Sci Immunol. 2018 Jun 15;3(24). DOI: 10.1126/sciimmunol.aat4956 Immunogenomics Lab Lymphocyte Signalling and Head: Prof Chris Goodnow Activation Lab Head: A/Prof Elissa Deenick Celebrating giving Rheumatology and Autoimmunity Group Mucosal Autoimmunity Lab Mr Ken Allen AM and Mrs Jill Allen Leader: Dr Joanne Reed Head: A/Prof Cecile King
“We’ve been aware of the Garvan Institute as a global centre Transplantation of medical research for quite some time. Its reputation for Immunology Lab ground-breaking research, as well as a personal interest in one Head: A/Prof Shane Grey particular disease that has impacted our family, compelled my wife Jill and I to help Garvan and the Hope Research team Immunopathology Group Leader: A/Prof William Sewell
30 2018 Garvan Annual Report 2018 Spotlight UNSW Cellular Genomics Futures Institute launches
The Garvan-led UNSW Cellular The sheer amount of data that will Genomics Futures Institute is set to be generated from each of many accelerate research in cellular genomics thousands of cells requires data and single-cell sequencing – and to analytical tools, machine learning uncover new targets and treatments and data visualisation techniques for disease. that will be developed through the multi‑disciplinary nature of the UNSW The UNSW Futures Institute will focus on Cellular Genetics Futures Institute. the new technology of cellular genomics, which seeks to characterise the genetic “I’m delighted that Garvan is playing a outputs of individual cells, thousands of crucial leadership role in this new UNSW cells at a time. Futures Institute, which will tackle major challenges in single-cell genomics – Professor Chris Goodnow, Garvan’s the next great revolution in medicine,” Executive Director, is the inaugural says Professor Goodnow. Director of the UNSW Cellular Genomics Futures Institute, and Associate Associate Professor Powell adds, Professor Joseph Powell, Head of the “The new UNSW Futures Institute is Garvan-Weizmann Centre for Cellular a fantastic recognition of Garvan’s “I’m delighted that Garvan Genomics, is the Deputy Director. leadership in cellular genomics through The Institute also brings together the Garvan-Weizmann Centre for is playing a crucial UNSW’s researchers from across Cellular Genomics, and it provides an medicine, science, and engineering, outstanding opportunity for Garvan leadership role in this new including from the Ramaciotti Centre to work more closely with UNSW to UNSW Futures Institute, for Genomics and the Kirby Institute. drive the translation of our research in cellular diagnostics and therapies Cellular genomics aims to overcome to health outcomes. which will tackle major a major stumbling block in the study of human cells in health and disease. “Importantly, the UNSW Futures Institute challenges in single-cell Many diseases, such as cancers and is set to accelerate the work of the genomics – the next great autoimmune diseases, arise from Garvan-Weizmann Centre, which was changes in only one or a few cells in the launched last year and whose research revolution in medicine.” body. But, until recently, technological is exploring which individual cells limitations have meant that we couldn’t contribute to the progression of diseases – Prof Chris Goodnow look directly at the genetic output of such as cancer, autoimmune disease those rare cells. Instead, researchers and neurodegenerative disorders and have had to look at millions of cells how these cells develop.” homogenised together, severely limiting The UNSW Cellular Genomics Futures what can be learned about the cells that Institute is one of four UNSW Futures initiate disease. Institutes to launch this year. The other three UNSW Futures Institutes focus on ageing, global energy systems and materials and manufacturing.
garvan.org.au 31 Garvan Annual Report 2018
We see a future where health is transformed. It’s within reach.
32 Garvan2018 Garvan Annual Annual Report Report 2018 garvan.org.au/neuroscience
Division Report Neuroscience
From the Head Published in the journal Molecular Cell, the method, called Associate Professor ‘Whippet’, has the potential to bring RNA sequencing closer Antony Cooper to the bedside. Previous methodologies were data and time intensive, with analysis taking several days and gigabytes of The brain is probably the most data. Whippet promises to process a reading within 30 minutes complex organ in the body – and can be done on a laptop. This can lead to faster, more and diseases associated with accurate diagnoses for a range of conditions. the brain such as Parkinson’s, Alzheimer’s, eating disorders – Understanding the function of genetic variants (or differences have devastating symptoms and consequences. in our DNA code) associated with any disease is essential for determining the cause and progression of disease and the best In the Neuroscience Division we seek to understand the way to detect, treat and prevent it. Many of the genetic variants molecular mechanisms that drive changes in the brain. This associated with disease currently have an unknown function. includes the ways nerve cells communicate with each other and Whippet has the potential to read RNA quickly and accurately what goes wrong in disorders like neurodegenerative disease. which is essential to understanding the mechanisms that underpin neurological, and many other, diseases. The finding We utilise many techniques, including molecular biology, also opens the field of RNA sequencing for exploration in large genomics, transgenic animal models, sophisticated imaging populations and cohort trials. and testing. We hope to find ways to regenerate the nervous system and to better understand the brain’s control of body Sterne-Weiler et al., Mol Cell. 2018 Oct 4;72(1):187-200.e6. functions, particularly the regulation of energy balance DOI: 10.1016/j.molcel.2018.08.018. (intake and expenditure), which can affect mood, weight gain and physical fitness. Research highlight The more we think we know about the brain, the more we uncover new areas and find connections to explore. This is Could a brain switch jumpstart ‘brown fat’ action? why we collaborate extensively internationally, and of course locally and within Garvan, to pool our expertise and make A team led by Professor Herbert Herzog has uncovered a progress in these dreadful diseases. way our brain keeps us safe by helping maintain a stable bodyweight – and what it does when things go awry. The Translating our research into the clinic is particularly urgent findings, uncovered in mice, reveal how we might rev up the because people with these diseases are desperate to find brain’s ‘panic switch’ for good in the face of an obesity crisis. treatment options that work – especially at the late stage where they’re often diagnosed. “If you’re starving and losing weight, your brain shuts down energy-consuming processes it deems non-critical, like bone formation and reproduction. It puts all its resources Research highlight to keeping every inch of fat,” says Professor Herzog, whose team led the study. New method for RNA analysis “On the other hand, if you continuously over-eat, your brain Dr Robert Weatheritt, with collaborators at the University recognises there’s excess energy and since too much stored of Toronto, published a new method for rapid and accurate fat is dangerous, it has systems in place to get rid of excess reading of RNA data. RNA, or ribonucleic acid, is an important calories in a different way.” messenger linking our genome – the entire DNA code – to proteins, the machinery of the cell. garvan.org.au 3333 Division Report Neuroscience
One of those systems is so-called ‘brown fat’. Recent discoveries Celebrating giving into brown adipose tissue are redefining the meaning of ‘good fat’. It’s remarkable for its ability to burn excess calories as heat Howard Houliston — instead of storing them, leading to weight gain. Howard Houliston has donated to Garvan every month since It’s known to be activated by cold temperatures, but it’s also 2009, and also generously contributes his time and expertise to activated by diet. the Foundation. He’s a strong believer in the value of helping.
Diet switches on brown fat through a receptor called NPFFR2. “I started volunteering at Garvan as a result of my then employer, A closer look at NPFFR2 revealed it controls the alarm bell: a who advocated employees to do volunteer work. protein known as NPY — which goes off when there are drastic changes in weight. “I support several charities, but feel that medical research to prevent disease is better than letting a disease happen and then trying These findings suggest that fine-tuning the NPFFR2 signal — to address the problem. We should certainly help people who are and NPY as a result — could be a way to maximise brown fat suffering, but also try to prevent that suffering wherever we can.” activation, and help burn excess energy before it’s stored as fat.
Zhang et al., Nat Commun. 2018 Nov 9;9(1):4722. Neuroscience Research Laboratories and Groups DOI: 10.1038/s41467-018-06462-0. Eating Disorders Lab Head: Prof Herbert Herzog News highlight Energy Expenditure Group Inaugural Scrimshaw Fellow appointment Leader: Dr Lei Zhang
Dr Robert Weatheritt was named the inaugural Scrimshaw Neuroendocrinology Group Fellow at the Paspaley boutique in Sydney’s Martin Place Leader: Dr Yanchuan Shi in December. Paspaley have been long-time philanthropic supporters of the Garvan Institute. Hearing Research Lab Head: Prof David Ryugo Robert will head the Neurotranscriptomics Laboratory, as an EMBL Australia Group Leader within the Institute. Brain Circuits for Hearing Group His focus is on unravelling the complexity of human Leader: Dr Michael Muniak brain development and uncovering what happens when it goes wrong. Parkinson’s Disease and Neurodegeneration Lab Head: A/Prof Antony Cooper “I am delighted to be able to support a scientist as innovative and inquisitive as Dr Weatheritt as he continues his research at Epitranscriptomics and RNA Dynamics Group the Garvan Institute,” said Russell Scrimshaw, who along with his Leader: Dr Eva Maria Novoa Pardo wife Sue, established the Scrimshaw Fellowship and is Chairman of the Garvan Research Foundation Board of Directors. “As the Neurotranscriptomics Lab complexities of the human brain begin to be more fully understood, Head: Dr Robert Weatheritt Dr Weatheritt’s research will be vital to help uncover the root of neurodevelopmental disorders.”
34 2018 Garvan Annual Report 2018 Spotlight Microsoft cloud computing grant to support Garvan’s genomic research
Microsoft is supporting the development “We are working with people’s sensitive of Garvan’s Genetic Index, through an health information, so it’s crucial we use Azure high performance computing grant. best practice to secure this data and actively seek collaborators for whom The Genetic Index is a resource for the this is a priority,” said Dr Kaplan. international scientific community that will include summary data of 5,000 whole The Genetic Index is part of an extensive human genomes. Thanks to the Microsoft suite of genomics-focused research Azure grant, Garvan is planning to perform initiatives at Garvan that seek to impact complex production bioinformatics for on human health, including DreamLab, these genomes on the Azure Australia the Australian Genomic Cancer Medicine Central cloud. Program, the Garvan‑Weizmann Partnership and the Clinical “With Microsoft’s support, Garvan will Immunogenomics Research Consortium Dr Warren Kaplan and James Kavanagh, Microsoft Azure further accelerate our genome research, Australia (CIRCA). Engineering Lead and help to bring closer a new and important era of healthcare,” said Dr Warren Kaplan, Chief of Informatics at Garvan’s Kinghorn Centre for Clinical Genomics.
“With Microsoft’s support, To support genomic discovery Garvan will further internationally, the Genetic Index will be made available to researchers around accelerate our genome the world. Researchers will be able to get insights into the genetic basis of research, and help to bring health and disease by looking up the closer a new and important frequency of genetic changes in the index. For example, if a change is rare, this could era of healthcare.” be evidence that it contributes to a disease, whereas a common change is less likely – Dr Warren Kaplan to be damaging.
garvan.org.au 35 garvan.org.au/kccg
Centre Report Kinghorn Centre for Clinical Genomics
In 2018, A/Prof Sarah Kummerfeld and Mary-Anne Young were News highlight appointed as the Scientific and Clinical Heads of the Kinghorn Centre for Clinical Genomics (KCCG), respectively, to provide New resource for clinical genomics research strategic direction and oversee the current and future activities. Sarah’s expertise is in computational biology and bioinformatics, The Clinical Genomics Research Resource – an online tool with experience spanning both academic and industry research. – aims to introduce clinicians and clinician-researchers to Mary-Anne is an eminent clinical and research genetic counselor genomics research and familiarise them with key considerations in Australia and has contributed to genomics policy-making and for conducting clinical genomics research. strategic direction at a national level. It walks users through key considerations for clinical genomics From the Heads research, covering topics like ethics, participant interactions and the multidisciplinary team. It also addresses project and As the two new co-heads of KCCG, we’re looking forward to experimental design, and the challenges associated with leading the Centre to advance the use of genomic (and other different genomic technologies and genomic data. The content -omic) information in patient care. Our combined knowledge, includes links to professional guidelines and case studies to skills and experience extends from basic research with massive allow users to apply their knowledge. cohorts at the intersection of basic research and translation, right through to clinical implementation. This important resource recognises the complexity of genomic research and the challenges that result from the sheer volume In 2016, Garvan’s KCCG was proud to herald a new era in genetic of data and the sensitive nature of genomic information. diagnosis with the launch of Genome.One – Australia’s first clinical whole-genome sequencing service. We’re pleased that in The resource was developed by Bioplatforms Australia, the November 2018, Australian Clinical Labs, a national pathology NSW Health Centre for Genetics Education and KCCG with company, acquired the Genome.One name and business model support from the NSW Ministry of Health Office of Health and from Garvan. Garvan’s partnership with Australian Clinical Labs Medical Research. enables genetic pathology company Genome.One to continue and expand its clinically accredited genomic sequencing reports. The Clinical Genomics Research Resource can This is a fantastic outcome and KCCG maintains a relationship be accessed on the Centre for Genetics Education with Genome.One, providing sequencing capabilities and website: www.genetics.edu.au/genomic translating its high-level genomic research into clinical practice, including novel tests and tools for improving quality and efficiency in genomic testing. Research highlight
We are grateful to Mr and Mrs John and Jill Kinghorn and Clinical genome filtering platform The Kinghorn Foundation for their catalytic and ongoing now available worldwide philanthropic investment in the Kinghorn Centre for Clinical Genomics and the next generation of omics-led research. This year, Garvan made its web platform Seave available to researchers and clinicians around the world. Seave is an online ‘genome filtering’ tool that helps pinpoint which DNA changes in an individual’s genome are likely to be the underlying cause of disease.
36 2018 Garvan Annual Report Mary-Anne Young A/Prof Sarah Kummerfeld
Seave was built by Dr Velimir Gayevskiy and Dr Mark Cowley The research looked at the entire genetic make-up of 42 patients in KCCG. An online platform, Seave supports and streamlines with dilated cardiomyopathy. The inherited heart disease genome filtering. may affect up to 1 in 500 Australians and causes the heart to enlarge and weaken. It is also the most common reason “When we sequence the genome of someone with undiagnosed for heart transplantation. disease, that’s just the beginning of the journey,” says Dr Cowley. “It’s the next steps – the analysis and interpretation of the After two decades of heart disease research and three DNA sequence – that are the most complex and difficult part years of genetic analysis, the study found there are clear of the process of finding a genetic diagnosis. Because of the benefits of using a whole genome sequencing test to help way Seave can sift through genomic information, it’s a hugely diagnose cardiomyopathy. In particular, it is a sensitive, and helpful tool for speeding the path to a diagnosis.” more comprehensive test than is currently used clinically, and it provides rich additional information that is likely to be The name ‘Seave’ was chosen to evoke the idea of sieving valuable in the future. and filtering genomic information. Minoche et al. Genetics in Medicine, 21(3), 650-662. It is already being used widely by clinicians and researchers DOI: 10.1038/s41436-018-0084-7 to help them diagnose and better understand many genetic conditions. Through the Sydney Genomics Collaborative, researchers are using Seave to investigate cardiovascular, Celebrating giving retinal, renal, movement and mitochondrial disorders, epilepsy, and rare and genetic conditions. Supporting research – Trevor Guest
Gayevskiy et al., Bioinformatics. 2019 Jan 1;35(1):122-125. “At my best friend’s funeral in 2013, I gave a donation to Garvan DOI: 10.1093/bioinformatics/bty540 in lieu of a floral tribute. I was subsequently invited to tour the Garvan facilities and The Kinghorn Cancer Centre. That tour was hosted by Professor John Shine — he was wearing his white lab Research highlight coat and I had no idea then that the previous Executive Director of Garvan was giving of his time to explain the operations of a A better test for heart disease in high-risk families huge medical research organisation. I was overwhelmed by the size and the high quality of Garvan’s medical research facilities. This year, researchers from Garvan and the Victor Chang I immediately committed to being a Partner for the Future Cardiac Research Institute harnessed the power of DNA to through a recognition of Garvan in my Will. detect the deadly heart disease dilated cardiomyopathy – long before symptoms arise. In the largest patient study of its kind, a “Since my initial commitment, I decided to personally support collaborative investigation put whole genome sequencing to the a number of Garvan’s medical research programs, the most test, measuring its effectiveness as a first-line clinical diagnostic recent being towards the Genomic Cancer Medicine Program. tool for dilated cardiomyopathy, an inherited heart disease. I’m also very interested in Garvan’s research into rheumatoid arthritis, as my daughter Sharon has the disease.
“I regard the Garvan Institute as a leader in its field, with respect to ongoing communication of Garvan’s discoveries to the public and to its base of loyal donors.”
garvan.org.au 37 garvan.org.au/garvan-weizmann
Centre Report Garvan-Weizmann Centre for Cellular Genomics
From the Head Mr John Roth and Ms Jillian Segal AO, Mr and Mrs Laurie Associate Professor and Di Sutton, The Johnny Kahlbetzer Family — and our many Joseph Powell generous donors to the Garvan-Weizmann Partnership.
Following its creation in 2017, the Garvan-Weizmann Centre for Research highlight Cellular Genomics has evolved into one of the most sophisticated How do you mend an injured heart? cellular genomics facilities in the world. Hearts can’t fix themselves. But Associate Professor Joseph Powell and collaborators from the University of Queensland have Cellular genomics is a revolutionary technology that’s uncovered a huge amount of previously hidden information that transforming biological and medical research. may teach the heart to repair itself.
Where whole genome sequencing is the study of all our DNA The in-depth study revealed how human stem cells can be turned averaged over millions of cells, cellular genomics is the study of into heart cells. The work involved measuring changes in gene the genetic makeup of a single cell – from the cell’s entire DNA activity, using cellular genomics, in tens of thousands of individual code (its genome), to the secondary code that organises the cells as they move through the stages of heart development. To genome (its epigenome), and the total genetic output of the cell explore this process, the researchers mimicked, in the lab, how (its transcriptome). a heart develops in the embryo. They started with skin-derived human stem cells (from adults), which are capable of becoming Garvan-Weizmann’s cutting-edge cellular genomics technologies any cell type in the body. They were able to guide the cells, over make it possible to unlock and discover how cells work individually, time, and reprogram them to become heart cells (cardiomyocytes). and how they function together. We can see answers within cells in ways that were impossible only a few years ago. Sometimes a “We are now investigating at what stages during heart single cell amongst thousands can drive a disease reaction. development, and in what cell subtypes, the genetic risks of cardiovascular disease become most dangerous,” The Centre is one of the few global sites where state-of-the-art says Associate Professor Powell. technologies are seamlessly integrated under one roof, including the latest platforms in flow cytometry, microfluidics, genomics, Friedman et al., Cell Stem Cell 2018 Oct 4;23(4):586-598.e8. high-performance computing and bioinformatics. Importantly, DOI: 10.1016/j.stem.2018.09.009. the Centre’s expert researchers and their strong links with clinical services accelerates the capability for single cell sequencing to be at the core of translation into new diagnostic tests and Research highlight precision treatment. Hope grows: finding the cause of autoimmune It is a priviledge to work closely with the Weizmann Institute of disease Science in Israel and Weizmann Australia through our prolific Garvan-Weizmann Partnership. We are grateful for the vital Autoimmune diseases – such as type 1 diabetes, multiple support from the NSW Government, our visionary donors: sclerosis, lupus, rheumatoid arthritis – develop when the body’s own immune system becomes overactive and begins to attack itself.
38 2018 Garvan Annual Report Hope Research is based on a premise first proposed by Professor Celebrating giving Chris Goodnow, more than 10 years ago – that ‘rogue’ clones cause autoimmunity. At the time, he couldn’t prove his theory Bob and Ruth Magid because the necessary technology didn’t exist. It now does, in the Garvan-Weizmann Centre for Cellular Genomics. In June, Bob and Ruth Magid generously donated $1 million to the Garvan-Weizmann Partnership to establish the Magid Fellow. Bob The project will tackle more than 40 different autoimmune said genomic medicine was not a field they had focused on before. diseases, where researchers already have a clear idea of how to “Our daughter, who lives in Israel, has become very close with the identify and isolate rogue cells or ‘clones’ using cellular genomics. Weizmann Institute there, so we decided to visit it, and we also toured the new Garvan-Weizmann Centre in Sydney.” This project has received funding from philanthropists and other funding bodies, including The Bill and Patricia Ritchie Foundation, “We left feeling very impressed by the researchers and the amazing Multiple Sclerosis Research Australia, Scleroderma Australia and work they’re doing. The fact they can look at a person’s DNA – the National Health and Medical Research Council. right down to the single cell level – and the potential that has for medical science, is amazing.” Find out more: www.garvan.org.au/hope-research Stephen Chipkin, Chair of the Weizmann Australia Board, described the donation as ‘a gift to the world’ because of the far-ranging Research highlight impact of genomic medicine advancements. “This funding of genomics research between these two great research institutes 2018 in the Garvan-Weizmann Partnership will not only help build a strong bridge between Australia and Israel – the medical research outcomes will be for the benefit The Garvan-Weizmann Centre for Cellular Genomics is the of all humankind.” cornerstone of the broader Garvan-Weizmann Partnership. In addition to cellular genomics research programs, the Garvan- The visionary donation will facilitate a new recruit under the Weizmann Partnership includes research collaborations in other leadership of Associate Professor Joseph Powell in the field of fields and education and visualisation programs, as well as cellular genomics and bioinformatics. The Magid Fellow will staff and student exchanges. travel between the two Institutes to accelerate collaborations and research discovery. Throughout 2018, we have:
• Sequenced 3,465,193 single cells, in 28 research projects, over 21 labs
• Hosted 6 staff and student exchanges between Australia and Israel
• Enrolled more than 1,500 patients onto clinical trials and studies within the Garvan-Weizmann Partnership
• Strengthened collaborations between 21 researchers at the Garvan and Weizmann Institutes.
garvan.org.au 39 Garvan Institute of Medical Research Board of Directors 2018
John Schubert AO – Chris Goodnow FAA FRS Chair (from May)
Dr Schubert is Chairman of Professor Chris Goodnow is the Garvan Institute of Medical an internationally renowned Research, Chairman of the Great immunologist. He joined Garvan in Barrier Reef Foundation, and a 2015 as Deputy Director, the Bill & director of the Garvan Research Patricia Ritchie Foundation Chair, Foundation Board. He has held and head of the Immunogenomics positions as Chairman of the Commonwealth Bank of Australia, Laboratory. Chris has had an extensive international research non-executive director of BHP Billiton Limited, BHP Billiton Plc, career. He has been a faculty member at Stanford University and and Qantas Airways Limited, Chief Executive Officer of Pioneer the Australian National University, and has been closely involved International Limited, Chairman of WorleyParsons Limited and in several biotechnology start-up companies. He is best known G2 Therapies Ltd, Chairman and MD of Esso Australia Ltd, and for discovering immune tolerance checkpoints by integrating non-executive director of Hanson Plc. molecular genetics and genomics with immunology, for which he received numerous awards and election to the Australian Academy of Science, the UK Royal Society, and the US National Annabelle Bennett AO SC Academy of Science.
The Hon. Dr Annabelle Bennett was until recently a Judge of Stephen Johns the Federal Court of Australia. She is presently Chancellor of Mr Johns is Chairman of Bond University, President of Brambles Limited and non- the Anti-Discrimination Board of executive director of Goodman NSW, Chair of Landservices SA, Group. He is a former chairman Arbitrator with the Court of Arbitration for Sport, and Chair of and non-executive director of the Australian Nuclear Science and Technology Organisation. Dr Leighton Holdings Limited and Bennett has extensive knowledge and experience in intellectual Spark Infrastructure Group, and property arising from her position as a Judge, as a senior former executive and non-executive director of Westfield Group. counsel specialising in Intellectual Property and as President of He has a Bachelor of Economics degree from the University of the Copyright Tribunal. Sydney and is a Fellow of the Institute of Chartered Accountants in Australia and the Institute of Company Directors.
Annette Cunliffe RSC Anne Keating Sister Annette was the Sisters of (to September) Charity Congregational Leader. She has been President of Ms Keating is the Chairman of the Conference of Leaders of Houlihan Lokey, Australia, an Religious Institutes, President investment bank, and a governor of Catholic Religious Australia, of the Cerebral Palsy Research Inaugural Chair of the Stewardship Foundation. She has served on Board of Catholic Health Australia, and a senior lecturer at the many public company boards Australian Catholic University. Until the end of 2018 she was in various sectors over the last 24 years including two medical one of two executive officers of the National Committee for device companies. She was an inaugural director of the Victor Professional Standards of the Catholic Church in Australia. Chang Cardiac Research Institute.
40 2018 Garvan Annual Report Garvan Institute of Medical Research Board of Directors 2018
Anthony Kelleher (to April) John Mattick AO FAA FTSE FAHMS HonFRCPA Professor Kelleher is the Senior (to May) Vice Dean Research of UNSW Medicine, UNSW and the Professor Mattick was the Head of the Immunovirology Garvan Executive Director and Pathogenesis Laboratory from 2012-2018, and now Chief of the Kirby Institute, Head Executive of Genomics England of the Infection, Immunity and Visiting Professor at the and Inflammation Theme, UNSW Medicine and a Clinical University of Oxford. He has had a distinguished career in Immunologist and Immunopathologist at St Vincent’s Hospital, molecular biology and genomics, most recently as an NHMRC Sydney. He is a Fellow of the Australian Academy of Health and Australia Fellow and Director of the Institute for Molecular Medical Science, a member of The Australian Society of HIV Bioscience and the Australian Genome Research Facility at the Medicine, the International AIDS Society, and the Australian and University of Queensland. He was awarded the 2011 IUBMB American Societies of Immunology and has been Practitioner (International Union of Biochemistry and Molecular Biology) Fellow of the NHMRC since 2006. Medal, the 2012 HUGO (Human Genome Organisation) Chen Medal, the 2014 University of Texas MD Anderson Cancer Center Bertner Award for Distinguished Contributions to Cancer Paul Kelly Research, the 2017 Lemberg Medal of the Australian Society for Biochemistry and Molecular Biology, and Fellowship of the Dr Kelly is a founding managing Australian Academies of Science, Technology & Engineering, partner of OneVentures, a leading and Health & Medical Sciences. Australian venture capital firm, and serves as Chair of the Investment Committee of its Helen Nugent AO Healthcare fund, and on the Risk Management Committee. Dr Nugent is the Chairman of An Australian physician, serial entrepreneur and experienced the National Disability Insurance biotechnology and life sciences executive, he currently has over Agency and Ausgrid, and a non- 35 years experience in clinical medicine and medical science, executive director of Insurance and 25 years experience in commercialising life science related Australia Group Limited. She has technologies in Australia, Europe and North America. been the Chairman of Veda Group, Australian Rail Track Corporation, Funds SA, Swiss Re (Australia) and Sydney Airport and a non- Thomas John (Jack) executive director of Macquarie Group, Origin Energy Limited, Martin AO FAA FRS Mercantile Mutual and the State Bank of NSW, among others. She is an Officer of the Order of Australia and a recipient of the Emeritus Professor Martin is a Australian Government Centenary Medal. John Holt Fellow, St Vincent’s Institute of Medical Research and Emeritus Professor of Medicine, University of Melbourne. He was previously the Director of St Vincent’s Institute of Medical Research and the Chairman of the University of Melbourne Department of Medicine. A Fellow of the Royal Society and of the Australian Academy of Science, he was also President of the International Bone and Mineral Society.
garvan.org.au 41 Garvan Institute of Medical Research Board of Directors 2018 continued
Patricia O’Rourke Russell Scrimshaw
Professor O’Rourke is the CEO Mr Scrimshaw is the Garvan of St Vincent’s Health Australia’s Research Foundation Board Public Hospitals Division. She also Chair. He is also Non-Executive serves on the board of the Chairman of Sirius Minerals Aikenhead Centre for Medical Plc, Non-Executive Chairman of Discovery. She is a graduate Tech Project Group P/L and the of the Australian Institute of Executive Chairman of Torrus Company Directors and a member of the Harvard Business Club Capital P/L, the Australian Philanthropic Fund, the Scrimshaw of Australia. Foundation and Scrimshaw Nominees P/L. Previously, he held executive positions at Fortescue Metals Group Ltd (FMG), Commonwealth Bank, Optus and IBM. He was also a non- Rodney Phillips executive Board Director for Genome.One P/L, Commonwealth Properties Ltd, EDS Australia, Mobilesoft Ltd, Telecom New Professor Phillips, Dean of UNSW Zealand Australia P/L, and Athletics Australia. Mr Scrimshaw is Medicine, is an immunologist a non-executive Director of the Garvan Institute. whose research impacted the world’s understanding of HIV/ AIDS and other infectious Jillian Segal AO diseases. He described, for the first time, how HIV evades the Ms Segal is the Deputy Chancellor body’s immune defences. Previously, Professor Phillips was UNSW Sydney, Chairman of AICC Vice-Dean of Medical Sciences at Oxford University and Director (NSW), General Sir John Monash of the Peter Medawar Building for Pathogen Research. Foundation and the Independent Parliamentary Expenses Authority (IPEA). She is a Trustee of the Anthony M. Schembri Sydney Opera House and a director of the Grattan Institute. She is a director of Rabobank Associate Professor Schembri, Australia Limited, Rabobank New Zealand Limited and Rabo CEO of St Vincent’s Health Australia Limited. She has been a senior regulator, lawyer and a Network, holds academic director of other listed and government organisations. appointments with the University of New South Wales and Australian Catholic University. A/Prof Schembri is a surveyor for the Australian Council of Healthcare Standards and Fellow of the Australasian College of Health Service Managers. He is a director of the Central and Eastern Sydney Primary Health Network, St Vincent’s Curran Foundation, the National Centre for Clinical Research of Emerging Drugs of Concern and Co‑Chair of the Nursing Research Institute of ACU/St Vincent’s.
42 2018 Garvan Annual Report Garvan Research Foundation Board of Directors 2018
Russell Scrimshaw – Michael Cannon-Brookes Chair Mr Cannon-Brookes is a Director Mr Scrimshaw is the Garvan of Cannon-Brookes Consulting Research Foundation Board Pty Ltd, and a CEO level Chair. He is also Non-Executive executive coach with Foresight Chairman of Sirius Minerals Global Coaching. He established Plc, Non-Executive Chairman Citibank in Australia in 1985. of Tech Project Group P/L and He retired from IBM in July 2012, the Executive Chairman of Torrus Capital P/L, the Australian where he was IBM’s Vice President, Global Strategy for Growth Philanthropic Fund, the Scrimshaw Foundation and Scrimshaw Markets, based in Shanghai, China. Mr Cannon-Brookes, a UK Nominees P/L. Previously, he held executive positions at citizen, took Australian citizenship in 1994. He graduated with Fortescue Metals Group Ltd (FMG), Commonwealth Bank, Honors in Law from Cambridge University. He was elected a Optus and IBM. He was also a non-executive Board Director for Global Board Member of Advance in 2013, and in the same year Genome.One P/L, Commonwealth Properties Ltd, EDS Australia, a Fellow of the Australian Institute of Company Directors Mobilesoft Ltd, Telecom New Zealand Australia P/L, and Athletics Australia. Mr Scrimshaw is a non-executive Director of the Garvan Institute. Gabriel Farago (to April)
Mr Farago practised as a solicitor Nick Abrahams and barrister for over 30 years, (from May) specialising in commercial disputes in Australia and Mr Abrahams is the Global Head overseas, before becoming a full- of Technology and Innovation at time writer. He is the international, Norton Rose Fulbright and has bestselling and multi-award- deep commercial expertise and winning Australian author of the Jack Rogan mysteries and global networks in the technology thrillers series for the thinking reader. In 1984, Mr Farago space. He is a non-executive became a member of the Knightly Order of Vitez. director on ASX300 software company, Integrated Research. He is a director of the Institute for Economics and Peace and is on the board of the Vodafone Foundation. Mr Abrahams is past Chris Goodnow FAA FRS President of the Australian Communications and Media Law (from May) Association and writes regularly on technology and future trends for The Australian Financial Review. He is the author of the Professor Chris Goodnow is Kindle Business book Digital Disruption in Australia. an internationally renowned immunologist. He joined Garvan in 2015 as Deputy Director, Jane Allen the Bill & Patricia Ritchie Foundation Chair, and head of Ms Allen runs a Governance the Immunogenomics Laboratory. Chris has had an extensive Advisory business. Previously international research career. He has been a faculty member she was a managing partner at at Stanford University and the Australian National University, Egon Zehnder, where she also and has been closely involved in several biotechnology start-up held a leadership role across companies. He is best known for discovering immune tolerance Asia Pacific. A member of Chief checkpoints by integrating molecular genetics and genomics Executive Women, Ms Allen has with immunology, for which he received numerous awards and an MBA from Harvard Business School and a Bachelor of Arts election to the Australian Academy of Science, the UK Royal from Smith College. She has also worked for Procter & Gamble Society, and the US National Academy of Science. in the US and Australia.
garvan.org.au 43 Garvan Research Foundation Board of Directors 2018 continued
John Mattick AO FAA FTSE Hamish McLennan FAHMS HonFRCPA (from May) (to May) Mr McLennan is a media and Professor Mattick was the Garvan marketing industry executive Executive Director from 2012- with over 30 years of experience. 2018, and now Chief Executive of He is Chairman of REA Group, Genomics England and Visiting Chairman of HT&E and a non- Professor at the University of executive director of Magellan Oxford. He has had a distinguished career in molecular biology Financial group. He was Executive Chairman and Chief Executive and genomics, most recently as an NHMRC Australia Fellow Officer of Ten Network Holdings until July 2015 and prior to and Director of the Institute for Molecular Bioscience and this he was Executive Vice President, Office of the Chairman, the Australian Genome Research Facility at the University of at News Corp (formerly News Corporation). Mr McLennan has Queensland. He was awarded the 2011 IUBMB (International also held the role of global Chairman of Young & Rubicam, part Union of Biochemistry and Molecular Biology) Medal, the 2012 of WPP, the world’s largest communications services group. In HUGO (Human Genome Organisation) Chen Medal, the 2014 2017, he joined technology start-up Tiger Pistol in an advisory University of Texas MD Anderson Cancer Center Bertner Award capacity. He has previously served on the Board of Directors for for Distinguished Contributions to Cancer Research, the 2017 the United Negro College Fund (UNCF) and the US Ad Council. Lemberg Medal of the Australian Society for Biochemistry and Molecular Biology, and Fellowship of the Australian Academies of Science, Technology & Engineering, and Health & Medical Simon Mordant AM Sciences. Mr Mordant is Executive Co- Chairman of Luminis Partners. Helen McCabe He is also the Chair of the Museum of Contemporary Ms McCabe is the Head of Art Australia and Lend Lease Lifestyle for nine.com.au at Nine Barangaroo Public Art Committee, Entertainment Co. Prior to this a board member of the Museum she was Editor-in-Chief at the of Contemporary Art in Los Angeles, MOMA PS1 in New York, The Australian Women’s Weekly, Wharton Executive Board in Asia, a Trustee of the American Deputy Editor of The Sunday Academy in Rome and a member of the Executive Committee Telegraph, Night Editor of The of Tate International Council and a member of the International Australian and held key roles on The Daily Telegraph. She is Council of the Museum of Modern Art in New York. also on the board of the Australian Indigenous Education Fund and an Ambassador for Adopt Change.
44 2018 Garvan Annual Report Garvan Research Foundation Board of Directors 2018 continued
John Schubert AO Peter Young AM
Dr Schubert is Chairman of Mr Young is currently a Principal the Garvan Institute of Medical for The Adelante Group, a Board Research, Chairman of the Great member of the Barangaroo Barrier Reef Foundation, and a Delivery Authority Board, and director of the Garvan Research a member of the Barangaroo Foundation Board. He has held Arts and Cultural Panel. He was positions as Chairman of the previously Chairman of Standard Commonwealth Bank of Australia, non-executive director of Life Investments Australia and subsequently Aberdeen Standard BHP Billiton Limited, BHP Billiton Plc, and Qantas Airways Investments Australia, Chairman of Barclays Australia, Chairman Limited, Chief Executive Officer of Pioneer International Limited, of the Queensland Investment Corporation (QIC), Chairman of Chairman of WorleyParsons Limited and G2 Therapies Ltd, the Transfield Services Infrastructure Fund, and Chairman of Chairman and MD of Esso Australia Ltd, and non-executive the Board of the Australian Federal Government-owned Export director of Hanson Plc. Finance and Insurance Corporation (EFIC). He is a former Non-Executive Director of Fairfax Media, the Sydney Theatre Company, PrimeAg Australia, a Trustee of NSW Art Gallery, and Jeanne-Claude Strong subsequently a Trustee of the Queensland Art Gallery, and a member of the Board of the Great Barrier Reef Foundation. He Dr Strong graduated in Medicine, is a recipient of the Australian Federal Government’s Centenary practicing in occupational and Medal and in 2008 was appointed a Member of the Order of preventative medicine; has a Australia (AM) for his services to business and commerce. postgraduate degree in Applied Finance and Investment, BA (literature), was on the Board of Bluearth, flew her Beechcraft Baron from California to Australia via Europe, and races Etchells yachts including recent wins in the Australasian, Queensland and Victorian state championships.
garvan.org.au 45 PhD completions 2018
Congratulations to all the students awarded PhDs in 2018
At Garvan, we have close to 100 PhD students researching in almost every disease area across the Institute. In partnership with UNSW Sydney, through which most of our students are enrolled, Garvan is committed to supporting the important contributions our students make in the development of scientific knowledge and skills for the future.
Mahmoud Abdelatti Amanda Khoury Thi My Hanh Pham Supervised by Prof Daniel Christ Supervised by Prof Susan Clark, Supervised by Prof Tuan Nguyen, Dr Fatima Valdes Mora Prof John Eisman “Converting therapeutic monoclonal antibodies into functional VH domains” “Untangling Mechanisms of the “Osteoporotic fracture: muscular Architectural Protein CTCF” determinants and transition to James Conway consequences” Supervised by A/Prof Paul Timpson, Weng Hua Khoo Dr David Croucher Supervised by Prof Peter Croucher, Brigitte Phillips A/Prof Tri Phan, A/Prof Alex Swarbrick Supervised by A/Prof Antony Cooper “Intravital imaging to monitor therapeutic response in moving hypoxic regions “Single cell transcript profiling of dormant “Discovery of Molecular Mechanisms resistant to PI3K pathway targeting myeloma cells identifies therapeutic and Underlying Lysosomal and Mitochondrial in pancreatic cancer” prognostic targets” Defects in Parkinson’s Disease”
Louise Cottle Wing Yin (Angelica) Lau Catherine Piggin Supervised by A/Prof Antony Cooper Supervised by Prof Robert Brink, Supervised by Prof Chris Ormandy Dr Tyani Chan “Investigating the ATP13A2 (PARK9) “Mechanisms of action of ELF5 and alpha-Synuclein inter-relationship “Novel function for BAFFR signalling in breast cancer” in Parkinson’s Disease” in the regulation of Germinal Centre and B cell memory” Samuel Rogers Daniele Cultrone Supervised by Dr Andrew Burgess Supervised by A/Prof Shane Grey Ansha Luthra Supervised by Prof Daniel Christ “Exploring the origin of chromosome “A functional genomics approach instability, through mitotic regulation to understand the role of A20 in “Improving bispecific antibody and MASTL kinase” human disease” production by tweaking cognate heavy‑light chain pairing” Lewin Small Simon Hardwick Supervised by Prof Greg Cooney, Supervised by Dr Timothy Mercer, Imogen Moran Prof Nigel Turner, Dr Amanda Brandon Prof John Mattick, Dr Martin Smith Supervised by A/Prof Tri Phan, Prof Robert Brink “In vivo mechanisms of lipid-induced “Designing synthetic spike-in controls for insulin resistance in muscle” next-generation sequencing and beyond” “Investigations into the formation and reactivation of memory B cells” Holly Holliday Supervised by A/Prof Alex Swarbrick, Lisa Oyston Dr Simon Junankar, Prof Chris Ormandy Supervised by Dr Greg Neely, Prof Herbert Herzog “Inhibitor of Differentiation 4 (ID4) suppresses myoepithelial differentiation “Conserved Genetic Modifiers of mammary stem cells via of Parkinson’s Disease” E-protein regulation”
46 2018 Garvan Annual Report PhD completions 2018 Spotlight 2018 Post-Doctoral Development Committee
The Post-Doctoral Development 2018 PDDC members Committee (PDDC) facilitates education and social events for post-docs and group Co-chairs: Dr Maria Findeisen leaders across the St Vincent’s Precinct (Garvan, Diabetes and Metabolism) to come together, network, engage and Dr David Herrmann (Garvan, Cancer) and collaborate. Secretaries: Dr Jessica Chitty The Committee members represent all (Garvan, Cancer) and Dr Simon Junankar research areas within Garvan, as well (Garvan, Cancer) as the Victor Chang Cardiac Research Institute and St Vincent’s Centre for Treasurer: Dr Matthew Summers Applied Medical Research. In 2018, (Garvan, Bone) the Committee organised: Members: Aude Dorison (Victor Chang), • 2018 Annual Post Doc Symposium Aurélie Cazet (Garvan), Benedetta Frida (joined with the 26th St Vincent’s Baldi (Garvan), Carole Ford (St Vincent’s Campus Research Symposium), Centre for Applied Medical Research), which had more than 100 attendees David Herrmann (Garvan), Jeng Yie from across the Precinct Chan (Garvan), Jessica Chitty (Garvan), Maria Findeisen (Garvan), Marcia Munoz • 2018 Careers Forum “How mentorship (Garvan), Matthew Summers (Garvan), can influence career progression and Melissa Mangala (Victor Chang), Niall decision making” Byrne (Garvan), Niantao Deng (Garvan), Sandy Stayte (St Vincent’s Centre for • Educational seminars/workshops Applied Medical Research), Simon focusing on the development of Junankar (Garvan), Yanchuan Shi (Garvan). research and soft skills
• Social and networking events
Simon Junankar, Sandy Stayte, Aude Dorison, Aurélie Cazet, Jeng Yie Chan, Melissa Mangala, David Herrmann, Jessica Chitty, Niantao Deng. Absent: Benedetta Frida Baldi, Carole Ford, Marcia Munoz, Matthew Summers, Niall Byrne, Yanchuan Shi.
garvan.org.au 47 Franklin Women’s Academic Partners
In 2018 Garvan cemented its and working together to achieve their commitment to gender equity by common goals. becoming an inaugural partner in Franklin Women’s Academic Partner Professor Marie Dziadek says the program, together with the Cancer partnership is an important step for Council NSW, Centenary Institute, Garvan. “Generating an institute-wide The George Institute for Global Health, culture of diversity and inclusion lies at MQ Health (Macquarie University Health the heart of establishing an organisation Sciences Centre), Kolling Institute, in which women, and indeed all staff, UNSW Sydney Medicine and Sydney thrive and achieve their true potential. Medical School. “Garvan shares this vision with Franklin Women is a grassroots Franklin Women and all its partner organisation in NSW, led by women organisations, and we look forward to working in the health and medical working collectively to accelerate this research sector. They are focused on cultural change.” building a community of women, with the goal of empowering them to pursue This partnership will allow Garvan to rewarding scientific careers and helping continue being proactive in implementing them address the systemic barriers policies and processes to promote faced by women in science and achieve gender equity. Garvan’s Flexible Working senior leadership positions. Hours Policy and initiatives such as Garvan’s Childcare Travel Awards, With this new partnership, Franklin spearheaded by Professor Dziadek, Women has recognised Garvan’s have already benefitted researchers commitment to supporting the career across the Institute. The Childcare progression of its female staff and Travel Awards allow primary caregivers, students, and achieving gender equity mostly women, to attend scientific at all levels of the organisation. conferences and committee meetings – critical steps in career progression – Garvan’s relationship with Franklin by providing funds for childcare. Women began in 2017, with the participation of Garvan researchers in the The Think Tank events organised inaugural Franklin Women’s Mentoring by Franklin Women look to find Program. In 2018 Prof Susan Clark and innovative and effective ways to Prof Stuart Tangye were mentors, and support the development of a more Dr Michelle McDonald and Dr Marina inclusive scientific community where Pajic were mentees. Following the women thrive. success of the first Mentoring Program, Garvan looks forward to the evolution of its relationship with Franklin Women,
“Generating an institute-wide culture of diversity and inclusion lies at the heart of establishing an organisation in which women, and indeed all staff, thrive and achieve their true potential.” – Prof Marie Dziadek
48 2018 Garvan Annual Report In Memoriam
Jane Bryant
It was with great sadness that we farewelled Jane Bryant (née Wiggers de Vries).
At the age of 24, Jane, a nurse at St Vincent’s Private Hospital, was diagnosed with triple negative breast cancer. She received a double mastectomy, radiotherapy and chemotherapy, and continued her work looking after patients, some of whom wouldn’t have been as unwell as she was at that time.
Jane did a great deal for Garvan in the short time we knew her. She supported research by donating tumour samples, raised thousands of dollars for breast cancer research and shared her story openly, honestly and powerfully. Most importantly, she befriended and inspired our researchers and everyone who met her. Sadly, Jane’s cancer returned – and in June of 2018 she passed away.
We are, and will always be, enormously grateful to Jane, her husband Cam and their family and friends for sharing part of their lives with us.
Ann Kirby
Ann Kirby (née Annemarie Plotke) came to Australia as a 10-year-old in 1939, and became the first woman to join the Council of the Law Society of NSW in 1970. Ann blazed the trail for later generations of female lawyers and was a quiet achiever who didn’t let prejudice and social barriers stop her achieving her goals.
Ann was a well-known philanthropist and major benefactor of the Emanuel Synagogue, Emanuel School and the Jewish Museum. She was passionate about education, gave generously to the Department of Hebrew, Biblical and Jewish Studies at Sydney University, establishing the Special Purpose JCA Plotke fund for teacher education.
Ann was a loyal supporter of Garvan’s work since 2004 and gave generously during her lifetime. In a significant act of generosity, Ann also took the important step of including Garvan as a beneficiary in her Will. We are truly grateful for Ann’s farsighted gift which will provide a legacy where everyone lives longer, healthier lives.
garvan.org.au 49 Leaders in Science and Society seminars
We’re grateful to the many speakers who presented at the Garvan Institute in 2018.
March June September
Prof Deborah Schofield, Professor Dr Lee Rubin, Harvard Department of Prof Rob Brink, Lab Head, Immunology, and Chair, Health Economics. Director, Stem Cell and Regenerative Biology, Garvan Institute GenIMPACT: Centre for Economic and Harvard University, US Social Impacts of Genomic Medicine, Prof Jonathan Baell, Larkins Fellow, Macquarie University Sydney Prof Elizabeth Hartland, Director of the Australian Translational Director and CEO, Hudson Medicinal Chemistry Facility, Monash April Institute of Medical Research Institute of Pharmaceutical Sciences
A/Prof Paul Timpson, Lab Head, July Prof David James, Leonard P. Ullmann Invasion and Metastasis, Garvan Institute Chair of Metabolic Systems Biology, Dr Carlos L Arteaga, Director, Charles Perkins Centre; Professor, Prof Susan Clark, NHMRC Senior Harold C. Simmons Comprehensive School of Life & Environmental Sciences Principal Research Fellow, Head of Cancer Center, UT Southwestern, US and Sydney Medical School Division, Genomics and Epigenetics, Garvan Institute Prof Jonathon Howard, Co‑Director, October Quantitative Biology Institute, A/Prof Justin O’Sullivan, Senior Yale University, US Prof John O’Sullivan, Group Leader in Research Fellow, Liggins Institute, Cardiometabolic Disease at the Heart University of Auckland, New Zealand August Research Institute and Charles Perkins Centre of the University of Sydney Prof Paul Zimmet, Professor of Dr Peter Tontonoz, Professor Diabetes, Monash University Melbourne of Pathology and Laboratory Prof Kathryn North AM, Director, Medicine, UCLA Los Angeles, US Murdoch Children’s Research Institute; May David Danks Professor of Child Health Prof Jamie Rossjohn, Head, Research at the University of Melbourne Dr Janet Iwasa, Assistant Professor Infection and Immunity Program, of Biochemistry, University of Utah, US Monash University Dr Jacky Goetz, Group Lead, Tumour Biomechanics, CR1 INSERM Prof Maree Teesson, Director, Dr Chris Armstrong, Acting NSW National Drug and Alcohol Chief Scientist November Research Centre, UNSW Prof Axel Kallies, Laboratory Head, Dr Jason Vassy, Clinician-investigator, Prof Ricky Johnstone, Head of Molecular Immunology, Walter and VA Boston Healthcare System and Gene Regulation Laboratory, Peter Eliza Hall Institute, Melbourne Brigham and Women’s Hospital; MacCallum Cancer Centre Melbourne Assistant Professor, Harvard Medical School, US
A/Prof Tara Murphy, Sydney Institute for Astronomy, University of Sydney
Prof Katherine Kedzierska, Head, Human T cell Immunity Laboratory, University of Melbourne
50 2018 Garvan Annual Report Leaders in Science A shared vision and Society seminars for a healthier future
Miriam Douglass and Libby were good Seeing her father suffer, Miriam believed friends and neighbours for over 12 there should be better options for years. Miriam became a surrogate cancer treatments and knew this grandmother to Libby’s daughters, and can only be achieved by increasing she and Libby shared many adventures our understanding of disease and together. When Miriam asked if Libby through funding visionary and would be the executor of her Will, Libby blue‑sky medical research. agreed because she knew that honouring Miriam told Libby that her estate also Miriam’s future wishes would closely align included her father’s legacy, and it with her own values. meant so much to know that her Miriam and Libby had a mutual experience future gift to medical research will of trying to get better care for their parents have a lasting impact. – and a mutual passion for bringing about Libby describes Miriam as a generous change and improving healthcare. and caring friend, full of eccentricities but Miriam Douglass For Libby, her mother suffered a brain always a source of joy and compassion, haemorrhage which required her to live in especially to children and animals. “I feel full-time care for 17 years. And for Miriam, truly blessed for knowing Miriam and I am her mother passed away when she was going to miss her friendship,” said Libby. very young from a suspected heart attack. With Miriam’s farsighted bequest, Garvan Miriam also cared for her father Alfred, has set up The Miriam Douglass Blue Sky who suffered with prostate cancer later Endowment Fund in her honour. We thank in life. Miriam said she felt helpless and both Miriam and Libby for their shared frustrated during this time and wanted to passion and vision for a healthier future do more. While Alfred underwent cancer for us all. treatments, Miriam was asking “What else Miriam Douglass was born in Wagga is available, what treatments can we try, Wagga in 1934 and sadly passed away what more can be done?” in Sydney in 2016.
With Miriam’s farsighted bequest, Garvan has set up The Miriam Douglass Blue Sky Endowment Fund in her honour. We thank both Miriam and Libby for their shared passion and vision for a healthier future for us all.
garvan.org.au 51 Partners for the Future
We extend our gratitude to all of these wonderful supporters who have chosen to leave a bequest to Garvan in their Wills.
Mrs Margaret Adams Mrs Barbara E Buttery Ms Daile Falconer and Mr Hedley Hall and Ms Ronelle Adams Dr John Campbell Mr Thomas Delisi Ms Helen Gibbons Mr Ray Addison Ms Vicki Case Mr & Mrs Gabriel and Mr John Hall Ms Christine Allen Mr Angelo Casella Joan Farago Mr Ron Hardaker Mrs Suzanne Allen Mr Tom Casella Mrs Grace Faulks Mrs Shirley Harding-Learmont Mr Emery Angles Mrs Veronica Christie Rob Ferguson Miss Helen Hardman Mr & Mrs V & E Annuk C E Clark Ms Jann Ferguson Mrs Bronwen Hargraves Ms Wilhelmina Antoniesen Mrs Judith Clark Ms Diane Ferrier Mr & Mrs Gary & Paulette Hay Mr Ian A N Armstrong Ms Trish Clifford Fred Fiegert Mr Brian Hayes Mr Peter Askew Ms Jill Coggan Mrs Frances Findley The Hayes Family Miss Margaret Atkinson Dr & Mrs Roger and Carole Cole Mr Ralph Forbes Mr & Mrs W & V Haynes The Australian Ladies Variety Mrs Robyn Collings Miss Shirley R Ford The Late Mr Philip Hemstritch Association Inc Mr Peter Collis Ms Jan Foster Ms Barbara Henderson Dr W. Michael Baker Dr Lynne Cook Mr & Mrs Michael and Mrs Frances Hession Ms Melissa J Ball Ms Dorothy Coombs Joy Foulsham Mr Scott Hession Mr & Mrs Joseph and Ms Jan Craig Dr & Mrs John and Mr Brian Hewson Betty Banhidi Ms Loris Crisp Diana Francis Miss Linda Hicks Mr David Barclay Mrs Philippa Croker Mr Donald Frazer Mr John Thomas Hill Mrs Ruth Barnes Mr & Mrs Alan and Mr Terry Gallagher Mr Kenneth Hillier Mr & Mrs David and Roslyn Currie Mrs Lina Joan Gallo and Ms Heather P Hindle Robyn Barnett Mr Graham W Curtis Mr Lauro Gallo Mrs Dawne Hintze Mr Wal Barrett Mr Rodney F Darke Mrs Gwen Gardiner Mr & Mrs Lionel & Gwen Hirning Mrs Esther Bartram Mr Kenneth Davies Ms Geraldine Garvan Mr Mike Hobbs Mr Donald Bastin Mr & Mrs Kevin & Sylvia Davies Ms Maureen Garvey-Ross In memory of the McDonough Mrs Hazel Maude Begley Mr Don and Mr John Gea Gea & Hogan Families Ms James Belger Mrs Christine Davison Mrs Carmel Gillett Mr Hilton Hollingdale Mrs Sheila Bell Miss Clare Dawes Mrs Margrett Gilson Ms Ruth Holmes Mr Leslie B Blackshaw Mr Michael Day Girgensohn Foundation Richard J Hudson Mr Ken Bloxsom Mr & Mrs Peter and Mr John Gissing Mrs Eileen Hunter Caroline Bock Susanne de Beuzeville Miss Excelsa Glinoga Miss Marilyn Hutchison Mr Alan Barnes and Ms Susanne de Ferranti Miss Edwina Glinoga Ms Edith Iseli Mr Peter Bolton Mrs Luise de Longueville Miss Estrella Glinoga Miss V Jenkins Ms Linda Booth Ms Peggy De Seriere Pam Goldberg Mr Byram Johnston OAM and Mr & Mrs Earle and Ms J Del Layton Mrs Mena Valerie Good Mrs Deborah Johnston Marlene Boutwell Mr & Mrs Tom and In loving memory of Lloyd Gwyn Jones and Ms Maree Bowman Donna Devitt Tracey Goodley Barbara Jones Mrs Meryl Bowman Mr John Dickens and Alan Goodwin Dr W G Grigor Mr & Mrs Alan & Anne Boyle Dr Ian Payne Mr & Mrs William and Mr & Mrs Arthur and Dr William R Bradford Mrs Marlene Dixon Jacqueline Goodyear Elizabeth Jones Mrs Judith Bradley Mr John Dobies Mrs Helen Victoria Graham Mrs Florence Jones Ms Mary Brauer Mrs Gabrielle Donovan Dr Robert Gray & Mrs Jane Gray Mr & Mrs Terry and Mr Trevor Bray Mrs Phillipa Dorin Ms Claire Greaves Helen Jones Mr Peter Brell Mr John Dowd Sharon Green & Marcel Skjald Ms Maryke Jonkman Mrs Meredith Briggs Ms Jennifer Duncan Mr Colin Green Mrs Luba Kaye Drs Ruth and Des Bright In loving memory of Miss Flo Greene Mr & Mrs Patrick and Mrs Brenda Bristow Patrick Dunphy Ms Patricia Griffen Beryl Keane Mrs June Bronner Mr Alan Durham In Memory of Mr Mark Keeley Philip & Wendy Brook Ms Jacqueline Dwyer Patricia Helen Guest Warwick & Carole Kendall Mrs Jill Brooks Mrs Valda Eastment Ms Angela Guildford Mrs Isabel (Rae) Kennedy Mr Don Brown Mrs Elizabeth Efinger In memory of Barbara Guy Ms Wendy Keys Dr Ken Buckle Mr Philip Elder Trevor Haines AO and Mrs Kate Khan Ms Juli Buckley The Evans Family Paul White Mr Bob Kijurina Mrs Elizabeth Bunyan Miss Moir Evans Mrs Fusae Hall Mr Frank Killion Mr David Burles Mrs Wai Chiew Fairley Mr & Mrs Jeffry & Lyn Kirby
52 2018 Garvan Annual Report Partners for the Future
Mr W Bruce Kirkpatrick OAM Mrs Alice Miglionico Mrs Jean Redman Ms Margaret Taylor and Mrs Juliet Kirkpatrick Mrs Mary Miller Mr & Mrs Don and Shirley Rees Derek Joseph Taylor Ms Lili Koch Ms Sharyn Minahan Mrs Julie Reid Mrs Barbara Taylor Hendrika Kramer Mr & Mrs David and Mrs Marjorie Renshaw Diana R. Terp Ms Josie La Spina Renata Money Mrs Ann C Rethers Ms Bonnie Thomas Mr Christopher Ladd Mr John Kelvin Moody Dr. Judith Reynolds Mrs Gaby Ticehurst Ms Gabriella Lang Mrs Angelina Moonen Trevor Rice Ms Audrey Timbs Mr Barry Thompson and Warren Morley Ms Nerida Richards Ms Mary Tonkin Ms Roberta Lauchlan Mrs Christine Morrin Ms Julia Richardson Mr Leonard Towers Mr Gottfried Lausegger Mrs Jeannette Muggridge Mr & Mrs Don A Robertson The Honorable Philip A Twigg QC In loving memory Ally Lawler Mr Geoffrey Murphy Ms Kathy Rockwell Mrs Robyn Usher Mrs Faye Lawrence Mrs Roberta Neale Ms Tanya Roddan Mrs Maya Van Rol Mary Lawson Miss Caroline Needham Mr & Mrs John and Mr & Mrs Ian and Sharon Vette Mrs & Mr Virginia & Kevin Leacy Mr & Mrs Michael and Barbara Rogan Mr Frank Virgara Mr Tony Leahy Valda Neels Mr & Mrs Christopher and Mr Byron and Mrs Helen Vlahos Ms Elizabeth Lee Mrs Margaret Neyle Nancye Rolfe Daphne Wagner Mrs Beth Lehman Dr Elizabeth Niven Mr Bruce Rosenberg Ms Julie Wahlberg Mrs Nina Leibovitch Mr Desmond Nolan Dr Edna Ross Mrs Verna Wakefield Mr & Mrs Cyril and Mr & Mrs Stewart and Mr George Saliba Ms Samantha Walder Benita Levene June Northam Mr John Sanders Mr William Alan Walker In memory of Wayne and Gretina Norton Ms Jan Douglas and Mr Michael Weekes Mrs Grace Shirley Lewis (Kit) Mrs Carol O’Carroll Mr Len Sanders Mr Ron Weir Mrs Shirley Lindoy JP Mrs Joan O’Hara Mr & Mrs Ken and Mr & Mrs Geoff and Ann Weller Mr Philip Lipscombe Mr Gary Lindsay O’Leary Judy Sargeant Mrs Karla Weller Keith Little Mrs Margaret O’Leary Ms Coral Saunders Mrs Jennifer Wells John Lockeridge Mr W R O’Leary Mrs Betty Saxby Ms Gail West Mrs Jude Logan Mr Peter Olive Patricia and Dieter Schafer Mrs Marvin West Mrs Sheila Loudon Miss Betty Olsen Mrs. Wilhelmina H. Schippers Mrs Judith Wheeldon AM Mrs Thora Loudon Mr & Mrs Ronald and Dr John Schubert AO and Mr William Wheeler Mrs Nelis Loustrau Naomi Osborn Mrs Prue Schubert Dr Yvonne White Ms Rosemary Lucas-Moore Miss Winnie Pang Barry M Schulz, AFC Mr John White Miss Shirley Luker Mr & Mrs Justin & Judith Parker Charles Seaberg Mr Robert Wickenden Ms Maria Lydaki Ms Jane Parker In memory of Mr Dennis Seward Ms Barbara Williams Ms Moyra Maestros Mr Cecil Partington Miss Thelma Shepherd Ms Faye Margaret Williams Mr Harold Manns Mr Chris Paspaley and Miss Julie Sheppard Mr & Mrs Geoffrey and Dr Harry Marget Ms Anna Boniface Ms Colleen Sheppard Gleness Williams Dr Norman Marshall Mr Rene Patat and Ms Shona Sherwin Ms Barbara Williams Miss Margaret J Martin Mr Geoffrey Priest Anthony Abrahams and Mrs S Wilson-Pearson Mrs Doreen N.E. Martin Mr Donald Payne Wendy Sillence Mrs Heather Windshuttle Miss Denise Martin Mrs Pauline Perry Jane & Barry Simpson Miss Vivienne Windsor Donna Mae Mason Ms Larna Perry Mrs J Sindel-Hand Ms Roberta Withnall Mr Lance Matheson Mrs June Pick Kathryn Ann Smith Mr & Mrs Karl and Mrs Nina Mavro Mrs E D Picton Miss Angela Sofoulis Madeline Wolf Mr Ross J May Mrs Margaret Pierce Ms Betty Song Mrs Dorothea Wright Ms Sharon McAuliffe Ms Anita Pittorino Mrs Kathleen South Diane Wright Mr Christopher McCabe Mr Tony Plunkett Mrs Cynthia Southwell Ms Janet Wright Mr Desmond J McCarthy Mr Alan Pollock William Spence Ms Kerry Wynne Mr Stuart McCulloch Mrs Elaine Porter Mrs Liese-Lore Spring Mrs Elizabeth Yates Mr & Mrs Terry and Mr & Mrs Lloyd & Joan Poulton Ms Maureen A Stephenson Mr V Young Lynette McGarrigle Mr & Mrs Edmund and Mr Rick Stevens Ms June Yuen Mrs Robynne McGinley Alviena Poznaks Ms Judith Stoll Mr John Robert McLure Mr & Mrs James and Mr Reginald H Streifler Mr & Mrs Warren J and Wendy Preece Dr Jeanne-Claude Strong Pamela A McNamara Mrs Tara Preston Mrs Louise Stuckey Ms Anne McNiven Mr Tony Price Mr & Mrs Peter and Ms Elizabeth Meredith Mrs Dorothy Pryce Diane Sturrock JenniferBrown Ms Joan Pye In Memory of the Late Mr & Mrs Gerald and Ms Judy Radecki Kathrin Nell A Wilshire Zoe Middleton Ms Margarita Rasink The JP & GM Sullivan Family
garvan.org.au 53 Garvan community
Our generous supporters come from all walks of life and give in various ways. They have different reasons for supporting Garvan, but they’re all committed to helping achieve our vision.
Our heartfelt appreciation goes to all those who supported Garvan in 2018.
Life Governors The Late Mrs Virginia Kahlbetzer Di Sutton A I Topper & Co Mr Len Ainsworth AM Mr Trevor Kennedy AM and Suttons Motors Management A L Zambo Pty Ltd Allind Pty Ltd Mrs Christina Kennedy The Late Dr John Tonkin Mrs Gladys Abbott Amadeus Energy Limited Mr & Mrs Ralph and Tour de Cure Mr Todd Abbott The Late Mr John Armati Lorraine Keyes Vodafone Foundation Australia The Abey Perera Family Foundation The Australian Lions Childhood King & Wood Mallesons Mr & Mrs John and Ablosix Pty Ltd Cancer Research Foundation The Kinghorn Foundation Megan Wade Accenture Australia Pty Ltd ASX Thomson Reuters The Lady Proud Foundation Wade Civil Engineering Pty Ltd Accenture Charity Foundation Lions Clubs The Walker Family Foundation AccorHotels Australia Australian Cancer International Foundation E J Whitten Foundation The Arcus Foundation Research Foundation Love Your Sister Witchery Mr Andrew Adamovich Mr David Baffsky AO and Bob and Ruth Magid Westfield Holdings Ltd Mrs Margaret Adams Mrs Helen Baffsky Mr & Mrs Roy and Mrs Leonre Adamson The Bill and Patricia Ritchie Cindy Manassen Volunteers Mr Michael Ahrens Foundation John and Deborah McMurtrie Mrs Tosin Adeyemi Mr Len Ainsworth The CLEARbridge Foundation Mr & Mrs David and Mrs Gloria Y Allen Antoinette Albert Mr Charles P Curran AC Renata Money Mrs Janet Barkell Mr Richard Aldridge Mr & Mrs Geoff and Dawn Dixon NAB Foundation Mrs Barbara E Buttery Mrs Kate Aldridge Mr & Mrs Peter and Val Duncan National Australia Bank Mr Graham W Curtis Ms Paula Aleixo Education Heritage Foundation The NELUNE Foundation Ms Margarita Field Mr Ken Allen AM and The Late Mr Alan Elder Ms Lysia O’Keefe Ms Justine M Flynn Mrs Jill Allen Mrs Janice Gibson and Ernest Dr Graham O’Neill Ms Claire Greaves Mr Murray Allen Heine Family Foundation The Late Mr K Packer AC Miss Lyndie Hemery Dr Lyn Allen The RT Hall Trust Mrs Roslyn Packer AC Ms Marianna Horvath-Kovacs Mrs Jane Allen The Late Lady (Mary) The Paramor Family Mr Howard Houliston Allen & Overy LLP Fairfax AC OBE George Patterson Pty Ltd Mrs Lynne Jones Shanghai Office Ferris Family Foundation Paul Ainsworth Family Ms Helen Kingsley The Alma Hazel Eddy Trust Mr Laurence S Freedman AM Foundation Mr W Bruce Kirkpatrick OAM Lesley and Tony Little The Late James Patrick Garvan The Petersen Family and Mrs Juliet Kirkpatrick Emeritus Professor and Family The Petre Foundation Mr Rory O’Carroll Derek Anderson AM The Late Miss Felicia D Garvan Rosemary Pryor Foundation Mr Theo Oo Mr Neil Anderson Mrs Agnes Ginges and the late Ridley Corporation Ltd Mrs Joan O’Regan The Angles Family Mr Berel Ginges Mrs Margaret Rose AM Mrs Kalgi Patel Mr & Mrs V and E Annuk The Late Mr Cyril Golding The Ross Trust Mrs Mairi Payten APP Corporation Pty Limited Mr & Mrs Richard and Roth Charitable Foundation Mrs Julie Reid Mr Geoffrey Applegate Louise Grinham Alan and Lynne Rydge Mr Richard Ruhle Arcadis Mr William A Gruy Mr Richard Scheinberg AM and Mrs Annie Selman Mr John Archer In Memory of Patricia Mrs Jacqui Scheinberg Ms Stella Stefanidis Mrs Betty Armbruster Helen Guest Schwab Charitable Fund Mrs Deirdre Stuart Mrs Margaret Arnott The Late Mr Philip Hemstritch Scrimshaw Foundation Mr Bill Upton Arthur A Bain Pty Ltd Mr & Mrs Paul and Mr John Roth and Mr Erwin Weastell Mr & Mrs MW & MM Atkinson Judy Hennessy Ms Jillian Segal AO Mrs Noreen White Ms Deborah Attard HIH Insurance Mr and Mrs Tim and Sally Sims Denise Yates Aurecon The Late Mr Pieter H Huveneers The late Mr Robert Strauss MBE Australian Communities John Brown Cook Foundation St Vincent’s Curran Foundation 2018 Supporters Foundation The Johnny Kahlbetzer Family Mr and Mrs Laurie and 1666 Foundation Australian Federal Police
54 2018 Garvan Annual Report Employees Mrs Yvonne Booth Mrs & Mr Irene and David Lesnie Foundation The Australian Ladies’ Mr Stephen Borland Timothy Chang David Z Burger Foundation Variety Association Inc Mr Peter Bower Mr Robert Chapman Mrs Alison Davies Australian Lions Childhood Boyer Family Ms Lynda Chapman Ms Joan Davis Cancer Research Foundation Mr Graham Bradley AM and Mr & Mrs Stephen and Mr Don and AVCAL Employees Mrs Charlene Bradley Mary Charlesworth Mrs Christine Davison Mr Robert Bachmann Mr & Mrs Peter and Ms Kerry Chikarovski Mr & Mrs Haydn and Sue Daw Ms Lynette Bain Lurline Bradley Dr Wee Sent Ch’ng Ms Susanne de Ferranti Mr & Mrs Harrie and Braemac Pty Ltd Mr Joe Cho De Lambert Largesse Foundation Noreen Baker Mr John A Brayshaw Mrs Veronica Christie Mrs P De Sauty Mrs Shirley Barbeau The BREIF Club of Sydney Mr Klaus Christochowitz Mrs Sally Dean BarChip Australia Pty Ltd Mr Warren Brettoner Mr Robert J Clarke The Deloitte Foundation Sydney Mr Michael Barker Mr & Mrs Robert and The CLEARbridge Foundation Mr Eddy DeMarco and Ms Robyn Barlow June Brice Mr Denis Cleary AM Mrs Gwen DeMarco Mr & Mrs David and Bridge Healthcare Pty Ltd Mrs Elaine Clode Mr Jonathan Denovan Robyn Barnett Drs Ruth and Des Bright Ms Kylie Coates Ms Judy deSouza-Rybar Mr Paul Barnett The Broinowski Foundation Mr Christopher Coleman Mr Dirk Diepeveen Barraba Cancer Patients Mrs Jane Brooks Concept Logistics (Australia) Mr & Mrs Geoff and Fundraising Group Mrs Joan Brown Pty Ltd Dawn Dixon Dr & Mrs Ian and Pam Barrett Mr Leo Browne Concept Logistics Interstate Mr & Mrs Leonard and Dr Denis Barrett Mr Norman Brunsdon AM Transport Pty Ltd Patricia Dixon Mr & Mrs Kevin and Mrs Kate Buchanan Ms Bridget Conybeare Dr Lucy Donovan Melony Barrie Mr Tony Buck Mr Thomas Coogan Russell and Anne Dorey Mr Graham Bartlett Ms Linda Buckley Ms Annette Cook Double Bay Probus Club BASF Australia Ltd Mr Donald Bursill Rosemary Heal and Gary Cook Mr Paul Downard Mr G Bates Dr George Bursle Mr & Mrs Tony and Mr Graeme Downer Mr David Bath Mr & Mrs John and Judy Cooper Dr Lee MacCormick Mrs Judith Batianoff Trish Burton Coregas Edwards Charitable Foundation Bauer Media Pty Limited Judy Butlin The Corio Foundation Draffan Pty Ltd Baxter Charitable Foundation Mr Ian Cairns Ms Malia Corry Ms Natalie Suzanne Dray Mr Brian Beasley Mrs Hilary Cairns Mrs Edda Cosmo Mr Michael Driscoll Mr & Mrs Barry and Mr & Mrs Alan and Mr Stanley Costigan DSI Underground Jennifer Beck Cecilia Calder Dr & Mrs Brett and Duchen Family Foundation Bekaert Maccaferri Mr John Callaghan Susan Courtenay Mr & Mrs Ian and Underground Solutions Mr Ian Cameron Ms Helen Coyne Anthea Duncan Mr Hubert Bell Mr Bruce Cameron Craig Mostyn & Co Pty Ltd David & Jane Duncan Mr Geoffrey Bennett Cammeray Golf Club Mrs Janice Crawford Mr Andrew Dunn Mr & Mrs William and Mr Chris Campanaris Croall Foundation and In loving memory of Catherine Bennett The Honourable Mergen Family Patrick Dunphy Mr Alexander Berlee Joseph Campbell QC Mr & Mrs Doug and Dunstan Family Foundation Mr Ronan Bernard Robert Campbell Marilyn Crossley Mr Ken Dwyer Mrs Barbara Beynon Mr Fraser Campbell Mr Charles P Curran AC Mrs Tess Eckert Ms Belinda Bible Campbell Scholtens Mr & Mrs Alan and Jeff & Janice Edmunds The Bill and Patricia Pty Limited Roslyn Currie Education Heritage Foundation Ritchie Foundation Mr Michael Cannon-Brookes SNR Ms Jean Curthoys Mrs Elizabeth Efinger BioTools and Mrs Helen Cannon-Brookes Mr & Mrs Robert and Mrs Sharon Egan Mrs Beverley Birnbaum Carla Zampatti Foundation Beryl Cusick Mr Brian Eggert Mr Philip Birnbaum Mrs Deborah Ann Carlsund Pete, Jill, Ashleigh and Ms Valerie Elder Mr Andrew Black Carlton Family Foundation Erin Cuthbert Mr John Ellacott Mr William Blackshaw Carpy Pty Ltd CWA Cervantes Branch Mrs Janice Gibson & Ernest Mrs Kaye Blaiklock Mr Paul Carroll Mr David Daley Heine Family Foundation Ms Valeska Bloch Ms Virginia Carter Mr Warren Daley Essential Energy Wing Commander James Dr John H Casey Mrs Lois Dann Estate of the Late Bruce Block, RAAF (retd) Mrs Maureen Cavill Mr Rodney F Darke Olga Mabel Woolger Mrs Beverley Bloomfield Centenary Foundation – Mrs Sara R Darling The R T Hall Trust Bluey Technologies Pty Ltd Judith Hodge Fund Mr Robert Dash Estée Lauder Companies BNP Paribas S & Y Center Mr Peter David Mr Peter Evans Mr Gaetano Boncardo CHAMP Private Equity David & Dulcie Henshall Eventide Homes NSW Mrs Mary Bonfante Ms Maureen Chan Foundation F M Hooper-Australian
garvan.org.au 55 Garvan community continued
Philanthropic Services Girgensohn Foundation Patricia Hely Mrs Judith Kay Foundation Mr John Glennie The Late Mr Philip Hemstritch Kevin & Louise Keady Ms Virginia Fairbairn Mrs Noni Glew Mrs Belinda Hendriksen Mr John Keam Mrs Gwenyth Falson Cherie Glick and Family for Joe Mr & Mrs Paul and Mrs M Keighley Mr W R Farley Ms Jean S Goh Judy Hennessy Professor Geoffrey Kellerman AO Mr & Mrs CW & JA Farmer K Goldsworthy Henry Pollack Foundation Warwick & Carole Kendall Miss Julia Farrell Mrs Judith Gollan Ms Frances Herd Mr Steve Kennedy Miss Jane Farrell Ms Janice Goncharoff Mrs Joy Hill Mrs Lee Kenny Miss Vicky Farrell Mr & Mrs Charles and Hilti (Aust) Mr Matthew Keswick Richard Fenning and Barbara Goodman Ms Michelle Hilton Mr Ravi Pishu Kewalram Wendy Volckman Mrs Colleen Goodwin Hindmarsh Investments Pty Ltd Mr & Mrs Ralph and Ms Helen Ferguson Mr & Mrs William and Ms Judy Hipsley Lorraine Keyes Ms Diane Ferrier Jacqueline Goodyear Dr Richard Ho Mr Mark Keynes Mr William Finighan Mr & Mrs Alan and Mr Mike Hobbs Dr Virendra Khanna Mrs Nona Fisher Lesley Goulburn Mr John G Hocking Mr Roderick W Kidd Mrs Wendy Fisher Ms Megan Gourlay Mr Joseph Hofmanis Mr Geoffrey H Kimpton Mr Robert Flint Ms Lorette Graham Mr James Holdsworth King & Wood Mallesons Mr James Flood Dr Leslie Green and Ms Jennifer Hole The Kinghorn Foundation Mr & Mrs Douglas and Mrs Ginny Green Mr Rod Hollingsworth Ms Lili Koch Lynne Flynn Sharon Green & Marcel Skjald Mr Robert Hopkins Mr Samuel Kushe Ms Verena Fok Mrs Wendy Griffits Mr & Mrs Tony and Mrs A Kustra Mr Grant Forster Groundhog Earthmoving Christine Housden Mr Theodore Kyriacos Ms Jane Forster and Mr Peter Guest Mr & Mrs Greg and The Lindsay and Heather Mr Glenn Eggleton Mrs Jenny Guy Gabriella Howard Payne Medical Research Mr Christian Forsterling Mr Bradley Hair Dr & Mrs David & Sarah Howell Charitable Foundation Mr John Forsyth and Mr Allan N Hall AM Mrs Sue Howieson Ms Josie La Spina Ms Ann Verschuer Mr Roger Hallaran Mrs Valerie Hrones Mrs Heather Lacey Mrs & Mr Fiona & David Foster Hallidays Heating & Cooling Mrs Lynette A Hudson The Lady Proud Foundation Ms Nancy Fox Dr Richard Hanbury Mr Robert Humphris OAM Mr Graeme Lambert Fox Family Foundation Ms Kerry Handwerk Mr David K Hunt Mr Peter Lamble Premier Media Group Peter and Patricia Hannaford Mrs Pat Huntley Mr William K Lancaster Francesca Di Natale Pty Ltd Susan Hannah William Hurley Dr Micheline Lane Mr Ross Franklin Mr and Mrs Duncan and Hydroflux Mr Steven Lang Mr Sunny Fung Lynley Hardie IAG/NRMA Insurance Mrs Beatrice Lang Mr & Mrs Peter & Sue Funnell Mr Neville Harpham Idle Acres Foundation Mrs Margaret Langford G & P Nock Foundation Mrs Ena Harries Inveruglas Pty Ltd Mrs Elizabeth Langley G P Harris Foundation Mrs Betsy Harrington Mr Graham Irving Mr David Lawson Mr Nick & Maryanne Gagliano Mr & Mrs Donald and Mrs Jill Irving Ms Le Thanh Ms Tonia Gale Margaret Harris Mr Phillip Isaacs Mrs Joan Lea Mr & Mrs Eric and Tonia Gale Mr Don Harris J Holden Family Foundation Mr Tony Leahy Galston District Garden Club Mr Loftus Harris AM and Dr George Jacobs and Mr & Mrs Michael and Gandel Philanthropy Mrs Jane Harris Dr Janice Hirshorn Wendy Leahy Ivan Gantar T & J Harris The Hon Justice Peter Mrs Catherine Lee Mr Justin H Gardener Ms Helen Harris M. Jacobson Ms Helen Lee George & Robyn Garis Mr Donald Harris AM Reverend Brian Jago Mr Lindsay Leeser Mr Ian Garling Mr & Mrs Paul and Gail Harris Dr Cary James Les Hiboux Pty Ltd Mrs Janice Garvan Mr Barry Hart Mr & Mrs Paul and Mr & Mrs John & Chris Leslie GCP Applied Technologies Mrs Jan Harvey Sutton Wendy Jeans Shui K Leung Mr Tim Gearing Mr Ian Hatch Mr Garry Jensen Mr & Mrs Rodney and Mr & Mrs Peter Gibbins Ms Cheryl Hatch Mr Kenneth Jewsbury Lynette Levis Mrs Janice Gibson and Miss Tina Hatsatouris John & Connie Kennedy In memory of Mrs Grace Ernest Heine Family Foundation Mr Tim Hawken Charitable Trust Shirley Lewis (Kit) Mrs Jane Gibson Mrs Jill Hawker Mr Patrick Jones Mr Ian Lewis Mr Peter Gibson Ms Colleen Hawkes Ms Gwendolene Jones Vicki Liberman Mr R J Gilchrist Mr & Mrs Bill and Joseph Palmer Foundation Lidia Perin Foundation Mrs Jean M Giles Alison Hayward KANDM Group Trust Mr Thomas Lin Mr & Mrs Andrew and Mrs Mary Hearn Dr Colleen Kane The Lionel & Yvonne Spencer Silvana Giles Heliflite Pty Limited Mr & Mrs George & Jill Karhan Trust Mr Alan Gilmore Mr & Mrs Herbert and Ms Helen Kasapis Lions Club of Balgowlah Inc
56 2018 Garvan Annual Report Lions Club of Diamond Valley Inc Mr Adam Milligan Lions Club of Speed Dr John Milner Mrs Maria O’Sullivan The Lions Club of Stirling Inc Milton-Ulladulla Cancer Support Group Mrs Helen Overheu Lions Clubs International Foundation Mrs Judit Mitro Pacific Equity Partners Mrs Sandra Lippiatt Mr & Mrs David and Renata Money Miss Winnie Pang Mr John B Little Ms Doreen Monk Ms Stavroula Papadatos Mr Anthony Little Mr & Mrs Philip & Margaret Moore Mr Andrew Papworth Liu Rose Restaurant Mr Harry Moore and Mrs Dot Moore The Paramor Family Mr Fangya Long Mr R E Moore Mr Craig Parker Mrs Mary Lourantaki Mr John Morgan Paspaley Pearls Mr Gordon Lowe Warren Morley Dr Sue Paton Ms Judy Lowy Mrs Catherine Moroney In Memory of Patricia Helen Guest Mr & Mrs David and Margo Lowy Dr Genevieve Mortiss Paul Ainsworth Family Foundation Ms Suzanne Lukacs Mrs Glennis Moss Miss Vina Pavitt Ms Jeannie Lyall Mr Brendon Moss Mr John Peaty Ms Helen Lynch AM Mr Darren Moss Pee Dee Creek Mr John Lynch Mostyn Family Foundation Mrs Denise Percival Ms Meryll Macarthur Mr Tony Mouatt Mrs Felicite Perez de la Sala Ms Alison MacDougall Mrs Catherine Moxham PerkinElmer Ms Maureen Macfarlan Mrs Jeannette Muggridge Perpetual Foundation – Marles & Manning Noah’s Great Chop Mrs Beverley Munday Charitable Endowment Mr Duncan Macintyre Mr Jeff Munday Perpetual Foundation – Macquarie Group Foundation Mr Tim Munro The Felicia Garvan Endowment Bob and Ruth Magid Mr & Mrs Robert & May Murison Perpetual Foundation – Mrs & Mr June and John Maher Mr Peter Murphy Hamilton Charitable Gift Account Mr & Ms Jamie and Alison Mahon Muscat & Co Perpetual Foundation – Mr & Mrs James and Janice Main Mr & Mrs Ian and Trish Napier The Kibblewhite Endowment Mrs Joan Mangan National Australia Bank Perpetual Foundation – The Stombuco Mr George Manning Ms Nicole Naylor Family Legacy Endowment Mr Wadie Mansour Ms Janette Mary O’Neil Mr & Mrs Peter and Annette Perry MAPEI Nelumbo Trust Fund Mr Peterson Mrs Sandra Marder The NELUNE Foundation Philosophy Australia In loving memory of Domenico Marrocco Netta and Norman Niven Endowment Phil & Vivien Green and Paul & Toni Platus Belmadar Pty Ltd (Dr Maggie Mackay) Mrs Almut Piatti Mrs Dianne Martin Miss Nanette Neville Pittwater Memorial Women’s Bowling Club Mary Henzell Investments Pty Ltd Mr P Newson Mr & Mrs Bart & Joy Plasier Mr Lance Matheson Ms Hilary Nicholson Mrs Suzannah Plowman Mrs Patricia McAlary Nick & Caroline Minogue Foundation Sally Pluis/Blake Mr Ian McAlpine Mrs Judith Nicol Mr Peter Polson Christine & Denis McConnell Mr Charles Nightingale Mr Anthony Ponti Mr Graham McConnochie Mr Robert Nixon Powerhouse Logistics Pty Ltd and Mrs Maree McCusker Mr Leigh Norman Powerhouse Consultancy Linda McGovern North Connex Project Company Mr & Mrs Allan and Claire Prior Mr Frank McGrath Wayne and Gretina Norton Mrs Dorothy Pryce Ms Anita McKenzie NSW Ministry of Health Mr John E A Pryor Dr Elaine McKinnon NSW Parliamentary Lions Club Ms Michele Pursche John and Pauline McLachlan Mr Simon Oaten Mr David Quane Mrs Narelle McLennan Mrs Judy O’Connor In loving memory of Kelda Quinn Mrs Shirley McLennan Mr Michael O’Dea KCSG AM Ramsay Health Care Limited Miss Susan McMahon and Mrs Marianne O’Dea Mr Roy Randall John and Deborah McMurtrie Ms Lysia O’Keefe Ms Margarita Rasink Mr & Mrs Warren J and Mrs Lorna Oliff Ms Eugenia Raskopoulos Pamela A McNamara Miss Betty Olsen Mr Brian Rathborne Ms Anne McNiven OncoSec Medical Mrs Patricia Raupach Mr Jim Mellon Mrs Annabelle O’Neil Mr Stephen R W Reed Mr Shane Merlino Dr Graham O’Neill Mr Bernard Remond Mrs Wendy Miles Mrs & Mr Beverley and Mrs Catherine Remond Mr Kenneth Millar Frank Osborn Mrs Ros Rhodes-White Haydn and Dorothy Miller Osteoporosis Southern Sydney Support Mr Hugh Rhodes-White Group Inc Ms Jane Rich garvan.org.au 57 Garvan community continued
Mr Angus Richards Mr Joseph Skrzynski AO and Mr & Mrs John and FM Weickhardt Ridley Corporation Ltd Ms Roslyn Horin Margaret te Strake Dr Berthold Weitkamp Ms Annabel M Ritchie Ms Pamela Sleeman Telstra Corporation Mr Andrew Wells Mrs Judith Roach Dr & Mrs Raymond and Mr Robert B Thomas AO Mr Howard Welsh Mr Stuart Robertson Robyn Sleet Mr & Mrs John & Joan Thomas Mr & Mrs Edward and Mr Peter Rockey SM O’Keefe Investments Mr Ian Thorpe Lorraine West The Rodney & Judith O’Neil Pty Ltd Tigerspike WestpacGroup Foundation SMEC Holdings Ms Mara-Jean Tilley Mr & Mrs Norman and Mrs Gloria Rolfe Mr Roger Smith Mrs Joy Timbrell Joy Wheatley In memory of Roger Rose Mrs Jennifer M Smith Miss Andrea Tomlin Wheatley Family Foundation Rosemary Pryor Foundation Dr Robert Smith Mr John Tracy Mrs Judith Wheeldon AM Mr Bruce Rosenberg Mr Stephen Smith Mr Paul Traeger Whitsunday Lions Club Inc Mr John Roth and Ms Judy Snow Trawalla Foundation Craig and Suzanne Whitworth Ms Jillian Segal AO Mr & Mrs Bruce and Mr Hugh Tregarthen Mr Andrew Whyte Bobbie Scotland Barbara Solomon Mrs & Mr Julia and Mrs Kate Wilkie Mr David Ross Mr & Mrs David and Simon Tregoning Mrs Myra Williams Mr Jim Ross Audrey Solomons Mr Walter Turnbull Ms Catherine Williams Mr & Mrs Edward and Dr Peter Southwell-Keely Tusa Pty Ltd/ Webb family Mrs Maureen Williams-Barrow Leora Ross Sparro Digital Marketing Twin Towns Services Mr Ian Willington Rotary Club of Dural Mrs Robin Spencer Community Foundation Limited Willowie Nominees Pty Ltd Mr David E Routley St George Football Association UK Online Giving Foundation Mrs Jon M Wilson Ms Alison Rowland St Vincent’s Curran Foundation Mr Unwin Dr Bruce Wilson Mrs Marietta Russell Mr & Mrs K J & F L Stanton Ms Sarah van der Geest Miss Vivienne Windsor Mr Robert Russell Mr David Stapledon Mrs Maya Van Rol Mr R Witchard Alan and Lynne Rydge Ms Martha Stauble Mrs Margaret Vere Mr & Mrs Karl and Sachdev Foundation Dr Chris Steketee Vermeer Madeline Wolf Ms Bridget Sack Miss Alison Stephen Vidler Family Trust Mr Peter Wolstenholme Justice Ronald Sackville AO Mr & Mrs Andreas and Ervin Vidor AM and Ms Lisa Wong and Mrs Pamela Sackville Sadhana Stephens Charlotte Vidor Reverend John Woo Gordon and Christine Windeyer Ms Leslie Stern VitraGroup Wood Family Foundation Foundation The Steven McKerihan Ms Anna Vlach Workday Inc Mrs Karen Samociuk Charitable Trust Mr & Mrs Peter and Mrs Penelope Wright John and Ros Sample Mrs Maureen Stevenson Chrissa Vlandis Mrs Alexandria Wright and family Wendy Stewart Vodafone Foundation Australia Michael & Shirley Wrigley Mrs Barbara R Sanders Duck Stone Mr & Mrs John and Megan Wade Mr Ronald Wyld Miss Leah Sawford Mrs Gillian Storey AM Mr Peter Wade Mr J M Yorke Say Family Foundation Mrs Rhonda Storey Wade Civil Engineering Pty Ltd Mr & Mrs Ralph & Robyn Youie David and Eva Scheinberg Mr Reginald H Streifler Mrs Khoe Wahyudin The Yulgilbar Foundation Mrs & Mr Juliet and Dr Jeanne-Claude Strong Mr Isaac Wakil AO Zen Imports Pty Ltd Conrad Schmidt Mr & Mrs Peter and Mrs Caroline Walder Ms & Mr Linda and Diane Sturrock Mr James Waley Community Fundraisers Stephen Schurr In Memory of the Late Mrs Ann Walker Australasian Tunnelling Society Mr & Mrs Ronald and Kathrin Nell A Wilshire In memory of John Walker (Sydney Chapter) Gloria Schwarz Mr & Mrs Lorrie and Di Sutton Mrs G M S Walker Mr Malcolm Baker Scleroderma Association of NSW Suttons Motors Management Mrs Nancy Walker Mr David Blau Ms Ines Scotland Mr & Mrs Jim and Fran Sweeny Mr Ian Wall Mr Sam Breed Mr Laurie W Seaman Sydney Women’s Mr Robert J Walsh Ms Lisa Chikarovski Ms Lucille Segal International Club Mr Barry Walsh Ms Judy Christian Mrs Robyn Selby Mr Trevor Sykes Ms Evelyn Walsh Mr William Doig Dr Hilton Selvey Tai-Chi for Seniors (Hughes) Mr & Mrs J B Walsh Fundraising Townsville Mrs Adrienne Seymour Mr Harry Tamvakeras Richard and Susan Ms Hannah Gibbon Mrs Judith Shanahan Mr Peter Tan Egerton-Warburton Foundation Mr Evan Jackson Ms Diane Sharland Mr Ivan Tan Dr John R Warneford Emily Jones Ms Deborah Sharp Ms Rose Tay Ms Margaret Weaver Mr Ryan Kolster Ms Lindsey Shaw Ms Victoria Taylor Mr Neville Webb Miss Janelle Love Mr William Sherrard Mr Wilbred Taylor Ms Dulcie Webb Mr Ian McAlpine Mrs Edith Shipway Miss Julie Taylor Ms Alexandra Wedutenko Noah’s Great Chop Skipper-Jacobs Charitable Trust Mrs Rosemary Taylor Mr Ken Wee Mr Mark Panitz Sky Catering Pty Ltd Mr Roger Taylor Mr & Mrs JW and Pretty in Pink
58 2018 Garvan Annual Report Mr Michael Scott Young Garvan Miss Kate Skulte Mr Will de Beaurepaire Mrs Susan Thorley Dr Niall Byrne Ms Eva Wong A/Prof Elissa Deenick Yang Yang Mr Lindsay Leeser Miss Lucia Robson Estates received in 2018 Ms Natasha Shah Estate of the late Douglas Agnew Estate of the late John Ball Estate of the late Peter Binnie Estate of the late Dorothy Boddy Estate of the late Lesley Bourke Estate of the late Ronald Brett Estate of the late Jennifer Cowling Estate of the late Carin Cummings Estate of the late Alan Currie Estate of the late Marie Dalkeith Estate of the late Mary Dallimore Estate of the late Dawn Daniel Estate of the late Laksiri De Silva Estate of the late Miriam Douglass Estate of the late Malcolm Foley Estate of the late Lynette Forbes Estate of the late Pauliene Fraser Estate of the late Dorothy French Estate of the late Stephen Gallagher Estate of the late Harold Garvan Estate of the late Neville Grace Estate of the late Beth Grainger Estate of the late George Gray Estate of the late Fay Harris In memory of John and Dawn Hughes Estate of the late Indrani Jayasinghe Estate of the late Ann Kirby Estate of the late Leo Mamontoff Estate of the late Hazel McNamara Estate of the late Mabs Melville Estate of the late Freda Moore Estate of the late Helen Morgan Estate of the late Joan Murphy Estate of the late Aveen O’Reilly Estate of the late Eleanor Podosky Estate of the late John Ramsbotton Estate of the late Claire Rayne Estate of the late Albert Reader Estate of the late Neville Saywell Estate of the late Robert Sharp Estate of the late Lesly Skilton Estate of the late Walter Spratt Estate of the late Reginald Stubbs Estate of the late Alexander Vuksanovic Estate of the late Nola Wagner Estate of the late Joyce Whitmore Estate of the late William Wood Estate of the late Lola Woodward
garvan.org.au 59 Publications 2018
Abou Sawan S, van Vliet S, Parel JT, Aleksova J, Kurniawan S, Vucak- Anderson KE, van Duijn E, Craufurd D, Beals JW, Mazzulla M, West DWD et Dzumhur M, Kerr P, Ebeling PR, Milat F, Drazinic C, Edmondson M, Goodman al. Translocation and protein complex Elder GJ. Aortic vascular calcification is N et al. Clinical Management of co-localization of mTOR is associated inversely associated with the trabecular Neuropsychiatric Symptoms of Huntington with postprandial myofibrillar protein bone score in patients receiving dialysis. Disease: Expert-Based Consensus synthesis at rest and after endurance Bone 2018; 113:118-123. DOI: 10.1016/j. Guidelines on Agitation, Anxiety, Apathy, exercise. Physiological Reports 2018; bone.2018.05.014 Psychosis and Sleep Disorders. Journal 6:e13628. DOI: 10.14814/phy2.13628 of Huntington’s Disease 2018; 7:239-250. Aleksova J, Wong P, McLachlan R, DOI: 10.3233/JHD-180293 Alajlouni D, Bliuc D, Tran T, Pocock Choy KW, Ebeling PR, Milat F, Elder N, Nguyen TV, Eisman JA, Center GJ. Sex hormone-binding globulin is a Atlantis E, Kormas N, Samaras K, Fahey JR. Nonstandard Lumbar Region in biomarker associated with nonvertebral P, Sumithran P, Glastras S et al. Clinical Predicting Fracture Risk. Journal Of fracture in men on dialysis therapy. Obesity Services in Public Hospitals in Clinical Densitometry 2018; DOI: 10.1016/j. Kidney international 2018; 94:372-380. Australia: a position statement based on jocd.2017.05.014 DOI: 10.1016/j.kint.2018.02.021 expert consensus. Clinical Obesity 2018; DOI: 10.1111/cob.12249 Alam K, Schofield D. Economic evaluation Algohary A, Viswanath S, Shiradkar of genomic sequencing in the paediatric R, Ghose S, Pahwa S, Moses D et al. Avery DT, Kane A, Nguyen T, Lau A, population: a critical review. European Radiomic features on MRI enable risk Nguyen A, Lenthall H et al. Germline- Journal of Human Genetics 2018; 26:1241- categorization of prostate cancer patients activating mutations in PIK3CD 1247. DOI: 10.1038/s41431-018-0175-6 on active surveillance: Preliminary findings. compromise B cell development and Journal of Magnetic Resonance Imaging function. Journal of Experimental Medicine Alamgeer M, Watkins DN, Banakh 2018; 48:818-828. DOI: 10.1002/jmri.25983 2018; 215:2073-2095. DOI: 10.1084/ I, Kumar B, Gough DJ, Markman B, jem.20180010 Ganju V. A phase IIa study of HA- Allanson BM, Weber MA, Jackett irinotecan, formulation of hyaluronic LA, Chan C, Lau L, Ziegler DS et Aziz D, Etemadmoghadam D, Caldon CE, acid and irinotecan targeting CD44 in al. Oral malignant gastrointestinal Au-Yeung G, Deng N, Hutchinson R et extensive-stage small cell lung cancer. neuroectodermal tumour with junctional al. 19q12 amplified and non-amplified Investigational New Drugs 2018; 36:288- component mimicking mucosal subsets of high grade serous ovarian 298. DOI: 10.1007/s10637-017-0555-8 melanoma. Pathology 2018; 50:648-653. cancer with overexpression of cyclin DOI: 10.1016/j.pathol.2018.07.002 E1 differ in their molecular drivers and Alarkawi D, Ali MS, Bliuc D, Center JR, clinical outcomes. Gynecologic oncology Prieto-Alhambra D. The Challenges and Alonso N, Estrada K, Albagha OME, 2018; 151:327-336. DOI: 10.1016/j. Opportunities of Pharmacoepidemiology Herrera L, Reppe S, Olstad OK et al. ygyno.2018.08.039 in Bone Diseases. Journal of Bone and Identification of a novel locus on Mineral Research Plus 2018; 2:187-194. chromosome 2q13, which predisposes Bagnall RD, Ingles J, Dinger ME, DOI: 10.1002/jbm4.10051 to clinical vertebral fractures Cowley MJ, Ross SB, Minoche AE independently of bone density. Annals of et al. Whole Genome Sequencing Aleksova J, Kurniawan S, Elder GJ. the Rheumatic Diseases 2018; 77:378-385. Improves Outcomes of Genetic The trabecular bone score is associated DOI: 10.1136/annrheumdis-2017-212469 Testing in Patients With Hypertrophic with bone mineral density, markers of Cardiomyopathy. Journal of the American bone turnover and prevalent fracture in Alshekaili J, Chand R, Lee CE, Corley College of Cardiology 2018; 72:419-429. patients with end stage kidney disease. S, Kwong K, Papa I et al. STAT3 DOI: 10.1016/j.jacc.2018.04.078 Osteoporosis International 2018; 29:14 47- regulates cytotoxicity of human CD57+ 1455. DOI: 10.1007/s00198-018-4468-y CD4+ T cells in blood and lymphoid Bahl N, Stone G, McLean M, Ho follicles. Scientific Reports 2018; 8:3529. KKY, Birzniece V. Decorin, a growth DOI: 10.1038/s41598-018-21389-8 hormone‑regulated protein in humans. European Journal of Endocrinology 2018; 178:147-154. DOI: 10.1530/EJE-17-0844
60 2018 Garvan Annual Report Bakshi I, Brown SHJ, Brandon AE, Bensellam M, Jonas JC, Laybutt DR. Bousfiha A, Jeddane L, Picard C, Ailal F, Suryana E, Mitchell TW, Turner N, Cooney Mechanisms of beta-cell dedifferentiation Bobby Gaspar H, Al-Herz W et al. The GJ. Increasing Acyl CoA thioesterase in diabetes: recent findings and 2017 IUIS Phenotypic Classification for activity alters phospholipid profile without future research directions. Journal of Primary Immunodeficiencies.Journal of effect on insulin action in skeletal muscle Endocrinology 2018; 236:R109-R143. Clinical Immunology 2018; 38:129-143. of rats. Scientific Reports 2018; 8:13967. DOI: 10.1530/JOE-17-0516 DOI: 10.1007/s10875-017-0465-8 DOI: 10.1038/s41598-018-32354-w Benthani FA, Herrmann D, Tran PN, Pangon Boyle F, Beith J, Burslem K, de Boer R, Hui Bakshi I, Suryana E, Small L, Quek L, Lucas MC, Allam AH et al. 'MCC' protein R, Lim E et al. Hormone receptor positive, LE, Brandon AE, Turner N, Cooney interacts with E-cadherin and beta-catenin HER2 negative metastatic breast cancer: GJ. Fructose bisphosphatase 2 strengthening cell-cell adhesion of HCT116 Impact of CDK4/6 inhibitors on the overexpression increases glucose colon cancer cells. Oncogene 2018; 37:663- current treatment paradigm. Asia-Pacific uptake in skeletal muscle. Journal 672. DOI: 10.1038/onc.2017.362 Journal of Clinical Oncology 2018; 14 Suppl of Endocrinology 2018; 237:101-111. 4:3-11. DOI: 10.1111/ajco.13064 DOI: 10.1530/JOE-17-0555 Best M, Newson AJ, Meiser B, Juraskova I, Goldstein D, Tucker K et al. The PiGeOn Brandon AE, Liao MBQ. Protein kinase Balaban S, Lee LS, Varney B, Aishah A, project: protocol of a longitudinal study C epsilon deletion in adipose tissue, but Gao Q, Shearer RF et al. Heterogeneity of examining psychosocial and ethical not in liver, improves glucose tolerance. fatty acid metabolism in breast cancer issues and outcomes in germline genomic Cell Metabolism 2018; DOI: 10.1016/j. cells underlies differential sensitivity sequencing for cancer. BMC Cancer 2018; cmet.2018.09.013 to palmitate-induced apoptosis. 18:454. DOI: 10.1186/s12885-018-4366-x Molecular Oncology 2018; 12:1623-1638. Brink R, Phan TG. Self-Reactive B DOI: 10.1002/1878-0261.12368 Best M, Newson AJ, Meiser B, Juraskova I, Cells in the Germinal Center Reaction. Goldstein D, Tucker K et al. The PiGeOn Annual Review of Immunology 2018; Balasubramaniam S, Riley LG, Vasudevan project: protocol for a longitudinal study 36:339-357. DOI: 10.1146/annurev- A, Cowley MJ, Gayevskiy V, Sue CM et al. examining psychosocial, behavioural immunol-051116-052510 EPG5-Related Vici Syndrome: A Primary and ethical issues and outcomes in Defect of Autophagic Regulation with cancer tumour genomic profiling. Brown HK, Allocca G, Ottewell PD, an Emerging Phenotype Overlapping BMC Cancer 2018; 18:389. DOI: 10.1186/ Wang N, Brown NJ, Croucher PI et al. with Mitochondrial Disorders. Journal of s12885-018-4310-0 Parathyroid Hormone (PTH) Increases Inherited Metabolic Disease Reports 2018; Skeletal Tumour Growth and Alters DOI: 10.1007/8904_2017_71 Beziat V, Li J, Lin JX, Ma CS, Li P, Tumour Distribution in an In Vivo Bousfiha A et al. A recessive form of Model of Breast Cancer. International Barnet MB, Blinman P, Cooper W, hyper-IgE syndrome by disruption of Journal of Molecular Sciences 2018; 19. Boyer MJ, Kao S, Goodnow CC. ZNF341-dependent STAT3 transcription DOI: 10.3390/ijms19102920 Understanding Immune Tolerance and activity. Science Immunology 2018; of Cancer: Re‑Purposing Insights 3:None. DOI: 10.1126/sciimmunol.aat4956 Burchfield JG, Kebede MA, Meoli CC, from Fetal Allografts and Microbes. Stockli J, Whitworth PT, Wright AL et Bioessays 2018; 40:e1800050. Birzniece V. Hepatic actions of androgens al. High dietary fat and sucrose results DOI: 10.1002/bies.201800050 in the regulation of metabolism. Current in an extensive and time-dependent Opinion in Endocrinology Diabetes and deterioration in health of multiple Barnet MB, Cooper WA, Boyer MJ, Kao S. Obesity 2018; 25:201-208. DOI: 10.1097/ physiological systems in mice. Journal of Immunotherapy in Non-Small Cell Lung MED.0000000000000405 Biological Chemistry 2018; 293:5731-5745. Cancer: Shifting Prognostic Paradigms. DOI: 10.1074/jbc.RA117.000808 Journal of Clinical Medicine 2018; 7:E151. Block MS, Vierkant RA, Rambau PF, DOI: 10.3390/jcm7060151 Winham SJ, Wagner P, Traficante N et al. Burnett DL, Langley DB, Schofield P, Hermes MyD88 and TLR4 expression in epithelial JR, Chan TD, Jackson J et al. Germinal Barnet MB, Zielinski RR, Warby A, ovarian cancer. Mayo Clinic Proceedings center antibody mutation trajectories Lewis CR, Kao S. Pseudoprogression 2018; 93:307-320. DOI: 10.1016/j. are determined by rapid self/foreign Associated with Clinical Deterioration and mayocp.2017.10.023 discrimination. Science 2018; 360:223- Worsening Quality of Life in Malignant 226. DOI: 10.1126/science.aao3859 Pleural Mesothelioma. Journal of Thoracic Boisson-Dupuis S, Ramirez-Alejo N, Oncology 2018; 12:e1-e2. DOI: 10.1016/j. Li Z, Patin E, Rao G et al. Tuberculosis Byrne FL, Olzomer EM, Brink R, Hoehn KL. jtho.2017.09.001 and impaired IL-23–dependent IFN-g Knockout of glucose transporter GLUT6 immunity in humans homozygous for has minimal effects on whole body Beaudoin JD, Novoa EM, Vejnar CE, a common TYK2 missense variant. metabolic physiology in mice. American Yartseva V, Takacs CM, Kellis M, Giraldez Science Immunology 2018; 3:eaau871 Journal of Physiology-Endocrinology AJ. Analyses of mRNA structure DOI: 10.1126/sciimmunol.aau8714 and Metabolism 2018; 315:E286-E293. dynamics identify embryonic gene DOI: 10.1152/ajpendo.00082.2018 regulatory programs. Nature Structural & Molecular Biology 2018; 25:677-686. DOI: 10.1038/s41594-018-0091-z
garvan.org.au 61 Publications 2018 continued
Byrne NM. Tumor Cell Dormancy and Chandrashekaran IR. Characterization of Chou A, Kim Y, Samra JS, Pajic M, Gill AJ. Reactivation in Bone: Skeletal Biology peptide interactions that regulate PKCε BRAF gene rearrangements can be and Therapeutic Opportunities. Journal activation. FEBS Letters 2018; 592:179-189. identified by FISH studies in pancreatic of Bone and Mineral Research Plus 2018; DOI: 10.1002/1873-3468.12953 acinar cell carcinoma. Pathology DOI: 10.1002/jbm4.10125 2018; 50:345-348. DOI: 10.1016/j. Chen W, Pocock N. Male Osteoporosis pathol.2017.09.027 Campbell H, Fleming N, Roth I, Mehta Awareness in the Elderly: an Analysis of S, Wiles A, Williams G et al. 133p53 Dual-Energy X-Ray Absorptiometry Use in Chou A, Toon CW, Clarkson A, Sheen A, isoform promotes tumour invasion and Australia Between 1995 and 2015. Journal Sioson L, Gill AJ. The epithelioid BAP1- metastasis via interleukin-6 activation of Clinical Densitometry 2018; 21:105-109. negative and p16-positive phenotype of JAK-STAT and RhoA-ROCK signalling. DOI: 10.1016/j.jocd.2016.10.008 predicts prolonged survival in pleural Nature Communications 2018; 9:254. mesothelioma. Histopathology 2018; DOI: 10.1038/s41467-017-02408-0 Chen W, Simpson JM, March LM, Blyth 72:509-515. DOI: 10.1111/his.13392 FM, Bliuc D, Tran T et al. Comorbidities Carpenter BL, Zhou W, Madaj Z, DeWitt AK, Only Account for a Small Proportion of Clarke J, Proudfoot J, Vatiliotis V, Verge Ross JP, Gronbaek K et al. Mother-child Excess Mortality After Fracture: A Record C, Holmes-Walker DJ, Campbell L et al. transmission of epigenetic information Linkage Study of Individual Fracture Types. Attitudes towards mental health, mental by tunable polymorphic imprinting. Journal of Bone and Mineral Research 2018; health research and digital interventions Proceedings of the National Academy of 33:795-802. DOI: 10.1002/jbmr.3374 by young adults with type 1 diabetes: Sciences of the United States of America A qualitative analysis. Health Expectations 2018; DOI: 10.1073/pnas.1815005115 Chen X, Harkness L, Jia Z, Prowse A, 2018; DOI: 10.1111/hex.12662 Monteiro MJ, Gray PP. Methods for Castano Z, San Juan BP, Spiegel A, Expansion of Three-Dimensional Cole-Clark D, Nair-Shalliker V, Bang A, Pant A, DeCristo MJ, Laszewski T et al. Cultures of Human Embryonic Stem Cells Rasiah K, Chalasani V, Smith DP. An IL-1beta inflammatory response driven Using a Thermoresponsive Polymer. initial melanoma diagnosis may increase by primary breast cancer prevents Tissue Engineering 2018; 24:146 -157. the subsequent risk of prostate cancer: metastasis-initiating cell colonization. DOI: 10.1089/ten.TEC.2017.0331 Results from the New South Wales Nature Cell Biology 2018; 20:1084-1097. Cancer Registry. Scientific Reports 2018; DOI: 10.1038/s41556-018-0173-5 Chin V, Nagrial A, Sjoquist K, O'Connor CA, 8:7167. DOI: 10.1038/s41598-018-25408-6 Chantrill L, Biankin AV et al. Chemotherapy Cazet AS, Hui MN, Elsworth BL, Wu and radiotherapy for advanced Collins AM, Jackson KJL. On being the SZ, Roden D, Chan CL et al. Targeting pancreatic cancer. Cochrane Database of right size: antibody repertoire formation stromal remodeling and cancer stem cell Systematic Reviews 2018; 3:CD011044. in the mouse and human. International plasticity overcomes chemoresistance DOI: 10.1002/14651858.CD011044.pub2 Journal of Immunogenetics 2018; 70:143- in triple negative breast cancer. 158. DOI: 10.1007/s00251-017-1049-8 Nature Communications 2018; 9:2897. Chitty JL, Filipe EC, Lucas MC, Herrmann DOI: 10.1038/s41467-018-05220-6 D, Cox TR, Timpson P. Recent advances Compeer EB, Kraus F, Ecker M, Redpath in understanding the complexities G, Amiezer M, Rother N et al. A mobile Cehic MG, Nundall N, Greenfield JR, of metastasis. Methods in Molecular endocytic network connects clathrin- Macdonald PS. Management Strategies Biology 2018; 7: DOI: 10.12688/ independent receptor endocytosis to for Posttransplant Diabetes Mellitus after f1000research.15064.2 recycling and promotes T cell activation. Heart Transplantation: A Review. Journal Nature Communications 2018; 9:1597. of Transplantation 2018; 2018:1025893. Cho JH, Sprent J. TCR tuning of T cell DOI: 10.1038/s41467-018-04088-w DOI: 10.1155/2018/1025893 subsets. Immunological Reviews 2018; 283:129-137. DOI: 10.1111/imr.12646 Conway JRW, Warren SC, Herrmann D, Chaffer CL, Goetz JG. CD44 orchestrates Murphy KJ, Cazet AS, Vennin C et al. metastatic teamwork. Developmental Chou A, Froio D, Nagrial AM, Parkin A, Intravital imaging to monitor therapeutic Cell 2018; 47:691-693. DOI: 10.1016/j. Murphy KJ, Chin VT et al. Tailored first- response in moving hypoxic regions devcel.2018.11.038 line and second-line CDK4-targeting resistant to PI3K pathway targeting treatment combinations in mouse models in pancreatic cancer. Cell Reports Chan EKF, Cameron DL, Petersen DC, of pancreatic cancer. Gut 2018; 67:2142- 2018; 23:3312-3326. DOI: 10.1016/j. Lyons RJ, Baldi BF, Papenfuss AT et al. 2155. DOI: 10.1136/gutjnl-2017-315144 celrep.2018.05.038 Optical mapping reveals a higher level of genomic architecture of chained fusions Chou A, Itchins M, de Reuver et al. ATRX Cooper WA, Barnet MB, Kao SC, Scolyer in cancer. Genome Research 2018; 28:726- loss is an independent predictor of poor RA. Biomarkers that predict response to 738. DOI: 10.1101/gr.227975.117 survival in pancreatic neuroendocrine immunotherapy – no magic bullet. Cancer tumours. Human Pathology 2018; 82:249- Forum 2018; 42:92-101. 257. DOI: 10.1016/j.humpath.2018.07.032
62 2018 Garvan Annual Report Cox TR, Erler JT, Rumney RMH. Established De Sousa SMC, Sheriff N, Tran CH, Menzies Dragoljevic D, Kraakman MJ, Nagareddy models and new paradigms for hypoxia- AM, Tsang VHM, Long GV, Tonks KTT. Fall PR, Ngo D, Shihata W, Kammoun HL et driven cancer-associated bone disease. in thyroid stimulating hormone (TSH) may al. Defective cholesterol metabolism in Calcified Tissue International 2018; 102:163- be an early marker of ipilimumab-induced haematopoietic stem cells promotes 173. DOI: 10.1007/s00223-017-0352-6 hypophysitis. Pituitary 2018; 21:274-282. monocyte-driven atherosclerosis in DOI: 10.1007/s11102-018-0866-6 rheumatoid arthritis. European Heart Crumbaker M, Savdie R, Joshua AM. Journal 2018; 39:2158-2167. DOI: 10.1093/ Refining the assessment and implications Deenick EK, Morey A, Danta M, Emmett L, eurheartj/ehy119 of AR-V7 in castrate-resistant prostate Fay K, Gracie G et al. Reversible cancer. European Urology 2018; 73:736- Suppression of Lymphoproliferation and Dreyer SB, Jamieson NB, Upstill-Goddard 737. DOI: 10.1016/j.eururo.2017.11.005 Thrombocytopenia with Rapamycin R, Bailey PJ, McKay CJ, Biankin AV, Chang in a Patient with Common Variable DK. Defining the molecular pathology of Currey N, Daniel JJ, Mladenova DN, Immunodeficiency.Journal of Clinical pancreatic body and tail adenocarcinoma. Dahlstrom JE, Kohonen-Corish MRJ. Immunology 2018; 38:159-162. British Journal of Surgery 2018; Microsatellite instability in mouse models DOI: 10.1007/s10875-018-0477-z 105:e183-e191. DOI: 10.1002/bjs.10772 of colorectal cancer. Canadian Journal of Gastroenterology and Hepatology Deenick EK, Pelham SJ, Kane A, Ma Du YT, Piscitelli D, Ahmad S, Trahair 2018; 2018:Article ID 6152928. CS. Signal Transducer and Activator LG, Greenfield JR, Samocha-Bonet D DOI: 10.1155/2018/6152928 of Transcription 3 Control of Human et al. Effects of Glutamine on Gastric T and B Cell Responses. Frontiers in Emptying of Low- and High-Nutrient Curtis J, Watkins A, Teasdale S, Lederman Immunology 2018; 9:168. DOI: 10.3389/ Drinks in Healthy Young Subjects-Impact O, Kalucy M, Lappin J et al. 2-year follow- fimmu.2018.00168 on Glycaemia. Nutrients 2018; 10:E739. up: Still keeping the body in mind. Australian DOI: 10.3390/nu10060739 and New Zealand Journal of Psychiatry 2018; Deveson IW, Brunck ME, Blackburn J, DOI: 10.1177/0004867417753553 Tseng E, Hon T, Clark TA et al. Universal Duivenvoorden HM, Spurling A, O'Toole Alternative Splicing of Noncoding Exons. SA, Parker BS. Discriminating the Czeczor JK, Genders AJ, Aston-Mourney Cell Systems 2018; 6:p245-255. earliest stages of mammary carcinoma K, Connor T, Hall LG, Hasebe K et al. APP DOI: 10.1016/j.cels.2017.12.005 using myoepithelial and proliferative deficiency results in resistance to obesity markers. PLoS One 2018; 13:e0201370. but impairs glucose tolerance upon high Dissanayake WC, Sorrenson B, Cognard DOI: 10.1371/journal.pone.0201370 fat feeding. Journal of Endocrinology 2018; E, Hughes WE, Shepherd PR. beta-catenin 237:311-322. DOI: 10.1530/JOE-18-0051 is important for the development of an Earp M, Tyrer JP, Winham SJ, Lin HY, insulin responsive pool of GLUT4 glucose Chornokur G, Dennis J et al. Variants Dadaev T, Saunders EJ, Newcombe PJ, transporters in 3T3-L1 adipocytes. in genes encoding small GTPases and Anokian E, Leongamornlert DA, Brook MN Experimental Cell Research 2018; association with epithelial ovarian cancer et al. Fine-mapping of prostate cancer DOI: 10.1016/j.yexcr.2018.03.011 susceptibility. PLoS One 2018; 13:e0197561. susceptibility loci in a large meta-analysis DOI: 10.1371/journal.pone.0197561 identifies candidate causal variants. Dixon-Suen SC, Nagle CM, Thrift AP, Nature Communications 2018; 9:2256. Pharoah PDP, Ewing A, Pearce CL et al. Eisman JA, Geusens P, van den Bergh DOI: 10.1038/s41467-018-04109-8 Adult height is associated with increased J. The Emperor's New Clothes: What risk of ovarian cancer: a Mendelian Randomized Controlled Trials Don't Cover. Daniszewski M, Nguyen Q, Chy HS, Singh randomisation study. British Journal of Journal of Bone and Mineral Research 2018; V, Crombie DE, Kulkarni T et al. Single- Cancer 2018; 118:1123-1129. DOI: 10.1038/ 33:1394-1396. DOI: 10.1002/jbmr.3539 Cell Profiling Identifies Key Pathways s41416-018-0011-3 Expressed by iPSCs Cultured in Different Elder GJ, Malik A, Lambert K. The role of Commercial Media. iScience 2018; 7:30- Dong X, Liao Z, Gritsch D, Hadzhiev dietary phosphate restriction in chronic 39. DOI: 10.1016/j.isci.2018.08.016 Y, Bai Y, Locascio JJ et al. Enhancers kidney disease. Nephrology 2018; 23:1107- active in dopamine neurons are a 1115. DOI: 10.1111/nep.13188 David D, Anand D, Araujo C, Gloss B, primary link between genetic variation Fino J, Dinger M et al. Identification of and neuropsychiatric disease. Nature Elshorbagy AK, Samocha-Bonet D, OAF and PVRL1 as candidate genes Neuroscience 2018; 21:1482-1492. Jerneren F, Turner C, Refsum H, Heilbronn for an ocular anomaly characterized by DOI: 10.1038/s41593-018-0223-0 LK. Food Overconsumption in Healthy Peters anomaly type 2 and ectopia lentis. Adults Triggers Early and Sustained Experimental Eye Research 2018; 168:161- Doyle KL, Cunha C, Hort Y, Tasan R, Increases in Serum Branched-Chain Amino 170. DOI: 10.1016/j.exer.2017.12.012 Sperk G, Shine J, Herzog H. Role of Acids and Changes in Cysteine Linked neuropeptide Y (NPY) in the differentiation to Fat Gain. Journal of Nutrition 2018; De Sousa SMC, McCormack AI. of Trpm-5-positive olfactory microvillar 148:1073-1080. DOI: 10.1093/jn/nxy062 Aggressive Pituitary Tumors and Pituitary cells. Neuropeptides 2018; 68:90-98. Carcinomas. Endotext [Internet] 2018; DOI: 10.1016/j.npep.2018.02.007 DOI: https://www.ncbi.nlm.nih.gov/books/ NBK534881/
garvan.org.au 63 Publications 2018 continued
Esapa CT, Piret SE, Nesbit MA, Thomas Febbraio MA, Reibe S, Shalapour S, Ooi Gennarino VA, Palmer EE, McDonell LM, GP, Coulton LA, Gallagher OM et al. GJ, Watt MJ, Karin M. Preclinical Models Wang L, Adamski CJ, Koire A et al. A Mild An N-Ethyl-N-Nitrosourea (ENU) for Studying NASH-Driven HCC: How PUM1 Mutation Is Associated with Adult- Mutagenized Mouse Model for Autosomal Useful Are They? Cell Metabolism 2018; Onset Ataxia, whereas Haploinsufficiency Dominant Nonsyndromic Kyphoscoliosis DOI: 10.1016/j.cmet.2018.10.012 Causes Developmental Delay and Due to Vertebral Fusion. Journal of Bone Seizures. Cell 2018; 172:924-936 e11. and Mineral Research Plus 2018; 2:154-163. Fernandez JP, Vejnar CE, Giraldez AJ, DOI: 10.1016/j.cell.2018.02.006 DOI: 10.1002/jbm4.10033 Rouet R, Moreno-Mateos MA. Optimized CRISPR-Cpf1 system for genome editing Ghorbani S, Eyni H, Tiraihi T, Asl LS, Ewans LJ, Schofield D, Shrestha R, in zebrafish. Methods 2018; 150:11-18. Soleimani M, Atashi A et al. Combined Zhu Y, Gayevskiy V, Ying K et al. Whole- DOI: 10.1016/j.ymeth.2018.06.014 effects of 3D bone marrow stem cell- exome sequencing reanalysis at 12 seeded wet-electrospun poly lactic months boosts diagnosis and is cost- Filipe EC, Chitty JL, Cox TR. Charting the acid scaffolds on fa-thickness skin effective when applied early in Mendelian unexplored extracellular matrix in cancer. wound healing. International Journal disorders. Genetics in Medicine 2018; International Journal of Experimental of Polymeric Materials and Polymeric DOI: 10.1038/gim.2018.39 Pathology 2018; 99:58-76. DOI: 10.1111/ Biomaterials 2018; 67:905-912. iep.12269 DOI: 10.1080/00914037.2017.1393681 Fairfield H Falank C. The skeletal cell- derived molecule sclerostin drives Forrest L, Mitchell G, Thrupp L, Petelin Gielchinsky I, Chang J, Cusick T, Delprado bone marrow adipogenesis. Journal of L, Richardson K, Mascarenhas L, Young W, Nguyen Q, Yuen C et al. Prostate Cellular Physiology 2018; 233:1156 -1167. MA. Consumer attitudes towards the cancer in 432 men aged <50 years in DOI: 10.1002/jcp.25976 establishment of a national Australian the prostate-specific antigen era: a new familial cancer research database by outlook. BJU International 2018; 122:35-41. Fangmeier ML, Noble DWA, O'Dea RE, the Inherited Cancer Connect (ICCon) DOI: 10.1111/bju.14586 Usui T, Lagisz M, Hesselson D, Nakagawa Partnership. Journal of Community Genetics S. Computer Animation Technology 2018; DOI: 10.1007/s12687-017-0323-7 Gielchinsky I, Scheltema MJ, Cusick T, in Behavioral Sciences: A Sequential, Chang J, Shnier R, Moses D et al. Reduced Automatic, and High-Throughput Friedman CE, Nguyen Q, Lukowski sensitivity of multiparametric MRI for Approach to Quantifying Personality in SW, Helfer A, Chiu HS, Miklas J et al. clinically significant prostate cancer in Zebrafish (Danio rerio). Zebrafish 2018; Single-cell transcriptomic analysis of men under the age of 50. Research and 15:206-210. DOI: 10.1089/zeb.2017.1532 cardiac differentiation from human PSCs Reports in Urology 2018; 10:145-150. reveals HOPX-dependent cardiomyocyte DOI: 10.2147/rru.S169017 Farzi A, Lau J, Ip CK, Qi Y, Shi YC, Zhang maturation. Cell Stem Cell 2018; 23:586- L et al. Arcuate nucleus and lateral 598. DOI: 10.1016/j.stem.2018.09.009 Gloss BS, Dinger ME. Realizing the hypothalamic CART neurons in the significance of noncoding functionality mouse brain exert opposing effects on Fuksiewicz M, Kotowicz B, Rutkowski in clinical genomics. Experimental energy expenditure. eLife 2018; 7:e36494. A, Achinger-Kawecka J, Wagrodzki M, and Molecular Medicine 2018; 50:97. DOI: 10.7554/eLife.36494 Kowalska MM. The Assessment of DOI: 10.1038/s12276-018-0087-0 Clinical Usage and Prognostic Value Fazakerley DJ, Chaudhuri R, Yang P, of YKL-40 Serum Levels in Patients Gounder MM, Thomas DM, Tap WD. Maghzal GJ, Thomas KC, Krycer JR et With Rectal Cancer Without Distant Locally aggressive connective tissue al. Mitochondrial CoQ deficiency is a Metastasis. Technology in Cancer Research tumors. Journal of Clinical Oncology common driver of mitochondrial oxidants & Treatment 2018; 17:1533033818765209. 2018; 36:202-209. DOI: 10.1200/ and insulin resistance. eLife 2018; 7:pii: DOI: 10.1177/1533033818765209 JCO.2017.75.8482 e32111. DOI: 10.7554/eLife.32111 Garsed DW, Alsop K, Fereday S, Emmanuel Gregson CL, Newell F, Leo PJ, Clark GR, Fazekas-Lavu M, Reyes M, Malouf M, C, Kennedy CJ, Etemadmoghadam D et al. Paternoster L, Marshall M et al. Genome- Plit M, Havryk A, Campbell LV et al. High Homologous recombination DNA repair wide association study of extreme high prevalence of diabetes before and after pathway disruption and retinoblastoma bone mass: Contribution of common lung transplantation: Target for improving protein loss are associated with genetic variation to extreme BMD outcome? Internal Medicine Journal 2018; exceptional survival in high-grade serous phenotypes and potential novel BMD- DOI: 10.1111/imj.13963 ovarian cancer. Clinical Cancer Research associated genes. Bone 2018; 114:62-71. 2018; 24:569-580. DOI: 10.1158/1078- DOI: 10.1016/j.bone.2018.06.001 Fazekas-Lavu M, Tonks KTT, Samaras 0432.CCR-17-1621 K. Benchmarks of Diabetes Care in Men Living With Treated HIV-Infection: A Tertiary Center Experience. Frontiers in Endocrinology 2018; 9:634. DOI: 10.3389/ fendo.2018.00634
64 2018 Garvan Annual Report We see a future where everyone lives a longer healthier life. It’s within reach.
garvan.org.au 65 Publications 2018 continued
Grierson KE, Bou-Haidar P, Dumper J, Hassanzadeh-Barforoushi A, Law AMK, Ho-Le TP, Nguyen TV. Mathematics Fagan PA. The assessment of pulsatile Hejri A, Asadnia M, Ormandy CJ, Gallego- Research in Association of Southeast tinnitus – a systematic review of Ortega D, Ebrahimi Warkiani M. Static Asian Nations Countries: A Scientometric underlying pathologies and modern droplet array for culturing single live Analysis of Patterns and Impacts. diagnostic approaches. Australian Journal adherent cells in an isolated chemical Frontiers in Research Metrics and Analytics of Otolaryngology 2018; DOI: 10.21037/ microenvironment. Lab on a Chip 2018; 2018; DOI: https://doi.org/10.3389/ ajo.2018.09.08 18:2156-2166. DOI: 10.1039/c8lc00403j frma.2018.00003
Grossmann M, Ramchand SK, Milat Hastie R, Lim E, Sluka P, Campbell L, Ho-Pham LT, Chau PMN, Do AT, Nguyen F, Vincent A, Lim E, Kotowicz MA et Horne AW, Ellett L et al. Vinorelbine HC, Nguyen TV. Type 2 diabetes is al. Assessment and management of potently induces placental cell death, associated with higher trabecular bone bone health in women with oestrogen does not harm fertility and is a potential density but lower cortical bone density: receptor-positive breast cancer receiving treatment for ectopic pregnancy. the Vietnam Osteoporosis Study. endocrine therapy: Position statement EBioMedicine 2018; 29:166-176. Osteoporosis International 2018; 29:2059- of the Endocrine Society of Australia, DOI: 10.1016/j.ebiom.2018.01.041 2067. DOI: 10.1007/s00198-018-4579-5 the Australian and New Zealand Bone & Mineral Society, the Australasian Hastings JF, Han JZR, Shearer RF, Ho-Pham LT, Ho-Le TP, Mai LD, Do TM, Menopause Society and the Clinical Kennedy SP, Iconomou M, Saunders DN, Doan MC, Nguyen TV. Sex-difference Oncology Society of Australia. Clinical Croucher DR. Dissecting multi-protein in bone architecture and bone fragility Endocrinology 2018; 89:280-296. signaling complexes by Bimolecular in Vietnamese. Scientific Reports 2018; DOI: 10.1111/cen.13735 Complementation Affinity Purification 8:7707. DOI: 10.1038/s41598-018-26053-9 (BiCAP). JoVE-Journal of Visualized Guennewig B, Bitar M, Obiorah I, Hanks Experiments 2018; DOI: 10.3791/57109 Hodson N, Philp A. The Importance of J, O'Brien EA, Kaczorowski DC et al. THC mTOR Trafficking for Human Skeletal exposure of human iPSC neurons impacts Haydar N, McDonald MM. Tumor Cell Muscle Translational Control. Exercise genes associated with neuropsychiatric Dormancy—a Hallmark of Metastatic and Sport Sciences Reviews 2018; disorders. Translational Psychiatry 2018; Growth and Disease Recurrence in Bone. DOI: 10.1249/JES.0000000000000173 8:89. DOI: 10.1038/s41398-018-0137-3 Current Molecular Biology Reports 2018; 4:50-58. DOI: https://doi.org/10.1007/ Holliday H, Baker LA, Junankar SR, Guerin A, Kerner G, Marr N, Markle s40610-018-0088-8 Clark SJ, Swarbrick A. Epigenomics JG, Fenollar F, Wong N et al. IRF4 of mammary gland development. haploinsufficiency in a family with Hayes VM JaratlerdsiriW. Prostate cancer Breast Cancer Research 2018; 20:100. Whipple's disease. eLife 2018; 7:e32340. genomics and racial health disparity. DOI: 10.1186/s13058-018-1031-x DOI: 10.7554/eLife.32340 Oncotarget 2018; 9:36650-36651. DOI: 10.18632/oncotarget.26399 Holt LJ, Brandon AE, Small L, Suryana Gunton JE, Girgis CM. Vitamin D E, Preston E, Wilks D et al. Ablation of and muscle. Bone 2018; 8:163-167. Hayes VM, Bornman MSR. Prostate Grb10 Specifically in Muscle Impacts DOI: 10.1016/j.bonr.2018.04.004 Cancer in Southern Africa: Does Africa Muscle Size and Glucose Metabolism in Hold Untapped Potential to Add Value to Mice. Endocrinology 2018; 159:1339-1351. Gupta R, Cooper WA, Selinger C, Mahar the Current Understanding of a Common DOI: 10.1210/en.2017-00851 A, Anderson L, Buckland ME, O'Toole Disease? Journal of Global Oncology 2018; SA. Fluorescent in situ hybridization in DOI: 10.1200/JGO.2016.008862 Hope TA, Afshar-Oromieh A, Eiber M, surgical pathology practice. Advances Emmett L, Fendler WP, Lawhn-Heath C, in Anatomic Pathology 2018; 25:223-237. Hjorth M, Febbraio MA. Exercise as Rowe SP. Imaging Prostate Cancer With DOI: 10.1097/pap.0000000000000194 medicine for survivors of paediatric Prostate-Specific Membrane Antigen cancer. Nature Reviews Endocrinology PET/CT and PET/MRI: Current and Gurevitch J, Koricheva J, Nakagawa S, 2018; DOI: 10.1038/s41574-018-0065-6 Future Applications. American Journal Stewart G. Meta-analysis and the science of Roentgenology 2018; 211:286-294. of research synthesis. Nature 2018; Ho J, Hamizan AW, Alvarado R, Rimmer DOI: 10.2214/ajr.18.19957 555:175-182. DOI: 10.1038/nature25753 J, Sewell WA, Harvey RJ. Systemic Predictors of Eosinophilic Chronic Hoque M, Abbassi RH, Froio D, Man J, Hardwick SA, Chen WY, Wong T, Rhinosinusitis. American Journal of Johns TG, Stringer BW et al. Changes in Kanakamedala BS, Deveson IW, Ongley Rhinology & Allergy 2018; 32:252-257. cell morphology guide identification of SE et al. Synthetic microbe communities DOI: 10.1177/1945892418779451 tubulin as the off-target for protein kinase provide internal reference standards for inhibitors. Pharmacological Research metagenome sequencing and analysis. Ho-Le TP, Pham HM, Center JR, Eisman 2018; 134:166-178. DOI: 10.1016/j. Nature Communications 2018; 9:3096. JA, Nguyen HT, Nguyen TV. Prediction of phrs.2018.06.023 DOI: 10.1038/s41467-018-05555-0 changes in bone mineral density in the elderly: contribution of "osteogenomic profile".Archives of Osteoporosis 2018; 13:68. DOI: 10.1007/s11657-018-0480-2 66 2018 Garvan Annual Report Hormer BA, Verma D, Gasser E, Jacquelin S, Straube J, Cooper L, Vu T, Keane JT, Elangovan H, Stokes RA, Wieselthaler-Holzl A, Herzog H, Tasan RO. Song A, Bywater M et al. Jak2V617F Gunton JE. Vitamin D and the Liver- Hippocampal NPY Y2 receptors modulate and Dnmt3a loss cooperate to induce Correlation or Cause? Nutrients 2018; memory depending on emotional myelofibrosis through activated enhancer- 10:None. DOI: 10.3390/nu10040496 valence and time. Neuropharmacology driven inflammation. Blood 2018; 132:2707- 2018; 143:20-28. DOI: 10.1016/j. 2721. DOI: 10.1182/blood-2018-04-846220 Kee AJ, Chagan J, Chan JY, Bryce NS, neuropharm.2018.09.018 Lucas CA, Zeng J et al. On-target action of Jaratlerdsiri W, Chan EKF, Gong T, Petersen anti-tropomyosin drugs regulates glucose Hoye AM, Tolstrup SD, Horton ER, DC, Kalsbeek AMF, Venter PA et al. Whole metabolism. Scientific Reports 2018; Nicolau M, Frost H, Woo JH et al. Tumor Genome Sequencing Reveals Elevated 8:4604. DOI: 10.1038/s41598-018-22946-x endothelial marker 8 promotes cancer Tumor Mutational Burden and Initiating progression and metastasis. Oncotarget Driver Mutations in African Men with Kelemen LE, Earp M, Fridley BL, Chenevix- 2018; 9:30173-30188. DOI: 10.18632/ Treatment-Naive, High-Risk Prostate Cancer. Trench G, Fasching PA, Beckmann MW oncotarget.25734 Cancer Research 2018; 78:6736-6746. et al. rs495139 in the TYMS-ENOSF1 DOI: 10.1158/0008-5472.CAN-18-0254 region and risk of ovarian carcinoma of Htet TD, Eisman JA, Elder GJ, Center mucinous histology. International Journal JR. Worsening of soft tissue dystrophic Jimenez-Reinoso A, Marin AV, Subias of Molecular Sciences 2018; 19:2473. calcification in an osteoporotic patient M, Lopez-Lera A, Roman-Ortiz E, Payne DOI: 10.3390/ijms19092473 treated with teriparatide. Osteoporosis K et al. Human plasma C3 is essential International 2018; 29:517-518. for the development of memory B, but Kim J, Lee JY, Cho K, Hong SW, Kim KS, DOI: 10.1007/s00198-017-4330-7 not T, lymphocytes. Journal of Clinical Sprent J et al. Spontaneous Proliferation Immunology 2018; 141:1153-1154. of CD4(+) T Cells in RAG-Deficient Hosts Huttner IG. A-Band Titin Truncation in DOI: 10.1016/j.jaci.2017.09.037 Promotes Antigen-Independent but IL-2- Zebrafish Causes Dilated Cardiomyopathy Dependent Strong Proliferative Response and Hemodynamic Stress Intolerance. Jin D, Sprent J. GM-CSF Culture Revisited: of Naive CD8(+) T Cells. Frontiers in Circulation. Genomic and Precision Preparation of Bulk Populations of Immunology 2018; 9:1907. DOI: 10.3389/ Medicine 2018; 11:e002135. DOI: 10.1161/ Highly Pure Dendritic Cells from Mouse fimmu.2018.01907 CIRCGEN.118.002135 Bone Marrow. Journal of Immunology 2018; 201:3129-3139. DOI: 10.4049/ Kirk EP, Barlow-Stewart K, Selvanathan A, Ikonomopoulou MP, Fernandez-Rojo MA, jimmunol.1800031 Josephi-Taylor S, Worgan L, Rajagopalan Pineda SS, Cabezas-Sainz P, Winnen S et al. Beyond the panel: preconception B, Morales RAV et al. Gomesin inhibits Kalimutho M, Sinha D, Jeffery J, Nones K, screening in consanguineous couples melanoma growth by manipulating key Srihari S, Fernando WC et al. CEP55 is a using the TruSight One "clinical exome". signaling cascades that control cell death determinant of cell fate during perturbed Genetics in Medicine 2018; DOI: 10.1038/ and proliferation. Scientific Reports 2018; mitosis in breast cancer. EMBO Molecular s41436-018-0082-9 8:11519. DOI: 10.1038/s41598-018-29826-4 Medicine 2018; 10:e8566. DOI: 10.15252/ emmm.201708566 Kneebone A, Hruby G, Harris G, Rasiah Inoue T, Moran I, Shinnakasu R, Phan TG, K, Vass J, Whalley D et al. Contemporary Kurosaki T. Generation of memory B cells Kammoun HL, Allen TL, Henstridge salvage post prostatectomy radiotherapy: and their reactivation. Immunological Reviews DC, Barre S, Coll RC, Lancaster GI et Early implementation improves 2018; 283:138-149. DOI: 10.1111/imr.12640 al. Evidence against a role for NLRP3- biochemical control. Journal of Medical driven islet inflammation in db/db mice. Imaging and Radiation Oncology 2018; Isaacs M, Costin M, Bova R, Barrett HL, Molecular Metabolism 2018; 10:66-73. 62:240-247. DOI: 10.1111/1754-9485.12684 Heffernan D, Samaras K, Greenfield JR. DOI: 10.1016/j.molmet.2018.02.001 Management of Amiodarone-Induced Kocbek S, Kocbek P, Stozer A, Zupanic T, Thyrotoxicosis at a Cardiac Transplantation Kang C, Liang C, Ahmad KE, Gu Y, Siow Groza T, Stiglic G. Building interpretable Centre. Frontiers in Endocrinology 2018; SF, Colebatch JG et al. High Degree of models for polypharmacy prediction in 9:482. DOI: 10.3389/fendo.2018.00482 Genetic Heterogeneity for Hereditary older chronic patients based on drug Cerebellar Ataxias in Australia. Cerebellum prescription records. PeerJ 2018; 6:e5765. Jackson R, Kartoglu I, Stringer C, Gorrell 2018; DOI: 10.1007/s12311-018-0969-7 DOI: 10.7717/peerj.5765 G, Roberts A, Song X et al. CogStack – experiences of deploying integrated Kara EE, Bastow CR, McKenzie DR, Gregor Kong XF, Martinez-Barricarte R, Kennedy information retrieval and extraction CE, Fenix KA, Babb R et al. Atypical J, Mele F, Lazarov T, Deenick EK et al. services in a large National Health Service chemokine receptor 4 shapes activated Disruption of an antimycobacterial Foundation Trust hospital. BMC Medical B cell fate. Journal of Experimental circuit between dendritic and helper Informatics and Decision Making 2018; Medicine 2018; 215:801-813. DOI: 10.1084/ T cells in human SPPL2a deficiency. 18:47. DOI: 10.1186/s12911-018-0623-9 jem.20171067 Nature Immunology 2018; 19:973-985. DOI: 10.1038/s41590-018-0178-z
garvan.org.au 67 Publications 2018 continued
Koster R, Panagiotou OA, Wheeler WA, Langley DB, Christ D. Crystal structure Li J, Choi PS, Chaffer CL, Labella K, Karlins E, Gastier-Foster JM, Caminada de of duck egg lysozyme isoform II (DEL‑II). Hwang JH, Giacomelli AO et al. An Toledo SR et al. Genome-wide association BMC Structural Biology 2018; 18:10. alternative splicing switch in FLNB study identifies the GLDC/IL33 locus DOI: 10.1186/s12900-018-0090-7 promotes the mesenchymal cell state associated with survival of osteosarcoma in human breast cancer. eLife 2018; patients. International Journal of Cancer Lasschuit JWJ, Greenfield JR. High 7:e37184. DOI: 10.7554/eLife.37184 2018; 142:1594-1601. DOI: 10.1002/ijc.31195 Risk Foot Service reduces number of Emergency Department presentations and Lim CH, Sun Q, Ratti K, Lee SH, Zheng Y, Koutsakos M. Circulating TFH cells, length of stay. Diabetes & Metabolism Journal Takeo M et al. Hedgehog stimulates hair serological memory, and tissue 2018; DOI: 10.1016/j.diabet.2018.07.002 follicle neogenesis by creating inductive compartmentalization shape human dermis during murine skin wound healing. influenza-specific B cell immunity. Science Lau J, Farzi A, Qi Y, Heilbronn R, Mietzsch Nature Communications 2018; 9:4903. Translational Medicine 2018; 10:1-15. M, Shi YC, Herzog H. CART neurons in the DOI: 10.1038/s41467-018-07142-9 DOI: 10.1126/scitranslmed.aan8405 arcuate nucleus and lateral hypothalamic area exert differential controls on energy Lim E, Beith J, Boyle F, de Boer R, Hui Kroon HM, van der Bol WD, Tonks KT, homeostasis. Molecular Metabolism 2018; R, McCarthy N et al. Emerging data and Hong AM, Hruby G, Thompson JF. 7:102-118. DOI: 10.1016/j.molmet.2017.10.015 future directions for CDK4/6 inhibitor Treatment of Clinically Positive Cervical treatment of patients with hormone Lymph Nodes by Limited Local Node Leathersich SJ, Vogel JP, Tran TS, receptor positive HER2-non-amplified Excision and Adjuvant Radiotherapy Hofmeyr GJ. Acute tocolysis for metastatic breast cancer. Asia-Pacific in Melanoma Patients with Major uterine tachysystole or suspected Journal of Clinical Oncology 2018; 14 Suppl Comorbidities. Annals of Surgical Oncology fetal distress. Cochrane Database of 4:12-21. DOI: 10.1111/ajco.13065 2018; 25:3476-3482. DOI: 10.1245/ Systematic Reviews 2018; 7:CD009770. s10434-018-6692-2 DOI: 10.1002/14651858.CD009770.pub2 Lin FP, Groza T, Kocbek S, Antezana E, Epstein RJ. Cancer Care Treatment Kumar KR, Wali G, Davis RL, Lee JY, Kim J, Yi J, Kim D, Kim HO, Han D Outcome Ontology: A Novel Computable Mallawaarachchi AC, Palmer EE, et al. Phenotypic and Functional Changes Ontology for Profiling Treatment Gayevskiy V et al. Expanding the spectrum of Peripheral Ly6C(+) T Regulatory Cells Outcomes in Patients With Solid Tumors. of PEX16 mutations and novel insights Driven by Conventional Effector T Cells. JCO Clincal Cancer Informatics 2018; into disease mechanisms. Molecular Frontiers in Immunology 2018; 9:437. DOI: 10.1200/CCI.18.00026 Genetics and Metabolism 2018; 16:46-51. DOI: 10.3389/fimmu.2018.00437 DOI: 10.1016/j.ymgmr.2018.07.003 Lin HM, Lee BY, Castillo L, Spielman C, Lee NJ, Ali N, Zhang L, Qi Y, Clarke I, Enriquez Grogan J, Yeung NK et al. Effect of FAK Kumar SS, McManus H, Radovich T, RF et al. Osteoglycin, a novel coordinator of inhibitor VS-6063 (defactinib) on docetaxel Greenfield JR, Viardot A, Williams KM et bone and glucose homeostasis. Molecular efficacy in prostate cancer. Prostate 2018; al. Interrogation of a longitudinal, national Metabolism 2018; 13:30-44. DOI: 10.1016/j. 78:308-317. DOI: 10.1002/pros.23476 pharmacy claims dataset to explore molmet.2018.05.004 factors that predict the need for add-on Lin HM, Nikolic I, Yang J, Castillo L, Deng therapy in older and socioeconomically Lee NJ, Clarke IM, Enriquez RF, Nagy V, N, Chan CL et al. MicroRNAs as potential disadvantaged Australians with type 2 Penninger J, Baldock PA, Herzog H. Central therapeutics to enhance chemosensitivity diabetes mellitus patients (T2DM). RANK signalling in NPY neurons alters bone in advanced prostate cancer. Scientific European Journal of Clinical Pharmacology mass in male mice. Neuropeptides 2018; Reports 2018; 8:7820. DOI: 10.1038/ 2018; DOI: 10.1007/s00228-018-2506-5 68:75-83. DOI: 10.1016/j.npep.2018.02.004 s41598-018-26050-y
Kumar S, Samaras K. The Impact of Weight Lenders N, McCormack A. Malignant Lindegaard B, Abildgaard J, Heywood SE, Gain During HIV Treatment on Risk of Pre- transformation in non-functioning Pedersen BK, Febbraio MA. Female sex diabetes, Diabetes Mellitus, Cardiovascular pituitary adenomas (pituitary carcinoma). hormones are necessary for the metabolic Disease, and Mortality. Frontiers in Pituitary 2018; 21:217-229. DOI: 10.1007/ effects mediated by loss of Interleukin 18 Endocrinology 2018; 9:705. DOI: https://doi. s11102-017-0857-z signaling. Molecular Metabolism 2018; 12:89- org/10.3389/fendo.2018.00705 97. DOI: 10.1016/j.molmet.2018.04.005 Leong TL, Gayevskiy V, Steinfort DP, De Lancaster GI, Langley KG, Berglund NA, Massy MR, Gonzalez-Rajal A, Marini KD Lindemann K, Gao B, Mapagu C, Fereday Kammoun HL, Reibe S, Estevez E et al. et al. Deep multi-region whole-genome S, Emmanuel C, Alsop K et al. Response Evidence that TLR4 Is Not a Receptor for sequencing reveals heterogeneity and gene- rates to second-line platinum-based Saturated Fatty Acids but Mediates Lipid- by-environment interactions in treatment- therapy in ovarian cancer patients Induced Inflammation by Reprogramming naive, metastatic lung cancer. Oncogene challenge the clinical definition of Macrophage Metabolism. Cell Metabolism 2018; DOI: 10.1038/s41388-018-0536-1 platinum resistance. Gynecologic Oncology 2018; 27:1096-1110 e5. DOI: 10.1016/j. 2018; 150:239-246. DOI: 10.1016/j. cmet.2018.03.014 ygyno.2018.05.020
68 2018 Garvan Annual Report Liu G, Mukherjee B, Lee S, Lee AW, Wu Mai HT, Tran TS, Ho-Le TP, Pham TT, Matsuda H, Mullapudi ST, Yang YHC, AH, Bandera EV et al. Robust tests for Center JR, Eisman JA, Nguyen TV. Masaki H, Hesselson D, Stainier DYR. additive gene-environment interaction Low-trauma rib fracture in the elderly: Whole Organism Chemical Screening in case-control studies using gene- Risk factors and mortality consequence. Identifies Modulators of Pancreatic environment independence. American Bone 2018; 116:295-300. DOI: 10.1016/j. beta Cell Function. Diabetes 2018; Journal of Epidemiology 2018; 187:366- bone.2018.08.016 DOI: 10.2337/db17-1223 377. DOI: 10.1093/aje/kwx243 Maiella S, Olry A, Hanauer M, Lanneau V, Mattick JS. The State of Long Non-Coding Liu Q, Thoms JAI, Nunez AC, Huang Y, Lourghi H, Donadille B et al. Harmonising RNA Biology. Non-coding RNA 2018; 4:17. Knezevic K, Packham D et al. Disruption of phenomics information for a better DOI: 10.3390/ncrna4030017 a -35 kb Enhancer Impairs CTCF Binding interoperability in the rare disease field. and MLH1 Expression in Colorectal Cells. European Journal of Medical Genetics 2018; Mattick JS, Dinger M, Schonrock N, Clinical Cancer Research 2018; 24:4602- DOI: 10.1016/j.ejmg.2018.01.013 Cowley M. Whole genome sequencing 4611. DOI: 10.1158/1078-0432.CCR-17-3678 provides better diagnostic yield and future Mallawaarachchi AC, Furlong TJ, Shine value than whole exome sequencing. Loh K, Shi YC, Bensellam M, Lee K, Laybutt J, Harris PC, Cowley MJ. Population Medical Journal of Australia 2018; 209:197- DR, Herzog H. Y1 receptor deficiency in data improves variant interpretation in 199. DOI: 10.5694/mja17.01176 beta-cells leads to increased adiposity autosomal dominant polycystic kidney and impaired glucose metabolism. disease. Genetics in Medicine 2018; Mattick JS. Four ways precision medicine Scientific Reports 2018; 8:11835. DOI: 10.1038/s41436-018-0324-x is making a difference. 2018; DOI: N/A DOI: 10.1038/s41598-018-30140-2 (magazine article) Manchanda R, Patel S, Gordeev VS, Lukowski SW, Tuong ZK, Noske K, Antoniou AC, Smith S, Lee A et al. Cost- McCormack A, Dekkers OM, Petersenn Senabouth A, Nguyen QH, Andersen SB effectiveness of population-based BRCA1, S, Popovic V, Trouillas J, Raverot G et al. et al. Detection of HPV E7 Transcription BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Treatment of aggressive pituitary tumours at Single-Cell Resolution in Epidermis. mutation testing in unselected general and carcinomas: results of a European Journal of Investigative Dermatology population women. JNCI-Journal of the Society of Endocrinology (ESE) survey 2016. 2018; 138:2558-2567. DOI: 10.1016/j. National Cancer Institute 2018; 110:714- European Journal of Endocrinology 2018; jid.2018.06.169 725. DOI: 10.1093/jnci/djx265 178:265-276. DOI: 10.1530/EJE-17-0933
Ma C, Tonks KT, Center JR, Samocha- Marini KD, Croucher DR, McCloy RA, McDonald MM, Morse A, Birke O, Yu NYC, Bonet D, Greenfield JR. Complex interplay Vaghjiani V, Gonzalez-Rajal A, Hastings JF Mikulec K, Peacock L et al. Sclerostin among adiposity, insulin resistance and et al. Inhibition of activin signaling in lung antibody enhances bone formation in a bone health. Clinical Obesity 2018; 8:131- adenocarcinoma increases the therapeutic rat model of distraction osteogenesis. 139. DOI: 10.1111/cob.12240 index of platinum chemotherapy. Science Journal of Orthopaedic Research 2018; Translational Medicine 2018; 10:eaat3504. 36:1106-1113. DOI: 10.1002/jor.23726 MacGregor S, Ong JS, An J, Han X, DOI: 10.1126/scitranslmed.aat3504 Zhou T, Siggs OM et al. Genome-wide McDonald MM, Morse A, Schindeler association study of intraocular pressure Marletaz F, Firbas PN, Maeso I, Tena JJ, A, Mikulec K, Peacock L, Cheng T et uncovers new pathways to glaucoma. Bogdanovic O, Perry M et al. Amphioxus al. Homozygous Dkk1 Knockout Mice Nature genetics 2018; 50:1067-1071. functional genomics and the origins of Exhibit High Bone Mass Phenotype Due DOI: 10.1038/s41588-018-0176-y vertebrate gene regulation. Nature 2018; to Increased Bone Formation. Calcified DOI: 10.1038/s41586-018-0734-6 Tissue International 2018; 102:105-116. MacLennan AH, Kruer MC, Baynam G, DOI: 10.1007/s00223-017-0338-4 Moreno-De-Luca A, Wilson YA, Zhu C Marshall JPS, Estevez E, Kammoun et al. Cerebral palsy and genomics: an HL, King EJ, Bruce CR, Drew BG et al. McMahon CN Petoumenos K. High rates international consortium. Developmental Skeletal muscle-specific overexpression of incident diabetes and prediabetes are Medicine and Child Neurology 2018; of heat shock protein 72 improves evident in men with treated HIV followed 60:209-210. DOI: 10.1111/dmcn.13643 skeletal muscle insulin-stimulated for 11 years. AIDS 2018; 32:451-459. glucose uptake but does not alter whole DOI: 10.1097/QAD.0000000000001709 Macdonald GC, Hesselson SE, Chan JY, body metabolism. Diabetes Obesity & Jenkins AB, Laybutt DR, Hesselson D, Metabolism 2018; DOI: 10.1111/dom.13319 Meagher NS, Schuster K, Voss A, Budden Campbell LV. Deletion distal to the PAX6 T, Pang CNI, deFazio A et al. Does the coding region reveals a novel basis for Martinez-Barricarte R, Markle JG. primary site really matter? Profiling familial cosegregation of aniridia and Human IFN-y immunity to mycobacteria mucinous ovarian cancers of uncertain diabetes mellitus. Diabetes Research is governed by both IL-12 and IL-23. primary origin (MO-CUP) to personalise and Clinical Practice 2018; 148:64-71. Science Immunology 2018; 3:30, eaau6759. treatment and inform the design of clinical DOI: 10.1016/j.diabres.2018.12.002 DOI: 10.1126/sciimmunol.aau6759 trials. Gynecologic Oncology 2018; 150:527- 533. DOI: 10.1016/j.ygyno.2018.07.013
garvan.org.au 69 Publications 2018 continued
Medina-Gomez C, Kemp JP, Trajanoska Morse A, Cheng TL, Schindeler A, McDonald Natanzon Y, Earp M, Cunningham JM, K, Luan J, Chesi A, Ahluwalia TS et al. MM, Mohanty ST, Kneissel M et al. Dkk1 Kalli KR, Wang C, Armasu SM et al. Life-Course Genome-wide Association KO Mice Treated with Sclerostin Antibody Genomic Analysis Using Regularized Study Meta-analysis of Total Body BMD Have Additional Increases in Bone Volume. Regression in High-Grade Serous and Assessment of Age-Specific Effects. Calcified Tissue International 2018; 103:298- Ovarian Cancer. Cancer Informatics American Journal of Human Genetics 2018; 310. DOI: 10.1007/s00223-018-0420-6 2018; 17:1176935118755341. 102:88-102. DOI: 10.1016/j.ajhg.2017.12.005 DOI: 10.1177/1176935118755341 Morse A, Schindeler A, McDonald MM, Metcalfe SA, Hickerton C, Savard J, Kneissel M, Kramer I, Little DG. Sclerostin Nguyen A, Khoo WH, Moran I, Croucher PI, Stackpoole E, Tytherleigh R, Tutty E et al. Antibody Augments the Anabolic Bone Phan TG. Single Cell RNA Sequencing of Australians' views on personal genomic Formation Response in a Mouse Model of Rare Immune Cell Populations. Frontiers in testing: focus group findings from the Mechanical Tibial Loading. Journal of Bone Immunology 2018; 9:1553. DOI: 10.3389/ Genioz study. European Journal of Human and Mineral Research 2018; 33:486-498. fimmu.2018.01553 Genetics 2018; DOI: 10.1038/s41431-018- DOI: 10.1002/jbmr.3330 0151-1 Nguyen AD, Lee NJ, Enriquez RF, Khor Muniak MA, Ayeni FE, Ryugo DK. Hidden EC, Wee NK-Y, Zhang L et al. Uncoupling Metcalfe SA, Hickerton C, Savard J, hearing loss and endbulbs of Held: protein-1 is protective of bone mass Stackpoole E, Tytherleigh R, Tutty E et al. Evidence for central pathology before under mild cold stress conditions. Australians’ perspectives on support around detection of ABR threshold increases. Bone 2018; 106:167-178. DOI: 10.1016/j. use of personal genomic testing: Findings Hearing Research 2018; 364:104-117. bone.2015.05.037 from the Genioz study. European Journal DOI: 10.1016/j.heares.2018.03.021 of Medical Genetics 2018; DOI: https://doi. Nguyen EV, Centenera MM, Moldovan org/10.1016/j.ejmg.2018.11.002 Nair P, Venkatesh B, Center JR. Vitamin D M, Das R, Irani S, Vincent AD et al. deficiency and supplementation in critical Identification of novel response and Minoche AE, Horvat C, Johnson R, illness-the known knowns and known predictive biomarkers to Hsp90 inhibitors Gayevskiy V, Morton SU, Drew AP et al. unknowns. Critical Care 2018; 22:276. through mass spectrometry-based Response to Brodehl et al. Genetics in DOI: 10.1186/s13054-018-2185-8 proteomic profiling of patient-derived Medicine 2018; DOI: 10.1038/s41436-018- prostate tumor explants. Molecular & 0292-1 Nair P, Venkatesh B, Hoechter DJ, Buscher Cellular Proteomics 2018; 17:1470-1486. H, Kerr S, Center JR, Myburgh JA. DOI: 10.1074/mcp.RA118.000633 Minoche AE, Horvat C, Johnson R, Vitamin D status and supplementation in Gayevskiy V, Morton SU, Drew AP et al. adult patients receiving extracorporeal Nguyen LT, Nguyen UDT, Nguyen TDT, Genome sequencing as a first-line genetic membrane oxygenation. Anaesthesia Ho-Pham LT, Nguyen TV. Contribution test in familial dilated cardiomyopathy. and Intensive Care 2018; 46:589-595. of bone turnover markers to the Genetics in Medicine 2018; DOI: 10.1038/ DOI: 10.1177/0310057X1804600609 variation in bone mineral density: a s41436-018-0084-7 study in Vietnamese men and women. Nair SS, Luu PL, Qu W, Maddugoda M, Osteoporosis International 2018; 29:2739- Mladenova D, Barry G, Konen LM, Pineda Huschtscha L, Reddel R et al. Guidelines 2744. DOI: 10.1007/s00198-018-4700-9 SS, Guennewig B, Avesson L et al. Adar3 for whole genome bisulphite sequencing Is Involved in Learning and Memory in of intact and FFPET DNA on the Illumina Nguyen QH, Lukowski SW, Chiu HS, Mice. Frontiers in Neuroscience 2018; 12:1- HiSeq X Ten. Epigenetics & Chromatin 2018; Senabouth A, Bruxner TJC, Christ AN 17. DOI: 10.3389/fnins.2018.00243 11:24. DOI: 10.1186/s13072-018-0194-0 et al. Single-cell RNA-seq of human induced pluripotent stem cells reveals Moran I, Grootveld AK, Nguyen A, Phan Nakanishi Y, Ikebuchi R, Chtanova T, cellular heterogeneity and cell state TG. Subcapsular Sinus Macrophages: Kusumoto Y, Okuyama H, Moriya T transitions between subpopulations. The Seat of Innate and Adaptive et al. Regulatory T cells with superior Genome Research 2018; 28:1053-1066. Memory in Murine Lymph Nodes. immunosuppressive capacity emigrate DOI: 10.1101/gr.223925.117 Trends in Immunology 2018; 1526:35-48. from the inflamed colon to draining lymph DOI: 10.1016/j.it.2018.11.004. nodes. Mucosal Immunology 2018; 11:437- Nguyen TV, Eisman JA. Assessment of 448. DOI: 10.1038/mi.2017.64 Fracture Risk: Population Association Moran I, Nguyen A, Khoo WH, Butt D, Versus Individual Prediction. Journal of Bourne K, Young C et al. Memory B Nash BM, Symes R, Goel H, Dinger ME, Bone and Mineral Research 2018; 33:386- cells are reactivated in subcapsular Bennetts B, Grigg JR, Jamieson RV. NMNAT1 388. DOI: 10.1002/jbmr.3367 proliferative foci of lymph nodes. variants cause cone and cone-rod dystrophy. Nature Communications 2018; 9:3372. European Journal of Human Genetics 2018; Nielsen J, Bubela T, Chalmers DRC, Johns DOI: 10.1038/s41467-018-05772-7 DOI: 10.1038/s41431-017-0029-7 A, Kahl L, Kamens J et al. Provenance and risk in transfer of biological materials. PLoS Biology 2018; 16:e2006031. DOI: 10.1371/journal.pbio.2006031
70 2018 Garvan Annual Report Nobis M, Warren SC, Lucas MC, Murphy Parrish RR, Grady J, Codadu NK, Racca C, Pidsley R, Lawrence MG, Zotenko E, KJ, Herrmann D, Timpson P. Molecular Trevelyan AJ. Graphical user interface for Niranjan B, Statham A, Song J et al. mobility and activity in an intravital simultaneous profiling of activity patterns Enduring epigenetic landmarks define imaging setting – implications for cancer in multiple neuronal subclasses. Data in the cancer microenvironment. Genome progression and targeting. Journal Brief 2018; 20:226-233. DOI: 10.1016/j. Research 2018; 28:625-638. DOI: 10.1101/ of Cell Science 2018; 131:jcs.206995. dib.2018.07.069 gr.229070.117 DOI: 10.1242/jcs.206995 Parrish RR, Grady J, Codadu NK, Pinho AV, Van Bulck M, Chantrill L, Norman M, Wainstein B, Anazodo A, Trevelyan AJ, Racca C. Simultaneous Arshi M, Sklyarova T, Herrmann D et al. Turner A, Ma C, Payne K et al. Combined profiling of activity patterns in multiple ROBO2 is a stroma suppressor gene Immunodeficiency with Ring Chromosome neuronal subclasses. Journal of in the pancreas and acts via TGF-beta 21. Journal of Clinical Immunology 2018; Neuroscience Methods 2018; 303:16-29. signalling. Nature Communications 2018; 38:251-256. DOI: 10.1007/s10875-018-0493-z DOI: 10.1016/j.jneumeth.2018.03.012 9:5083. DOI: 10.1038/s41467-018-07497-z
O'Brien KA, Horscroft JA, Devaux J, Penzias G, Singanamalli A, Elliott R, Pokorny AMJ, Chin VT, Nagrial AM, Yip Lindsay RT, Steel AS, Clark AD et al. Gollamudi J, Shih N, Feldman M et al. D, Chantrill LA. Metastatic pancreatic PPARalpha-independent effects of nitrate Identifying the morphologic basis for ductal adenocarcinoma: diagnosis and supplementation on skeletal muscle radiomic features in distinguishing treatment with a view to the future. metabolism in hypoxia. Biochimica Et different Gleason grades of prostate Internal Medicine Journal 2018; 48:637- Biophysica Acta-Molecular Basis of Disease cancer on MRI: Preliminary findings. PLoS 644. DOI: 10.1111/imj.13810 2018; DOI: 10.1016/j.bbadis.2018.07.027 One 2018; 13:e0200730. DOI: 10.1371/ journal.pone.0200730 Pollock RD, O'Brien KA, Daniels LJ, Pajic M, Froio D, Daly S, Doculara L, Nielsen KB, Rowlerson A, Duggal NA et al. Millar E, Graham PH et al. miR-139-5p Peters TJ, French HJ, Bradford ST, Pidsley Properties of the vastus lateralis muscle modulates radiotherapy resistance in R, Stirzaker C, Varinli H et al. Evaluation in relation to age and physiological breast cancer by repressing multiple gene of cross-platform and interlaboratory function in master cyclists aged 55- networks of DNA repair and ROS defense. concordance via consensus modelling of 79 years. Aging Cell 2018; 17:e12735. Cancer Research 2018; 78:501-515. genomic measurements. Bioinformatics DOI: 10.1111/acel.12735 DOI: 10.1158/0008-5472.CAN-16-3105 2018; DOI: 10.1093/bioinformatics/bty675 Poulton C, Azmanov D, Atkinson V, Beilby Palmer EE, Schofield D, Shrestha R, Pfajfer L, Mair NK, Jimenez-Heredia J, Ewans L, Gration D et al. Silver Russel Kandula T, Macintosh R, Lawson JA R, Genel F, Gulez N, Ardeniz O et al. syndrome in an aboriginal patient from et al. Integrating exome sequencing Mutations affecting the actin regulator Australia. American Journal of Medical into a diagnostic pathway for epileptic WDR1 lead to aberrant lymphoid Genetics Part A 2018; 176:2561-2563. encephalopathy: Evidence of clinical utility immunity. Journal of Allergy and Clinical DOI: 10.1002/ajmg.a.40502 and cost effectiveness. Molecular Genetics Immunology 2018; 142:1589-1604. & Genomic Medicine 2018; 6:186-199. DOI: 10.1016/j.jaci.2018.04.023 Puts MTE, Sattar S, Kulik M, MacDonald DOI: 10.1002/mgg3.355 ME, McWatters K, Lee K et al. A randomized Pham TT, Nguyen DN, Dutkiewicz E, phase II trial of geriatric assessment Papachristou EK, Kishore K, Holding Center JR, Eisman JA, Nguyen TV. A and management for older cancer AN, Harvey K, Roumeliotis TI, profiling analysis of contributions of patients. Supportive Care in Cancer 2018; Chilamakuri CSR et al. A quantitative cigarette smoking, dietary calcium intakes, DOI: 10.1007/s00520-017-3820-7 mass spectrometry-based approach to and physical activity to fragility fracture in monitor the dynamics of endogenous the elderly. Scientific Reports2018; 8:10374. Quesnel-Vallieres M, Weatheritt RJ, chromatin-associated protein complexes. DOI: 10.1038/s41598-018-28660-y Cordes SP, Blencowe BJ. Autism Nature Communications 2018; 9:2311. spectrum disorder: insights into DOI: 10.1038/s41467-018-04619-5 Phan TG, Tangye SG. B cells race convergent mechanisms from the clock to get a second wind. transcriptomics. Nature Reviews Genetics Parkin A, Man J, Chou A, Nagrial AM, Nature Immunology 2018; 19:791-793. 2018; DOI: 10.1038/s41576-018-0066-2 Samra J, Gill AJ et al. The Evolving DOI: 10.1038/s41590-018-0166-3 Understanding of the Molecular and Rambau PF, Vierkant RA, Intermaggio Therapeutic Landscape of Pancreatic Picard C, Bobby Gaspar H, Al‑Herz W, MP, Kelemen LE, Goodman MT, Herpel Ductal Adenocarcinoma. Diseases 2018; Bousfiha A, Casanova JL, Chatila T E et al. Association of p16 expression 6:103. DOI: 10.3390/diseases6040103 et al. International Union of with prognosis varies across ovarian Immunological Societies: 2017 Primary carcinoma histotypes: an Ovarian Tumor Immunodeficiency Diseases Committee Tissue Analysis consortium study. Journal Report on Inborn Errors of Immunity. of Pathology: Clinical Research 2018; 4:250- Journal of Clinical Immunology 2018; 38:96- 261. DOI: 10.1002/cjp2.109 128. DOI: 10.1007/s10875-017-0464-9
garvan.org.au 71 72 2018 Garvan Annual Report Publications 2018 continued
Ramnath D, Irvine KM, Lukowski SW, Reeve AK, Grady JP, Cosgrave EM, Rogers S, McCloy RA, Parker BL, Gallego- Horsfall LU, Loh Z, Clouston AD et al. Bennison E, Chen C, Hepplewhite PD, Ortega D, Law AMK, Chin VT et al. MASTL Hepatic expression profiling identifies Morris CM. Mitochondrial dysfunction overexpression promotes chromosome steatosis-independent and steatosis- within the synapses of substantia instability and metastasis in breast driven advanced fibrosis genes. Journal nigra neurons in Parkinson's disease. cancer. Oncogene 2018; 37:4518-4533. of Clinical Investigation Insight 2018; NPJ Parkinson's Disease 2018; 4:9. DOI: 10.1038/s41388-018-0295-z 3:e120274. DOI: 10.1172/jci.insight.120274 DOI: 10.1038/s41531-018-0044-6 Rojas-Canales DM, Waibel M, Forget A, Rana HK, Akhtar MR, Ahmed MB, Reibe S, Febbraio MA. Relieving ER stress Penko D, Nitschke J, Harding FJ et al. Lio P, Quinn JMW, Huq F, Moni MA. to target NASH-driven hepatocellular Oxygen-permeable microwell device Genetic effects of welding fumes on carcinoma. Nature Reviews Endocrinology maintains islet mass and integrity during the progression of neurodegenerative 2018; DOI: 10.1038/s41574-018-0145-7 shipping. Endocrine Connections 2018; diseases. Neurotoxicology 2018; 71:93-101. 7:490-503. DOI: 10.1530/Ec-17-0349 DOI: 10.1016/j.neuro.2018.12.002 Reibe S, Hjorth M, Febbraio MA, Whitham M. GeneXX: An online tool for Roswall P, Bocci M, Bartoschek M, Rasmussen V, Forrest LE, Rogasik M, the exploration of transcript changes in Li H, Kristiansen G, Jansson S et al. Girodet M, Meeus P, Sunyach MP et al. skeletal muscle associated with exercise. Microenvironmental control of breast A comparison of Australian and French Physiological Genomics 2018; DOI: 10.1152/ cancer subtype elicited through paracrine families affected by sarcoma: perceptions physiolgenomics.00127.2017 platelet-derived growth factor-CC of genetics and incidental findings. signaling. Nature Medicine 2018; 24:463- Personalized Medicine 2018; 15:13-24. Reid IR, Baldock PA, Cornish J. Effects 473. DOI: 10.1038/nm.4494 DOI: 10.2217/pme-2017-0035 of Leptin on the Skeleton. Endocrine Reviews 2018; 39:938-959. DOI: 10.1210/ Rouet R, Jackson KJL, Langley DB, Rath EM, Cheng YY, Pinese M, Sarun KH, er.2017-00226 Christ D. Next-Generation Sequencing of Hudson AL, Weir C et al. BAMLET kills Antibody Display Repertoires. Frontiers chemotherapy-resistant mesothelioma cells, Ricciardelli C, Bianco-Miotto T, Jindal S, in Immunology 2018; 9:118. DOI: 10.3389/ holding oleic acid in an activated cytotoxic Butler LM, Leung S, McNeil CM et al. The fimmu.2018.00118 state. PLoS One 2018; 13:e0203003. magnitude of androgen receptor positivity DOI: 10.1371/journal.pone.0203003 in breast cancer is critical for reliable Rouet R, de Onate L, Lie J, Murthy N, prediction of disease outcome. Clinical Wilson RC. Engineering CRISPR-Cas9 Rath N, Munro J, Cutiongco MF, Jagiello Cancer Research 2018; 24:2328-2341. RNA-Protein Complexes for Improved A, Gadegaard N, McGarry L et al. Rho DOI: 10.1158/1078-0432.CCR-17-1199 Function and Delivery. CRISPR Journal kinase inhibition blocks pancreatic ductal 2018; 1:None. adenocarinoma invasion and tumor Rizzetto S, Koppstein DNP, Samir J, growth. Clinical Cancer Research 2018; Singh M, Reed JH, Cai CH et al. B-cell Ruderman I, Holt SG, Kirkland GS, Maslen 78:3321-3336. DOI: 10.1158/0008-5472. receptor reconstruction from single-cell S, Hawley CM, Oliver V et al. Outcomes Can-17-1339 RNA-seq with VDJPuzzle. Bioinformatics of cinacalcet withdrawal in Australian 2018; 34:2846-2847. DOI: 10.1093/ dialysis patients. Internal Medicine Journal Raverot G, Burman P, McCormack AI, bioinformatics/bty203 2018; DOI: 10.1111/imj.14036 Heaney AP, Petersenn S, Popovic V et al. European Society of Endocrinology Roach PJ, Francis R, Emmett L, Hsiao E, Ruospo M, Palmer SC, Natale P, Craig clinical practice guidelines for the Kneebone A, Hruby G et al. The impact JC, Vecchio M, Elder GJ, Strippoli GF. management of aggressive pituitary of 68Ga-PSMA PET/CT on management Phosphate binders for preventing and tumours and carcinomas. European intent in prostate cancer: results of treating chronic kidney disease-mineral Journal of Endocrinology 2018; 178:G1- an Australian prospective multicenter and bone disorder (CKD-MBD). Cochrane G24. DOI: 10.1530/EJE-17-0796 study. Journal of Nuclear Medicine 2018; Database of Systematic Reviews 2018; DOI: 10.2967/jnumed.117.197160 8:CD006023. DOI: 10.1002/14651858. Rebbeck TR, Friebel TM, Friedman CD006023.pub3 E, Hamann U, Huo D, Kwong A et al. Robinson DH, Churilov L, Lin NU, Lim E, Seah Mutational spectrum in a worldwide study D. Attitudes of patients with metastatic Samocha-Bonet D, Debs S, Greenfield of 29,700 families with BRCA1 or BRCA2 cancer towards research biopsies. Asia- JR. Prevention and Treatment of Type 2 mutations. Human Mutation 2018; 39:593- Pacific Journal of Clinical Oncology 2018; Diabetes: A Pathophysiological-Based 620. DOI: 10.1002/humu.23406 14:231-238. DOI: 10.1111/ajco.12783 Approach. Trends in Endocrinology and Metabolism 2018; DOI: 10.1016/j. Rogers MJ, Munoz MA. From vesicle tem.2018.03.014 to cytosol. eLife 2018; 7:e38847. DOI: 10.7554/eLife.38847
garvan.org.au 73 Publications 2018 continued
Sanchez-Parra C, Jacovetti C, Dumortier Schrode KM, Muniak MA, Kim YH, Sharma AK, Toussaint ND, Masterson O, Lee K, Peyot ML, Guay C et al. Lauer AM. Central Compensation in R, Holt SG, Rajapakse CS, Ebeling PR Contribution of the Long Non-Coding Auditory Brainstem after Damaging et al. Deterioration of Cortical Bone RNA H19 to Neonatal and Adult Rodent Noise Exposure. eNeuro 2018; 5:1-19. Microarchitecture: Critical Component beta-Cell Mass Expansion. Diabetes 2018; DOI: 10.1523/ENEURO.0250-18.2018 of Renal Osteodystrophy Evaluation. 67:2254-2267. DOI: 10.2337/db18-0201 American Journal of Nephrology 2018; Schuetz C Anazawa T. B cell replacement 47:376-384. DOI: 10.1159/000489671 Saricilar EC, Hamizan A, Alvarado R, therapy: the next 10 years. Transplantation Rimmer J, Sewell W, Tatersall J et 2018; 102:215-229. DOI: 10.1097/ Shearer RF, Frikstad KM, McKenna J, al. Optimizing Protein Harvest From TP.0000000000001937 McCloy RA, Deng N, Burgess A et al. The E3 Nasal Brushings for Determining Local ubiquitin ligase UBR5 regulates centriolar Allergy Responses. American Journal of Schumacher FR, Al Olama AA, Berndt SI, satellite stability and primary cilia. Rhinology & Allergy 2018; 32:244-251. Benlloch S, Ahmed M, Saunders EJ et al. Molecular Biology of the Cell 2018; 29:1542- DOI: 10.1177/1945892418777668 Association analyses of more than 140,000 1554. DOI: 10.1091/mbc.E17-04-0248 men identify 63 new prostate cancer Scheltema MJ, Chang JI, Bohm M, van susceptibility loci. Nature Genetics 2018; Shrosbree JE, Elder GJ. Acute den Bos W, Blazevski A, Gielchinsky I et al. 50:928-936. DOI: 10.1038/s41588-018-0142-8 hypocalcaemia following denosumab in Pair-matched patient-reported quality of heart and lung transplant patients with life and early oncological control following Shadur B, Abuzaitoun O, NaserEddin osteoporosis. Internal Medicine Journal focal irreversible electroporation versus A, Even-Or E, Zaidman I, Stepensky P. 2018; 48:681-687. DOI: 10.1111/imj.13744 robot-assisted radical prostatectomy. Management of XLP-1 and ITK deficiency: World Journal of Urology 2018; 36:1383- The challenges posed by PID with an Signal B, Gloss BS, Dinger ME, Mercer 1389. DOI: 10.1007/s00345-018-2281-z unpredictable spectrum of disease TR. Machine learning annotation of manifestations. Clinical Immunology 2018; human branchpoints. Bioinformatics 2018; Scheltema MJ, Chang JI, van den Bos W, 198:39-45. DOI: 10.1016/j.clim.2018.12.016 34:920-927. DOI: 10.1093/bioinformatics/ Gielchinsky I, Nguyen TV, Reijke TM et btx688 al. Impact on genitourinary function and Shadur B, Zaidman I, NaserEddin A, Lokshin quality of life following focal irreversible E, Hussein F, Oron HC et al. Successful Skvortsova K, Iovino N, Bogdanovic O. electroporation of different prostate hematopoietic stem cell transplantation Functions and mechanisms of epigenetic segments. Diagnostic and Interventional for osteopetrosis using reduced intensity inheritance in animals. Nature Reviews Radiology 2018; 24:268-275. DOI: 10.5152/ conditioning. Pediatric Blood & Cancer 2018; Molecular Cell Biology 2018; 19:774-790. dir.2018.17374 65:e27010. DOI: 10.1002/pbc.27010 DOI: 10.1038/s41580-018-0074-2
Schmitz-Peiffer C. Anarchy in the UPR: Shamriz O, Shadur B, NaserEddin A, Small L, Brandon AE, Quek LE, Krycer A Ca(2+)-insensitive PKC inhibits SERCA Zaidman I, Simanovsky N, Elpeleg O et JR, James DE, Turner N, Cooney activity to promote ER stress. Bioscience al. Respiratory manifestations in LPS- GJ. Acute activation of pyruvate Reports 2018; DOI: 10.1042/BSR20170966 responsive beige-like anchor (LRBA) dehydrogenase increases glucose protein-deficient patients. European oxidation in muscle without changing Schofield D, Shrestha R, Cunich M. The Journal of Pediatrics 2018; 177:1163-1172. glucose uptake. American Journal of economic impacts of using adalimumab DOI: 10.1007/s00431-018-3171-5 Physiology-Endocrinology and Metabolism (Humira((R))) for reducing pain in people with 2018; 315:E258-E266. DOI: 10.1152/ ankylosing spondylitis: A microsimulation Sharma AK, Toussaint ND, Elder GJ, ajpendo.00386.2017 study for Australia. International Journal of Masterson R, Holt SG, Robertson PL et Rheumatic Diseases 2018; 21:1106-1113. al. Magnetic resonance imaging based Small L, Brandon AE, Turner N, Cooney DOI: 10.1111/1756-185X.13277 assessment of bone microstructure GJ. Modelling insulin resistance in rodents as a non-invasive alternative to by alterations in diet. What have "high fat" Schofield P, Vazquez-Lombardi R, histomorphometry in patients with and high calorie diets revealed? American Abdelatti M, Nevoltris D, Goodnow CC, chronic kidney disease. Bone 2018; 114:14- Journal of Physiology-Endocrinology Christ D, Reed JH. Sequencing and 21. DOI: 10.1016/j.bone.2018.05.029 and Metabolism 2018; 314:E251-E265. Affinity Determination of Antigen-Specific DOI: 10.1152/ajpendo.00337.2017 B Lymphocytes from Peripheral Blood. Sharma AK, Toussaint ND, Elder GJ, Methods in Molecular Biology 2018; Rajapakse CS, Holt SG, Baldock P et Small L, Gong H, Yassmin C, Cooney GJ, 1827:287-309. DOI: 10.1007/978-1-4939- al. Changes in bone microarchitecture Brandon AE. Thermoneutral housing 8648-4_15 following kidney transplantation- does not influence fat mass or glucose Beyond bone mineral density. Clinical homeostasis in C57BL/6 mice. Journal Transplantation 2018; 32:e13347. of Endocrinology 2018; 239:313-324. DOI: 10.1111/ctr.13347 DOI: 10.1530/JOE-18-0279
74 2018 Garvan Annual Report Stepensky P, Keller B, Shamriz O, von Teasdale SB, Ward PB, Jarman R, Wade To SQ, Kwan EM, Fettke HC, Mant Spee-Mayer C, Friedmann D, Shadur T, Rossimel E, Curtis J et al. Is Obesity in A, Docanto MM, Martelotto L et al. B et al. T(+) NK(+) IL-2 Receptor Young People With Psychosis a Foregone Expression of androgen receptor splice gamma Chain Mutation: a Challenging Conclusion? Markedly Excessive Energy variant 7 or 9 in whole blood does not Diagnosis of Atypical Severe Combined Intake Is Evident Soon After Antipsychotic predict response to androgen-axis- Immunodeficiency.Journal of Clinical Initiation. Frontiers in Psychiatry 2018; targeting agents in metastatic castration- Immunology 2018; 38:527-536. 9:None. DOI: ARTN 72510.3389/ resistant prostate cancer. European DOI: 10.1007/s10875-018-0514-y fpsyt.2018.00725 Urology 2018; 73:818-821. DOI: 10.1016/j. eururo.2018.01.007 Sterne-Weiler T, Weatheritt RJ, Best Thavaneswaran S, Sebastian L, Ballinger AJ, Ha KCH, Blencowe BJ. Efficient M, Best M, Hess D, Lee CK et al. Cancer Tough IR, Forbes S, Herzog H, Jones and Accurate Quantitative Profiling of Molecular Screening and Therapeutics RM, Schwartz TW, Cox HM. Bidirectional Alternative Splicing Patterns of Any (MoST): a framework for multiple, parallel GPR119 Agonism Requires Peptide YY Complexity on a Laptop. Molecular signal‑seeking studies of targeted therapies and Glucose for Activity in Mouse and Cell 2018; 72:187-200. DOI: 10.1016/j. for rare and neglected cancers. Medical Human Colon Mucosa. Endocrinology molcel.2018.08.018 Journal of Australia 2018; 209:354-355. 2018; 159:1704-1717. DOI: 10.1210/ en.2017-03172 Stirzaker C, Song JZ, Statham AL, Clark Thientosapol ES, Bosnjak D, Durack SJ. Bisulphite Sequencing of Chromatin T, Stevanovski I, van Geldermalsen Trainer PJ, Newell-Price JDC, Ayuk Immunoprecipitated DNA (BisChIP-seq). M, Holst J et al. SAMHD1 enhances J, Aylwin SJB, Rees A, Drake W et al. Methods in Molecular Biology 2018; 1708:285- immunoglobulin hypermutation by A randomised, open-label, parallel 302. DOI: 10.1007/978-1-4939-7481-8_15 promoting transversion mutation. group phase 2 study of antisense Proceedings of the National Academy of oligonucleotide therapy in acromegaly. Stocks B, Dent JR, Ogden HB, Zemp M, Sciences of the United States of America European Journal of Endocrinology 2018; Philp A. Post-exercise skeletal muscle 2018; 115:4921-4926. DOI: 10.1073/ 179:97-108. DOI: 10.1530/eje-18-0138 signaling responses to moderate-to pnas.1719771115 high-intensity steady-state exercise in the Trajanoska K, Morris JA, Oei L, Zheng HF, fed or fasted state. American Journal of Thompson JE, Egger S, Bohm M, Evans DM, Kiel DP et al. Assessment of Physiology-Endocrinology and Metabolism Siriwardana AR, Haynes AM, Matthews the genetic and clinical determinants of 2018; DOI: 10.1152/ajpendo.00311.2018 J et al. Superior biochemical recurrence fracture risk: genome wide association and long-term quality-of-life outcomes and mendelian randomisation study. Stoll L, Sobel J, Rodriguez-Trejo A, Guay are achievable with robotic radical British Medical Journal 2018; 362:k3225. C, Lee K, Veno MT et al. Circular RNAs as prostatectomy after a long learning curve- DOI: 10.1136/bmj.k3225 novel regulators of beta-cell functions in updated analysis of a prospective single- normal and disease conditions. Molecular surgeon cohort of 2206 consecutive Tran TS, Nguyen TV. Association Between Metabolism 2018; 9:69-83. DOI: 10.1016/j. cases. European Urology 2018; 73:664-671. Alendronate and All-Cause Mortality molmet.2018.01.010 DOI: 10.1016/j.eururo.2017.11.035 and Cardiovascular Mortality Among Hip Fracture: An Alternative Explanation. Szabo A, Sumegi K, Fekete K, Hocsak E, Thompson J, Stricker P. Imaging: MRI Journal of Bone and Mineral Research 2018; Debreceni B, Setalo G et al. Activation improves cost and accuracy of prostate DOI: 10.1002/jbmr.3570 of mitochondrial fusion provides a new cancer biopsy. Nature Reviews Urology treatment for mitochondria-related 2018; 15:6. DOI: 10.1038/nrurol.2017.185 Tran T, Bliuc D, Hansen L, Abrahamsen diseases. Biochemical Pharmacology 2018; B, van den Bergh J, Eisman JA et al. 150:86-96. DOI: 10.1016/j.bcp.2018.01.038 Ting YS, Smith Sabc, Brown DA, Dodds Persistence of excess mortality following AJ, Fay KC, Ma DDF et al. CD200 is a individual non-hip fractures: A relative Szczepny A, Carey K, McKenzie L, useful diagnostic marker for identifying survival analysis. Journal of Clinical Jayasekara WSN, Rossello F, Gonzalez-Rajal atypical chronic lymphocytic leukemia Endocrinology & Metabolism 2018; 103:3205- A et al. The tumor suppressor Hic1 maintains by flow cytometry. International Journal of 3214. DOI: 10.1210/jc.2017-02656 chromosomal stability independent of Laboratory Hematology 2018; 40:533-539. Tp53. Oncogene 2018; 37:1939-1948. DOI: 10.1111/ijlh.12857 Tran T, Bliuc D, Hansen L, Abrahamsen DOI: 10.1038/s41388-017-0022-1 B, van den Bergh J, Eisman JA et al. Tio M, Rai R, Ezeoke OM, McQuade JL, Persistence of Excess Mortality Following Tangye SG. Is it dead or alive? TLR8 can Zimmer L, Khoo C et al. Anti-PD-1/PD-L1 Individual Nonhip Fractures: A Relative tell. Nature Immunology 2018; 19:324-326. immunotherapy in patients with solid Survival Analysis. Journal of Clinical DOI: 10.1038/s41590-018-0070-x organ transplant, HIV or hepatitis B/C Endocrinology & Metabolism 2018; 103:3205- infection. European Journal of Cancer 3214. DOI: 10.1210/jc.2017-02656 Taylor JE, Campbell LV. High diabetes 2018; 104:137-144. DOI: 10.1016/j. prevalence and insulin medication errors ejca.2018.09.017 Trivedi SJ, Tanous D. Coronary artery in hospital patients. Internal Medicine vasospasm in a patient with Churg- Journal 2018; 48:1529-1532. DOI: 10.1111/ Strauss syndrome. BMJ Case Rep 2018; imj.14124 DOI: 10.1136/bcr-2018-225321
garvan.org.au 75 Publications 2018 continued
Trouillas J, Burman P, McCormack AI, van Geel Tacm, Bliuc D, Geusens PPM, Verma R, Lee C, Jeun EJ, Yi J, Kim KS, Petersenn S, Popovic V, Dekkers O, Raverot Center JR, Dinant GJ, Tran T et al. Ghosh A et al. Cell surface polysaccharides G. Aggressive pituitary tumours and Reduced mortality and subsequent of Bifidobacterium bifidum induce the carcinomas: two sides of the same coin? fracture risk associated with oral generation of Foxp3(+) regulatory T European Journal of Endocrinology 2018; bisphosphonate recommendation cells. Science Immunology 2018; 3:None. 178:C7-C9. DOI: 10.1530/EJE-18-0250 in a fracture liaison service setting: DOI: 10.1126/sciimmunol.aat6975 A prospective cohort study. PLoS One Tsoli M, Wadham C, Pinese M, Failes 2018; 13:e0198006. DOI: 10.1371/journal. Viardot A, Purtell L, Nguyen TV, Campbell T, Joshi S, Mould E et al. Integration pone.0198006 LV. Relative Contributions of Lean and of genomics, high throughput Fat Mass to Bone Mineral Density: Insight drug screening, and personalized van den Bos W, Scheltema MJ, From Prader-Willi Syndrome. Frontiers in xenograft models as a novel precision Siriwardana AR, Kalsbeek AMF, Endocrinology 2018; 9:480. DOI: 10.3389/ medicine paradigm for high risk Thompson JE, Ting F et al. Focal fendo.2018.00480 pediatric cancer. Cancer Biology irreversible electroporation as primary & Therapy 2018; 19:1078-1087. treatment for localized prostate cancer. Vulinovic F, Krajka V, Hausrat TJ, Seibler DOI: 10.1080/15384047.2018.1491498 BJU International 2018; 121:716-724. P, Alvarez-Fischer D, Madoev H et al. DOI: 10.1111/bju.13983 Motor protein binding and mitochondrial Turner N, Lim XY, Toop HD, Osborne B, transport are altered by pathogenic Brandon AE, Taylor EN et al. A selective van der Poorten DK, McLeod D, Ahlenstiel TUBB4A variants. Human Mutation 2018; inhibitor of ceramide synthase 1 G, Read S, Kwok A, Santhakumar C et al. 39:1901-1915. DOI: 10.1002/humu.23602 reveals a novel role in fat metabolism. Gastric Cancer Screening in Common Nature Communications 2018; 9:3165. Variable Immunodeficiency.Journal of Wagle MV, Marchingo JM, Howitt J, DOI: 10.1038/s41467-018-05613-7 Clinical Immunology 2018; 38:768-777. Tan SS, Goodnow CC, Parish IA. The DOI: 10.1007/s10875-018-0546-3 Ubiquitin Ligase Adaptor NDFIP1 Usui T, Noble DWA, O'Dea RE, Fangmeier Selectively Enforces a CD8(+) T Cell ML, Lagisz M, Hesselson D, Nakagawa Vasilevsky NA, Foster ED, Engelstad ME, Tolerance Checkpoint to High-Dose S. The French press: a repeatable and Carmody L, Might M, Chambers C et al. Plain- Antigen. Cell Reports 2018; 24:577-584. high-throughput approach to exercising language medical vocabulary for precision DOI: 10.1016/j.celrep.2018.06.060 zebrafish (Danio rerio). PeerJ 2018; diagnosis. Nature Genetics 2018; 50:474-476. 6:e4292. DOI: 10.7717/peerj.4292 DOI: 10.1038/s41588-018-0096-x Walczak A, Patterson P, Thomas D. Trials and tribulations: improving outcomes for Valdes-Mora F, Handler K, Law AMK, Vasiljevski ER, Summers MA, Little DG, adolescents and young adults with rare Salomon R, Oakes SR, Ormandy Schindeler A. Lipid storage myopathies: and low survival cancers. Medical Journal CJ, Gallego-Ortega D. Single- Current treatments and future directions. of Australia 2018; 209:330-332. Cell Transcriptomics in Cancer Progress in Lipid Research 2018; 72:1-17. Immunobiology: The Future of Precision DOI: 10.1016/j.plipres.2018.08.001 Wang JJ, Reed JH, Colella AD, Russell Oncology. Frontiers in Immunology 2018; AJ, Murray-Brown W, Chataway TK 9:2582. DOI: 10.3389/fimmu.2018.02582 Vazquez-Lombardi R, Nevoltris D, et al. Molecular profiling and clonal Luthra A, Schofield P, Zimmermann C, tracking of secreted rheumatoid factors van Dijk D, Sharma R, Nainys J, Yim K, Christ D. Transient expression of human in primary Sjögren’s syndrome. Arthritis Kathail P, Carr AJ et al. Recovering gene antibodies in mammalian cells. Nature & Rheumatology 2018; 70:1617-1625. interactions from single-sell data using Protocols 2018; 13:99-117. DOI: 10.1038/ DOI: 10.1002/art.40539 data diffusion. Cell 2018; 174:716-729. nprot.2017.126 DOI: 10.1016/j.cell.2018.05.061 Wang L, Crawford JD, Reppermund S, Vazquez-Lombardi R, Nevoltris D, Rouet R, Trollor J, Campbell L, Baune BT et al. Body van Dijk SJ, Peters TJ, Buckley M, Zhou Christ D. Expression of IgG Monoclonals mass index and waist circumference J, Jones PA, Gibson RA et al. DNA with Engineered Immune Effector Functions. predict health-related quality of life, but methylation in blood from neonatal Methods in Molecular Biology 2018; 1827:313- not satisfaction with life, in the elderly. screening cards and the association 334. DOI: 10.1007/978-1-4939-8648-4_16 Quality of Life Research 2018; DOI: 10.1007/ with BMI and insulin sensitivity in early s11136-018-1904-6 childhood. International Journal of Obesity Vennin C, Murphy KJ, Morton JP, Cox 2018; 42:28-35. DOI: 10.1038/ijo.2017.228 TR, Pajic M, Timpson P. Reshaping the Wang QP, Browman D, Herzog H, Neely tumor stroma for treatment of pancreatic GG. Non-nutritive sweeteners possess cancer. Gastroenterology 2018; 154:820- a bacteriostatic effect and alter gut 838. DOI: 10.1053/j.gastro.2017.11.280 microbiota in mice. PLoS One 2018; 13:e0199080. DOI: 10.1371/journal. pone.0199080
76 2018 Garvan Annual Report Wang T, Bu CH, Hildebrand S, Jia G, Woodcock F, Doble B, Cancer 2015 Zardavas D, Te Marvelde L, Milne RL, Siggs OM, Lyon S et al. Probability Consortium. Mapping the EORTC‑QLQ-C30 Fumagalli D, Fountzilas G, Kotoula V et al. of phenotypically detectable protein to the EQ-5D-3L: An assessment of Tumor PIK3CA genotype and prognosis damage by ENU-induced mutations existing and newly developed algorithms. in early-stage breast cancer: a pooled in the Mutagenetix database. Medical Decision Making 2018; 38:954-967. analysis of individual patient data. Journal Nature Communications 2018; 9:441. DOI: 10.1177/0272989X18797588 of Clinical Oncology 2018; 36:981-990. DOI: 10.1038/s41467-017-02806-4 DOI: 10.1200/JCO.2017.74.8301 Wullkopf L, West AV, Leijnse N, Cox TR, Warren SC, Nobis M, Magenau A, Madsen CD, Oddershede LB, Erler JT. Zengin A, Maple-Brown LJ, Brennan- Mohammed YH, Herrmann D, Moran I et Cancer cells' ability to mechanically adjust Olsen S, Center JR, Eades S, Ebeling PR. al. Removing physiological motion from to extracellular matrix stiffness correlates Musculoskeletal health of Indigenous intravital and clinical functional imaging with their invasive potential. Molecular Australians. Archives of Osteoporosis 2018; data. eLife 2018; 7:e35800. DOI: 10.7554/ Biology of the Cell 2018; 29:2378-2385. 13:77. DOI: 10.1007/s11657-018-0493-x eLife.35800 DOI: 10.1091/mbc.E18-05-0319 Zeraati M, Dinger ME, Christ D. Selection Warton K, Graham LJ, Yuwono N, Xia T, Horton ER, Salcini AE, Pocock R, Cox of Antibody Fragments Against Structured Samimi G. Comparison of 4 commercial TR, Erler JT. Proteomic Characterization DNA by Phage Display. Methods in kits for the extraction of circulating of Caenorhabditis elegans Larval Molecular Biology 2018; 1827:197-209. DNA from plasma. Cancer Genetics Development. Proteomics 2018; 18:None. DOI: 10.1007/978-1-4939-8648-4_11 2018; 228-229:143-150. DOI: 10.1016/j. DOI: 10.1002/pmic.201700238 cancergen.2018.02.004 Zeraati M, Langley DB, Schofield P, Moye Yang X, Leslie G, Gentry-Maharaj A, Ryan AL, Rouet R, Hughes WE et al. I-motif Wee NKY, Enriquez RF, Nguyen AD, A, Intermaggio M, Lee A et al. Evaluation DNA structures are formed in the nuclei Horsnell H, Kulkarni R, Khor EC et al. Diet- of polygenic risk scores for ovarian of human cells. Nature Chemistry 2018; induced obesity suppresses cortical bone cancer risk prediction in a prospective 10:631-637. DOI: 10.1038/s41557-018- accrual by a neuropeptide Y-dependent cohort study. Journal of Medical Genetics 0046-3 mechanism. International Journal of Obesity 2018; 55:546-554. DOI: 10.1136/ 2018; DOI: 10.1038/s41366-018-0028-y jmedgenet-2018-105313 Zhang L, Ip CK, Lee IJ, Qi Y, Reed F, Karl T et al. Diet-induced adaptive Whitham M, Parker BL. Extracellular Yap JY, Wirasinha RC, Chan A, Howard thermogenesis requires neuropeptide vesicles provide a means for tissue cross DR, Goodnow CC, Daley SR. Indirect FF receptor-2 signalling. Nature talk during exercise. Cell Metabolism presentation in the thymus limits naive Communications 2018; 9:4722. 2018; 27:237-251 e4. DOI: 10.1016/j. and regulatory T-cell differentiation DOI: 10.1038/s41467-018-06462-0 cmet.2017.12.001 by promoting deletion of self-reactive thymocytes. Immunology 2018; 154:522- Zhu P, Zhang ZH, Huang XF, Shi YC, Willis AM, Smith SK, Meiser B, Ballinger 532. DOI: 10.1111/imm.12904 Khandekar N, Yang HQ et al. Cold ML, Thomas DM, Tattersall M, Young exposure promotes obesity and impairs MA. Development and pilot testing of Young AI, Timpson P, Gallego- glucose homeostasis in mice subjected to a decision aid for genomic research Ortega D, Ormandy CJ, Oakes SR. a highfat diet. Molecular Medicine Reports participants notified of clinically actionable Myeloid cell leukemia 1 (MCL-1), an 2018; 18:3923-3931. DOI: 10.3892/ research findings for cancer risk. Journal unexpected modulator of protein mmr.2018.9382 of Genetic Counseling 2018; 27:1055-1066. kinase signaling during invasion. Cell DOI: 10.1007/s10897-018-0223-y Adhesion & Migration 2018; 12:513-523. Zhu P, Zhang Z, Huang X, Liang S, DOI: 10.1080/19336918.2017.1393591 Khandekar N, Song Z, Lin S. RANKL Wirasinha RC, Singh M, Archer SK, Chan Reduces Body Weight and Food Intake A, Harrison PF, Goodnow CC, Daley Young MA, Forrest LE, Rasmussen VM, via the Modulation of Hypothalamic NPY/ SR. alphabeta T-cell receptors with a James P, Mitchell G, Sawyer SD et al. Making CART Expression. International Journal central CDR3 cysteine are enriched Sense of SNPs: Women's Understanding of Medical Sciences 2018; 15:969-977. in CD8alphaalpha intraepithelial and Experiences of Receiving a Personalized DOI: 10.7150/ijms.24373 lymphocytes and their thymic precursors. Profile of Their Breast Cancer Risks. Immunology and Cell Biology 2018; 96:553- Journal of Genetic Counseling 2018; Ziegler DS, Wong M, Mayoh C, Kumar 561. DOI: 10.1111/imcb.12047 DOI: 10.1007/s10897-017-0162-z A, Tsoli M, Mould E et al. Brief Report: Potent clinical and radiological response Wirasinha RC, Vijayan D, Smith NJ, Parnell Zammit NW, Grey ST. Equipping the to larotrectinib in TRK fusion-driven high- GP, Swarbrick A, Brink R et al. GPR65 inhibits islet graft for self defence: targeting grade glioma. British Journal of Cancer experimental autoimmune encephalomyelitis nuclear factor kappaB and implications 2018; DOI: 10.1038/s41416-018-0251-2 through CD4(+) T cell independent for tolerance. Current Opinion in Organ mechanisms that include effects on iNKT Transplantation 2018; 23:97-105. Zilberg C, Lee MW, Yu B, Ashford B, cells. Immunology and Cell Biology 2018; DOI: 10.1097/MOT.0000000000000482 Kraitsek S, Ranson M et al. Analysis of 96:128-136. DOI: 10.1111/imcb.1031 clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma. Modern Pathology 2018; 31:275-287. DOI: 10.1038/ modpathol.2017.128 garvan.org.au 77 Peer reviewed funding
From the Chief Scientific Officer
Many of our researchers receive fellowship and grant funding from the National Health and Medical Research Council (NHMRC) and other funding bodies to support their own salaries and their research programs.
Peer reviewed grants are selected in a highly competitive process, with a panel of expert scientists assessing these applications. Due to funding constraints, only a small proportion of applications are funded in each round and many high quality proposals remain unfunded. Therefore, the fundraising efforts and contributions of Garvan’s donors are absolutely necessary to support all our researchers’ life‑changing work. Private funds help our researchers continue their important projects until they're able to acquire competitive grant funding. Professor Marie Dziadek, Chief Scientific Officer Garvan researchers had another excellent year in 2018 with many grant and fellowship proposals funded by NHMRC and other funding bodies, as listed on the right.
78 2018 Garvan Annual Report Peer reviewed funding Garvan-led grants 2018
Funding Body Type of Principal Co-Investigators Project Title Amount Years of Grant Investigator Funded Funding Amgen Investigator Jacqueline The effect of antiresorptive $372,089 2 Australia Pty Ltd Initiated Center medication on outcomes post Research fracture (Amgen-45 and Up) Agreement Avner Pancreatic Innovation David Herbert Herzog, Dual targeting of metabolic and $99,952 1 Cancer Grant Herrmann Tatyana Chtanova immunological aberrations in Foundation Ltd pancreatic cancer by combining Neuropeptide Y inhibition with immunotherapy Bioplatforms Project Joseph Powell Cellular Genomics Data Platform $1,000,000 3 Australia Limited Grant (BPA) Cancer Council Project Chris Susan Clark, Samantha Overcoming endocrine resistance $448,949 3 NSW Grant Ormandy Oakes, Carlo Palmieri in breast cancer (University of Liverpool, UK) Project Thomas Cox Wolfgang Jarolimek Targeting Lysyl Oxidases (LOX) $450,000 3 Grant (Pharmaxis) in Pancreatic Cancer CanTeen – Clinical David Thomas Mandy Ballinger, Mark AYA-MoST: a Molecular Screening $950,000 3 the Australian Trials Cowley, John Simes and Therapeutics trial for Australian organisation for Initiative (NHMRC Clinical Trials adolescents and young adults with young people Centre, USyd), Jeremy advanced cancer living with cancer Lewin (Peter Mac), Antoinette Anazodo (Sydney Children’s Hospital) Diabetes General Yanchuan Shi Don Chisholm Investigation of the role of $60,000 1 Australia Grant adipocyte-specific Y1 receptors Research Trust in controlling the browning of white adipose tissue in diet‑induced obesity General Trevor Biden A novel macrophage-derived $60,000 1 Grant mediator of beta cell dysfunction General Ross Laybutt The protein folding isomerase $60,000 1 Grant FKBP11 protects against type 2 diabetes Millennium Jerry Jen Snaith, Dorit Samocha- Phenotypic characterisation of $150,000 2 Award Greenfield Bonet, Jane Holmes adults with type 1 diabetes: towards Walker & Christian Girgis personalised adjunctive treatment (Westmead Hospital) of insulin resistance Job Research Project Stuart Tangye STAT3-mediated regulation of $200,000 2 Foundation Grant the human immune response - unravelling the complexities of disease pathogenesis of Job’s syndrome Juvenile Project Shane Grey Greg Korbutt (University Islet dependent tolerance for $487,931 2 Diabetes Grant of Alberta, Canada) insulin independence without Research immunosuppression Foundation MS Research Incubator Daniel Suan Chris Goodnow, Determining the single-cell genomic $25,000 1 Australia Grant Mandeep Singh landscape of autoreactive "rogue" lymphocytes in the pathogenesis of multiple sclerosis
garvan.org.au 79 Garvan-led grants 2018 continued
Funding Body Type of Principal Co-Investigators Project Title Amount Years of Grant Investigator Funded Funding MTP Connect- Project Luke Hesson David Thomas, Marcel Enabling Precision Cancer Clinical $400,000 1 MedTech and Grant Dinger, Mark Cowley, Trials: A molecular profiling Pharma Growth Anthony Joshua, Lisa platform for the Australian clinical centre Horvath, Michael Winlo trials industry and SMEs (Linear Clinical Research company), John Simes (NHMRC Clinical Trials Centre), Charlotte Lemech (NSW Early phase Clinical Trials Alliance), Evan Dodds (Illumina) MTP Connect- Program Luke Hesson David Thomas A clinically-accredited and $891,500 2 MedTech and Grant commercial-ready genome Pharma Growth profiling platform to enable centre precision cancer medicine National Investigator Alex Joseph Powell, Sandra The Breast Cancer Cell Atlas $760,521 2 Breast Cancer Grant Swarbrick O'Toole, Elgene Lim Foundation Investigator Neil Portman Elgene Lim, Liz Caldon, Targeting the p53 pathway in the $197,825 2 Grant Heloisa Milioli age of CDK4/6 inhibitor resistant ER positive breast cancer Investigator Sandra Alex Swarbrick, Soon Lee Improving treatment options for $247,130 2 Grant O'Toole (NSW Health Path / WSU), rare breast cancers – identifying Niantao Deng therapeutic targets in malignant phyllodes tumours Investigator Tatyana David Gallego-Ortega Developing novel innate-based $195,782 2 Grant Chtanova immunotherapies in triple negative breast cancer Investigator Christine Ablating SULF1: A novel and $241,247 2 Grant Chaffer targeted therapeutic strategy to inhibit breast cancer metastasis Investigator Liz Caldon Elgene Lim Therapeutic targeting of dual $582,432 3 Grant CDK4/6 inhibitor and endocrine resistant breast cancer National Project Clare Stirzaker Susan Clark, Matt Trau & Liquid Biopsy monitoring for Triple $141,835 1 Foundation Grant Darren Korbie (University Negative Breast Cancer: a Novel for Medical of Queensland) Epigenetic Test Research and Innovation
80 2018 Garvan Annual Report Funding Body Type of Principal Co-Investigators Project Title Amount Years of Grant Investigator Funded Funding National Health Project Paul Timpson Jennifer Morton (Beatson Tailored priming of pancreatic cancer $892,362 4 and Medical Grant Institute, UK), Yingxiao progression and metastatic targeting Research (Peter Mac) Wang using KD025, a phase II (ROCK2) Council (UCSD, USA) inhibitor: fine‑tuning treatment via single cell intravital imaging Project Marina Pajic Anthony Gill & Jas Samra "Fine-tuned" manipulation of $707,521 3 Grant (Royal North Shore the c-MET oncogenic pathway Hospital), Adnan Nagrial in pancreatic cancer: a new (Westmead Hospital) paradigm of personalised medicine Project David Walter Kolch (University Complex epistasis between JNK $686,653 3 Grant Croucher College Dublin) and PI3K pathway mutations in breast cancer Project Mark Febbraio Stefan Rose (John Christian The designer cytokine IC7: $1,081,560 4 Grant Albrechts-Universität zu a novel therapy for the Kiel) treatment of type 2 Diabetes Project Herbert Central control of diet $782,520 4 Grant Herzog induced thermogenesis Project Nikki Lee Central control of $692,755 3 Grant energy partitioning Project Yanchuan Shi Targeting NPY signaling in $664,920 3 Grant adipose tissue to promote thermogenesis and weight loss Parkinson's Project Antony Svetha Venkatesh & Blood RNA Biomarkers to $100,000 1 NSW Grant Cooper Sunil Gupta (Deakin Uni), measure Ddisease progression Boris Guennewig (University in Parkinson’s patients of Sydney) PKD Foundation Project John Shine Amali Mallawaarachchi Understanding the role of somatic $160,000 2 (Australia/ Grant variation and novel mutational United States) mechanisms in the genetic pathogenesis of PKD Rebecca L Project Joanne Reed Targeting rogue clones in systemic $100,000 2 Cooper Medical Grant autoimmune rheumatic diseases Research Foundation St Vincent's Project Elgene Lim Neil Portman Reactivating p53 to combat $40,000 1 Clinic Grant CDK4/6 inhibitor resistant ER Foundation positive breast cancer Project Venessa Chin Richard Gallagher, Neil Using genomics to understand $25,000 1 Grant Watkins, Richard Hillman HPV-associated squamous cell cancer of the head and neck Project Christine Elgene Lim Blocking IL1R1 signalling to inhibit $50,000 1 Grant Chaffer breast cancer metastasis Project Aurelie Cazet Alex Swarbrick, Joseph Single-cell analyses to tailor $50,000 1 Grant Powell, Anthony Joshua stratification in patients with intermediate-risk prostate cancer Project James Erin Heyer, David Thomas, Accurately diagnosing fusion genes $40,000 1 Grant Blackburn Toby Trahair (Sydney in paediatric and adolescent and Children Hospital) young (AYA) sarcomas Project Jerry Jennifer Snaith, Phenotypic characterisation $100,000 1 Grant Greenfield Dorit Samocha-Bonet, of adults with type 1 Jane Holmes-Walker Diabetes:exploring the role of liver (Westmead Hospital), and muscle insulin sensitivity Christian Girgis (University of Sydney) Sydney Project Mun Hui Describing the cellular $50,000 1 Breast Cancer Grant landscape of recurrent / Foundation metastatic breast cancer garvan.org.au 81 Fellowships and scholarships 2018
Funding Body Type of Award Awardee Project Title Amount Years of Funded Funding Australian Discovery Early Romain Rouet Targeted genome editing using engineered CRISPR- $409,574 3 Research Career Reseach Cas endonucleases Council Award Cancer Institute Career Fatima Valdes An epigenetic approach to target akuma-myeloid- $600,000 3 NSW Development Mora derived suppressor cells in breast cancer Fellowship Career Michelle Tumour-bone cell interactions: An opportunity $599,920 3 Development McDonald to harness the microenvironment to overcome Fellowship metastatic disease. Career Mark McCabe Non-invasive monitoring of tumour burden and $600,000 3 Development therapeutic response through liquid biopsy Fellowship and targeted gene capture Career Christine Manipulating IL-1b/IL-1R1 signalling to inhibit $600,000 3 Development Chaffer breast cancer metastasis. Fellowship Career Ozren Epigenetic regulation of germline cell fate $410,000 3 Development Bogdanovic during oncogenesis Fellowship Early Career Andre Minoche Defining the genomic and epigenetic landscape of $508,231 3 Fellowship high-risk paediatric cancer genomes using long-read sequencing National Health Career Ozren Epigenetic regulation of germline fate during $437,036 4 and Medical Development Bogdanovic embryonic development and oncogenesis Research Fellowship Council Career Marina Pajic Addressing the molecular heterogeneity of $483,404 4 Development pancreatic cancer: personalised medicine in action Fellowship Career Thomas Cox Delving deeper into the matrix: redefining the $483,404 4 Development extracellular matrix in cancer treatment Fellowship Research Tri Phan Targeting B cell dynamics in immunity, $649,175 4 Fellowship autoimmunity and cancer Research Daniel Christ Next generation antibody therapeutics $717,275 4 Fellowship Research Alex Swarbrick Discovering new therapeutic strategies for $649,175 4 Fellowship breast and prostate cancer at cellular resolution Research Susan Clark The cancer epigenome $888,270 4 Fellowship Early Career Simon Investigating the role of long non-coding RNAs $417,192 4 Fellowship Hardwick in neurological disorders using high-resolution transcriptomics Rebecca L Al and Val Andrew Philp Geriatrics – to harness the effects of exercise into $380,000 4 Cooper Medical Rosenstrauss therapies for diseases of ageing. Research Research Foundation Fellowship
82 2018 Garvan Annual Report Collaborative grants led by other institutions 2018
Funding Body Type of Grant Admin Garvan Investigator Co-Investigators Project Title Institution Australian Discovery UNSW Ozren Bogdanovic Jose Luis Gomez- Comprehensive characterisation Research Project Sydney Skarmeta, (CSIC Spanish of DNA demethylation pathways Council National Research Council) in vivo National Investigator University Sandra O'Toole PI Philip Gregory (UniSA) miR-342-a novel suppressor of Breast Cancer Grant of south Co-Is: Robin Anderson prometastatic gene network in Foundation australia (ONJCRI), Gregory Goodall triple-negative breast cancer (UniSA), Sandra O'Toole National Health Project Grant University of Vanessa Hayes Sole CI Establishing a genomic and Medical sydney signature for high-risk Research prostate cancer Council
Equipment grants 2018
Funding Body Project Title Principal Co-Investigators Amount Investigator Funded Cancer Institute Accessible and affordable real- Martin Smith David Thomas, Vanessa Hayes, $237,000 NSW time whole genome, methylome, Marcel Dinger, Mark Cowley and transcriptome sequencing for personalized cancer research. (GridIONx5 CapEx) Cancer Institute Vectra Polaris multispectral David Thomas Anthony Joshua, Alex Swarbrick, $465,910 NSW imaging platform for cancer Chris Ormandy, Elgene Lim, Tri Phan, immunology. Sandra O'Toole, Marina Pajic, Stuart Tangye Michelle Haber (Children's Cancer Institute)
garvan.org.au 83 Financial highlights
Statement of financial position as at 31st December 2018
Profit and loss statement
Expenditure on Revenue 2018 2017 2018 2017 A$’000 A$’000 research activities A$’000 A$’000
Research grants Employee benefits expense 57,386 52,597
NHMRC research grants 16,480 14,795 Sequencing consumable expense 5,466 9,728
Other peer reviewed research grants 12,200 6,839 Research expense 10,278 14,199
Other grants 5,992 4,726 Depreciation and amortisation expense 11,302 11,502
Commercial partnerships 246 533 Administration expense 10,344 11,116
34,918 26,893 Fundraising and marketing investment 3,244 3,260
NHMRC and UNSW Infrastructure grants Building and scientific expenses 8,862 6,827
NHMRC IRIISS grant 3,046 2,924 Finance costs 715 1,452
UNSW contribution 3,977 499 107,597 110,681
Total comprehensive 7,023 3,423 (332) (9,482) income for the year
NSW government support 7,169 16,256
Donations and bequests 41,148 27,024
Other income
Sequencing and facility charges 15,878 20,961
Investment/interest income 435 6,306
Software licencing revenue 816 672
Net gain on disposal of property, 0 (209) plant and equipment
Net gain on foreign exchange 89 0
Share of gain of associates accounted (211) (127) for using the equity method
17,007 27,603
Total revenue 107,265 101,199
84 2018 Garvan Annual Report Balance sheet
Assets 2018 2017 Liabilities 2018 2017 A$’000 A$’000 A$’000 A$’000
Current assets Current liabilities
Cash and cash equivalents 47,055 36,132 Trade and other payables 8,567 8,986
Trade and other receivables 6,848 9,468 Borrowings 159 2,224
Financial assets at fair value 33,018 39,962 Provisions 5,684 5,685 through profit and loss
Financial assets at amortised cost 9,236 4,319 Deferred Revenue 1,733 70
Sequencing Consumables 1,196 3,765 Total current liabilities 16,143 16,965
Biological assets 531 518 Non-current liabilities
Total current assets 97,884 94,164 Borrowings 12,266 12,478
Non-current assets Provisions 1,098 1,132
Investments accounted for 61 272 Other 906 1,043 using the equity method
Property, plant and equipment 82,513 86,692 Total non-current liabilities 14,270 14,653
Intangibles & others 100 968 Total liabilities 30,413 31,618
Total non-current assets 82,674 87,932 Net assets 150,145 150,478
Total assets 180,558 182,096 Funds
Reserves 132,593 111,020
Retained surpluses 17,552 39,458
Total funds 150,145 150,478
The Statement of Financial Position provided above, together with the attached Income Statement, have been extracted from the audited general purpose financial statements of Garvan Institute of Medical Research and its controlled entities. The summary financial information does not include all the information and notes normally included in a statutory financial report. The audited general purpose financial report can be obtained upon request to the Chief Operating Officer.
The statutory financial report (from which the summary financial information has been extracted) has been prepared in accordance with the requirements of the Corporations Act 2001, Australian Charities and Non-for-profits Commission Act 2012 and Regulations 2013, Australian Accounting Standards and other authoritative pronouncements of the Australian Accounting Standards Board.
garvan.org.au 85 2018 Annual Report Report Annual 2018 Research of Medical Institute Garvan
Garvan Institute of Medical Research
384 Victoria Street, Darlinghurst NSW, 2010 Australia
T + 61 2 9295 8100 F + 61 2 9295 8101 garvan.org.au
Garvan Institute of Medical Research ABN: 62 330 391 937
Photography Ali Nasseri, Peter Secheney
Additional photography Penelope Clay, Anne-Marie Cook, Alex Craig
Published April 2019 Copies of the Annual Report can be obtained by contacting:
Garvan Research Foundation [email protected] +61 2 9295 8110
facebook.com/garvaninstitute
twitter.com/garvaninstitute
youtube.com/garvaninstitute
linkedin.com/company/garvan- institute-of-medical-research